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Abstract 
Dynamic alterations in the actin cytoskeleton, under the regulation of the 
Rho/ROCK pathway, permit cell motility, cell-to-cell and cell-to-matrix 
adhesion, and have also been shown to participate in apoptosis and cell 
proliferation. These facets of cellular behaviour all have the capacity to become 
dysregulated in cancer; components of the Rho/ROCK pathway are known to play 
varying roles in these processes, both within primary tumours and within the 
tumour microenvironment.  
The LIM kinases are phosphorylated and activated by ROCK, leading to 
inactivation of cofilin and subsequent stabilisation of actin filaments. In 
addition, LIM kinase 2 serves as a p53 target and is upregulated in response to 
DNA damage. In some solid tumours (e.g. breast and prostate), LIM kinase levels 
are elevated. However, we found that LIM kinase 2 expression is downregulated 
in colon cancer, with a progressive reduction noted with advancing tumour 
stage. I found that LIMK2 expression in colon cancer is under epigenetic 
regulation, with hypermethylation of the promoters leading to transcriptional 
silencing; this implicates LIMK2 as a tumour suppressor gene in this context. This 
has potential translational implications as loss of LIMK2 could be utilised as a 
biomarker to stratify patients in the future. 
Elevated mechanical tension within the tumour microenvironment is known to be 
an adverse prognostic indicator due to its association with desmoplasia. ROCK 
activation has previously been shown to increase epidermal tissue stiffness and 
thickness, but little was known about the mechanisms by which this occurs. I 
found that ROCK activation leads to the deposition of extracellular matrix 
components, with a presumed consequent further increase in stromal stiffness. 
This indicates that a positive feedback cycle is established in the tumour 
microenvironment, maintaining a fibrotic stromal reaction that permits tumour 
progression. 
These results highlight the disparate roles that the actin cytoskeleton and 
constituents of the Rho/ROCK pathway play in tumour initiation and 
propagation, indicating the need for further research. 
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Preface 
The process by which a normal cell embarks and continues on the journey 
towards becoming a cancer is characterised by perturbations of many aspects of 
normal cell behaviour 1. This is reflected by the alterations seen in the 
cytoskeleton as cancer cells become motile, invasive, change their morphology, 
and respond differently to cues received from their microenvironment. 
As we seek to understand the influences at play in tumour initiation and 
development, the pivotal role of those pathways that directly and indirectly 
influence the cytoskeleton and those that are in turn altered by cytoskeletal 
changes are of paramount importance.  
  
12 
 
Acknowledgement 
Thanks to Mike for being such an inspiring and positive supervisor; you made my 
foray into science much more enjoyable. Thank you also to my advisor Jeff Evans 
for his support throughout my research. 
It has been a real pleasure being a part of R17 – I couldn’t have asked for a nicer 
group, so thank you to all members past and present. Particular thanks to June 
for all her help in the lab, Nicola for her assistance with the animal work, and 
Katerina, Mathieu & both Dominikas for tea breaks and encouragement. Last, 
littlest, but definitely not least, thanks to Linda, the happiest scientist I know. 
I’d also like to thank the other Beatson research fellows – it was good to have 
you guys around for moral support.  
I am also very grateful to CRUK for funding this research, and the Beatson 
Institute for providing such a great environment to work in. 
Finally, thanks to my parents, Anne and Peter, for their kind words of 
encouragement, and to my friends, especially Kate, Kirsty, Catie and Jenni, for 
giving me a laugh when the science didn’t. 
 
  
13 
 
Author’s Declaration 
I am the sole author of this thesis. All the work presented is entirely my own 
unless stated otherwise.  
14 
 
Abbreviations 
 
4-HT 4-hydroxytamoxifen 
5-AZA 5-azacytidine 
ADF Actin depolymerising factor 
ADP Adenosine diphosphate 
ANOVA Analysis of variance 
ATP Adenosine triphosphate 
BCA Bicinchoninic acid 
BSA Bovine serum albumin 
CAF Cancer-associated fibroblast 
CIN Chromosomal instability 
CpG Methyl cytosine modified CG dinucleotide 
CRC Colorectal cancer 
cSCC Cutaneous squamous cell cancer 
DAPI 4',6-diamidino-2-phenylindole 
DMEM Dulbecco's Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DNMT DNA methyltransferase 
ECM Extracellular matrix 
EGF Epidermal growth factor 
EMT Epithelial-mesenchymal transition 
ER Estrogen receptor 
F-actin Filamentous actin 
FAP Familial adenomatous polyposis 
FBS Fetal bovine serum 
G-actin Globular actin 
GAP GTPase activating protein 
GDF15  Growth differentiation factor 15 
GDI Guanine nucleotide dissociation inhibitor 
GDP  Guanosine diphosphate 
GEF Guanine nucleotide exchange factor 
GFP Green fluorescent protein 
GTP Guanosine triphosphate 
H&E Haematoxylin & eosin 
HNPCC Hereditary non-polyposis colon cancer 
IBD Inflammatory bowel disease 
IHC Immunohistochemistry 
K14 Cytokeratin 14 
KD Kinase dead 
KGM Keratinocyte growth medium 
KO Knock out 
LIMK LIM domain kinase 
MEF Mouse embryonic fibroblast 
MET LUC Metridia luciferase 
15 
 
MKL1 Megakaryoblastic leukaemia 1 
MLC Myosin light chain 
MMP Matrix metalloproteinase 
MMR  Mismatch repair system 
MSI Microsatellite instability 
MSP Methylation specific PCR 
PAK p21 activated kinase 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
RIN RNA integrity number 
RNA Ribonucleic acid 
ROCK Rho-associated coiled-coil kinase 
SEAP Secreted alkaline phosphatase 
SMA Smooth muscle actin 
SRE Serum response element 
TBS Tris buffered saline 
TGFβ Transforming growth factor beta 
TNC Tenascin C 
TSLP Thymic stromal lymphopoietin 
WT Wild type 
16 
 
1 Introduction 
1.1 The	actin	cytoskeleton	
Actin is one of the most abundant proteins observed in eukaryotes; it is found 
both as a globular monomer (G-actin), and as a polymeric chain of G-actin 
subunits (filamentous or F-actin) 2. The F-actin filament has structural polarity, 
as all subunits are oriented in the same direction. The “pointed” (negative) end 
possesses an actin subunit with an exposed ATP binding site, while the “barbed” 
(positive) end displays a cleft directed at an adjacent G-actin monomer. 
“Treadmilling”, or the cycle of actin polymerisation and depolymerisation, is an 
ongoing process by which ADP exchange for ATP promotes the addition of G-
actin monomers to the barbed end of F-actin filaments, and vice versa 3 (Figure 
1-1). Following formation and elongation of an F-actin filament, its stability and 
mechanical properties can be altered by accessory proteins (e.g. profilins) that 
bind alongside the polymer, determining the state of polymerisation, and cross-
linking and severing the actin filament 4. In addition, capping proteins can bind 
to the end of the filament and regulate its assembly and disassembly 5. 
Furthermore, F-actin filaments, in co-operation with myosin II filaments and 
integrins, form focal adhesion complexes, anchoring cells via the cytoskeleton to 
the extracellular matrix and to neighbouring cells, thus permitting cell-cell/cell-
matrix dialogue 6.   
17 
 
 
 
 
 
 
 
Figure 1-1 Actin treadmilling 
Cofilin binds to and severs F-actin, increasing the “treadmilling” rate of actin filaments. Adapted 
with permission from MBInfo: www.mechanobio.info; Mechanobiology Institute, National 
University of Singapore.  
 
 
 
 
 
 
18 
 
1.1.1 Regulation	of	the	actin-myosin	cytoskeleton	
1.1.1.1 The	Rho	GTPase	family	and	its	activators	
The Rho GTPase family is a group of molecules with pivotal functions in the 
regulation of cytoskeletal organisation 7. They are members of the Ras 
superfamily of small GTPases, but alter from other small GTPases in that their 
sequences possess a Rho insert domain within the GTPase domain. This insert is 
proposed as an activator of downstream proteins 8. There are 22 mammalian 
members of the Rho GTPase family; the most extensively studied members 
comprise Rac1, RhoA and Cdc42, small guanine triphosphatases. Three Rho 
isoforms exist: A, B and C. They transition between a GDP-bound state (inactive) 
and GTP-bound state (active). Their protein sequences are approximately 85% 
identical, with some divergence between members in the “insert loop”, a region 
that enables NADPH oxidase binding to Rac 9. RhoA is necessary for disassembly 
of cell adhesions during cell migration, while RhoB inhibits growth factor 
receptor trafficking 10. RhoC remodels the cytoskeleton via activation of mDIA1 
and FMNL2 11.  
The regulators of Rho protein function fall into 3 main subgroups: 
1. Guanine nucleotide exchange factors (GEFs). These function by catalysing 
the release of GDP, thus facilitating GTP binding; a consequent alteration 
in conformation of the switch region of the GTPase increases the binding 
affinity of effector proteins, thus prompting downstream signalling 12. 
2. GTPase-activating proteins (GAPs). These proteins improve the capacity 
of small GTPases to hydrolyse GTP to GDP, thus promoting inactivation 
and reversing effector binding, effectively terminating the signalling 
pathway 13.  
3. Guanine nucleotide dissociation inhibitors (GDIs). These regulatory 
proteins are located in the cytosol and, through complex formation with 
GDP-bound GTPases, prevent cycling of GTPases between the cytosol and 
the plasma membrane, thus inhibiting GEF-mediated activation of Rho 
GTPases 14. Rho GTPases are maintained as soluble cytosolic proteins by 
insertion into the hydrophobic pocket of the GDI 15. Upon their release, 
19 
 
Rho GTPases can insert into the lipid bilayer of the plasma membrane, 
permitting association with effector targets at the cell membrane 16.  
There are additional regulatory mechanisms known to play a role in influencing 
Rho GTPases, including micro RNAs, which regulate post-transcriptional 
processing of Rho GTPase-encoding mRNAs 17; palmitoylation (the covalent 
attachment of fatty acids to the membrane-bound proteins, thus modulating 
protein trafficking and protein-protein interactions) 18; post-translational 
phosphorylation 19, and the similar process AMPylation (the transfer of AMP from 
ATP to a threonine residue) 20, transglutamination 21, and ubiquitination 22. 
1.1.1.2 Rac1	and	Cdc42	pathways	
Rac1 controls the formation of lamellipodia, the cytoskeletal actin projections 
observed on the mobile edge of cells 23, while Cdc42 primarily regulates the 
formation of filopodia, the narrow cytoplasmic projections that extend beyond 
the leading edge of lamellipodia in migrating cells 24 . Multiple proteins have 
been identified as downstream binding partners of these Rho GTPases; several of 
these are serine/threonine kinases with the capacity to trigger signalling 
pathways by phosphorylating further target proteins. Downstream of Rac1 and 
Cdc42 are the 6 mammalian-encoded p21-activated kinases (PAKs), of which only 
PAKs 1–3 are able to bind Rac1 25; PAKs 1–6 are all capable of binding Cdc42 26. 
PAKs in turn phosphorylate substrates that affect cytoskeletal dynamics (through 
disassembly of stress fibres and focal adhesion complexes) including LIM kinases 
27 and myosin light chain kinase 28. 
In addition to kinase effectors, non-kinase scaffold proteins exist to transfer 
signals from Rho GTPases: e.g. N-WASP is activated by Cdc42 and consequently 
binds proteins to bring about actin polymerisation and subsequent filopodia 
formation 29.  
1.1.1.3 RhoA-ROCK	pathway	
RhoA also binds a number of effector proteins; the best characterised of these 
are the Rho-associated coiled-coil-containing protein kinases (ROCK1 and 
ROCK2), serine/threonine kinases with multiple Rho-binding domains within the 
coiled-coil region 30. RhoA must be in an activated, GTP-bound state in order to 
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bind to ROCK; upon Rho-GTP binding, there is thought to be a conformational 
change that induces kinase activity 31. ROCK1 and 2 share the same overall 
domain structure, with the kinase domain situated at the N-terminus, and a 
coiled-coil region bearing a Rho-binding domain (RBD). A pleckstrin homology 
domain with a cysteine-rich region exists at the C-terminus 32. ROCKS are 
capable of displaying an autoinhibitory conformation, with the C-terminal RBD 
and pleckstrin homology domains binding to the kinase domain, thus preventing 
kinase activity. When Rho-GTP binds to the RBD, a conformational change is 
induced, freeing the kinase domain and permitting activity 33. 
There is approximately 90% homology between the kinase domains of ROCK1 and 
ROCK2; they are therefore observed to phosphorylate a largely shared proportion 
of substrates 34. These include regulatory myosin light chain, the contractile 
force-generating subunit of the myosin macromolecule. Upon phosphorylation, 
primarily at serine 19, the ATPase activity of myosin increases, resulting in 
enhanced cell contractility and the formation of stress fibres 35 (Figure 1-2 and 
1-3). 
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Figure 1-2 The Rho/ROCK signalling cascade 
External signals from activated membrane receptors are translated by GEFs to activate RhoA/C. 
In turn, ROCK 1 and 2 are activated, and phosphorylate the target proteins MLC, LIMK1/2, and 
MYPT. Phosphorylation of MLC and, via LIMK, cofilin, results in actin fibre bundling and increased 
contractility. Adapted from Rath and Olson 36. 
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Figure 1-3 The Rho/ROCK signalling pathway showing additional substrates 
MYPT1: myosin phosphatase 1; ERM: ezrin/radixin/moesin. 
Adapted from Matsuoka and Yashiro 37. 
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ROCK also acts by phosphorylating the myosin phosphatase targeting (MYPT) 
proteins at sites Thr 696 and Thr 853. Phosphorylation of the first of these sites 
reduces myosin light chain phosphatase (MLCP) activity (a negative regulator of 
actomyosin contractility through dephosphorylation of MLC); phosphorylation of 
the latter also decreases MLCP activity, and additionally induces dissociation of 
MYPT1 from myosin 38,39.  
In addition, ROCK phosphorylates LIM kinases 1 and 2 on conserved threonine 
residues (Thr 508 in LIMK1 and Thr 505 in LIMK2). LIM domains are conserved 
features consisting of twin zinc finger-like motifs, which were first identified in 
Lin11, Isl1 and Mec-3 40. A consequence of LIM kinase (LIMK) phosphorylation is 
the phosphorylation and inactivation of the cofilin group of proteins (cofilin 1, 
cofilin 2, and actin depolymerising factor, ADF), leading to stabilisation of F-
actin filaments 41. 
ROCK1 is widely expressed in human tissue, including the heart, pancreas, lung, 
liver, skeletal muscle and kidney. It is not found in the brain 42. ROCK2 is 
expressed ubiquitously, and is observed within the brain 43. ROCK1 knock-out 
mice display failure of eyelid closure and omphalocoele phenotype (in which the 
intestine protruded through an abdominal wall defect). Most animals die shortly 
after birth 44. ROCK2 knock-out mice have also been generated; there is 90% 
embryonic lethality with this genotype, thought secondary to placental 
dysfunction, and the surviving pup are runts, albeit with subsequent normal 
development 45.  
1.1.2 ROCKS	
1.1.2.1 ROCKs	in	physiological	conditions	
Contractility  
Cell-matrix communication 
The best-recognised function of ROCK 1 and 2 is to enhance myosin-actin binding 
and thus contractility. This in turn promotes the assembly of stress fibres, 
composed of multiple actin filaments cross-linked by α-actinin, and generally 
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anchored to focal adhesions, providing a point of contact between the 
extracellular matrix and the actin cytoskeleton 46. This communication permits 
transmission of mechanical force via stress fibres to focal adhesion complexes, 
resulting in alterations in the conformation of e.g. integrins, and consequent 
signal transduction 47. Furthermore, the ability of stress fibres to sense the 
degree of mechanical tension in the milieu can directly regulate biomechanical 
and signalling pathways in cells, determining cell differentiation and ultimate 
cell fate 48.  
Cell motility 
Skeletal muscle myosin forms part of the sarcomere, and has the capacity to 
generate largely stable filaments 49. The interaction of myosin and actin in 
skeletal muscle is regulated by the calcium-sensitive tropomyosin-troponin 
complex 50. Smooth muscle and cytoplasmic myosin interact with actin through 
different mechanisms due to the absence of troponin 51; following stimulation, 
intracellular calcium concentrations increase, and calcium binds to calmodulin, 
thus activating myosin light chain kinase (MLCK) 52.  
In the presence of unphosphorylated MLC, MLCK phosphorylates MLC in 
association with the calcium-calmodulin complex, thus elevating myosin ATPase 
activity. MLCK is also capable of binding directly to myosin without the 
requirement for the calcium-calmodulin complex 53. If myosin exists in a fully 
phosphorylated state, MLCK becomes inhibitory indirectly through the actin-
binding domain 54. In the context of smooth muscle, MLC phosphorylation causes 
monomeric myosin molecules in solution to assemble into thick filaments. 
Inhibition of MLCK has been shown to prevent MLC phosphorylation and isometric 
force generation withn muscle 55.  
The polymerisation of G-actin monomers into F-actin filaments drives cell 
motility 4. A complex is formed from F-actin and myosin II filaments; the 
complex utilises energy from the hydrolysis of ATP to facilitate cytoskeletal 
contraction 56 . The force generated from actin-myosin contraction permits 
alteration of cell morphology, enabling cell movement. 
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Phosphorylation of myosin light chain (MLC) is a vital mechanism that regulates 
cell contractility 57. Following MLC phosphorylation, the myosin heavy chain is 
released and forms filaments, permitting the interaction between the myosin 
head and F-actin, and thus causing ATP-mediated movement of actin filaments. 
As previously described, activation of the Rho-ROCK signalling pathway results in 
phosphorylation of MLC and thus contributes to the regulation of cell motility 35. 
Apoptosis 
Apoptosis is the process of programmed cell death that occurs in response to 
extra- and intra-cellular stress. ROCK1, via caspase cleavage, is known to 
regulate the actin-myosin contraction force that mediates membrane blebbing, 
breakdown of the nucleus, and fragmentation of apoptotic cells 58. When 
apoptosis occurs due to flawed cell-ECM attachment, it is termed anoikis 59. This 
may arise due to loss of attachment, or when cells attempt to adhere to ECM 
that does not express the correct integrins, and thus fails to support cell 
survival60. 
Cell-cell junction regulation 
In addition to the regulation of cell contractility and cell-matrix adhesion, there 
are multiple pathways in which ROCKs are implicated as key players. These 
include the regulation of tight junctions, adhesive regions between neighbouring 
epithelial or endothelial cells that serve a barrier function by preventing 
molecules and ions passing between cells 61. ROCK activation has been found to 
increase the permeability of tight junctions in the context of endothelial cells, 
whereas the inverse appears to be the case in epithelial cells 61,62.  
Adherens junctions tend to occur at a more basal level than tight junctions, and 
are also subject to ROCK regulation. They are composed of cadherins, which 
span the cell membrane and interact with α, β and ɣ catenins. It has been shown 
that ROCK-induced cytoskeletal contraction disrupts and destabilises adherens 
junctions, a step implicated in the process of epithelial-mesenchymal transition 
63,64.  
 
26 
 
Cell proliferation 
There is evidence to suggest that ROCK participates in the regulation of cell 
proliferation; ROCK overexpression increases cell growth 65. In addition, ROCK 
inhibition leads to retarded cytokinesis 66, induces disordered separation of 
centrioles at the G1 phase of the cell cycle, and promotes early centrosome 
migration during mitosis 67. Furthermore, ROCK activation in the context of a 
conditionally active ROCK-ER fusion protein system in fibroblasts prompts G1/S 
cell cycle progression 68. 
Stem cell regulation 
Dissociation of human embryonic stem cells leads to increased phosphorylation 
of myosin light chain in a Rho/ROCK-dependent fashion, with subsequent 
blebbing and apoptosis 69. ROCK inhibition has been found to promote the 
survival of human embryonic stem cells 70. It is thought that this occurs as a 
consequence of avoidance of anoikis via increased cell-cell interactions and 
adhesion 71. Furthermore, ROCK inhibition enhances proliferation of stem cells 
72. 
1.1.2.2 ROCKs	in	cancer	
Expression 
Somatic mutations in both ROCK genes have been found in primary human 
tumours and in cancer cell lines 73. Mutations in the ROCK1 gene in breast cancer 
and non-small cell lung cancer have been shown to result in an increase in kinase 
activity as a consequence of loss of autoinhibition 73,74. There are also mutations 
present in the ROCK2 gene in primary gastric carcinomas, and in melanoma cell 
lines 73, which are again thought to lead to increased kinase activity. 
Elevated protein levels of ROCK have been documented in breast cancer, with a 
positive association between high ROCK expression, increased tumour grade, and 
poor survival outcomes 75. Other cancer types that also demonstrate a positive 
correlation between ROCK protein levels and reduced overall survival or a more 
aggressive phenotype include osteosarcoma 76, hepatocellular cancer 77, and 
bladder cancer 78. 
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Tumour microenvironment 
In addition to aberrant ROCK expression observed within tumour cells, the 
increased cytoskeletal contractility that occurs as a consequence of ROCK 
activation plays an important role in regulation of the tumour 
microenvironment. It is recognised that in many cancer types, including breast 79  
and pancreatic 80 cancers, a desmoplastic stroma is observed , and is noted to 
have a positive correlation with adverse clinical outcomes 81,82.  
ROCK signalling is known to increase tissue density through elevated production 
of collagen and other ECM components such as periostin and fibronectin 83,84. 
The consequences of this include activation of integrin-mediated signalling, 
epidermal hyperproliferation, and increased levels of tumour initiation, growth 
and progression in an animal model of ROCK activation 83. A positive feedback 
system appears to exist in that increased matrix density, and consequent 
stiffness, leads to an elevation in ROCK activity; this is thought to be related to 
the epigenetic silencing of Notch1 85. 
In addition, ROCK activation leads to increased levels of contractility within the 
cellular compartment of the tumour microenvironment, permitting deformation 
of the ECM, and creating “tracks” that facilitate cancer cell migration 86. This 
appears to be triggered in part by pro-inflammatory cytokines 87; however, 
evidence also suggests a positive feedback cycle exists between the ROCK and 
JAK/STAT pathways that may explain the perpetual signalling that ultimately 
permits invasion 87. In the context of lung adenocarcinoma, Rho/ROCK function 
is required to enable cancer-associated fibroblasts to invade a collagen matrix; 
ROCK inhibition abrogated the capacity of CAFs to invade 88. 
1.1.2.3 ROCK	inhibition	
ROCK inhibition has been studied in the context of a number of malignancies. 
The most widely utilised compounds include Fasudil (a moderate inhibitor, with 
a Ki of 330 nM) 89, Y27632 (a specific inhibitor of ROCK 1 and 2) 90, and H-1152P 
(a dimethylated analogue of Fasudil, and the most potent compound) 91 . All the 
aforementioned compounds are competitive inhibitors of the ATP-binding site of 
ROCK 92. In a broad range of cancer types, ROCK inhibition has been shown to 
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reduce cancer cell migration, proliferation and invasion, whilst simultaneously 
inducing apoptosis (Table 1-1). This confirms the central role played by ROCK in 
cancer progression, both through its function within tumour cells, and via 
modulation of the tumour microenvironment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
29 
 
 
Table 1-1 Result of ROCK inhibition in different tumour types 
 
 
Tumour	type Experimental	
model 
ROCK	inhibitor Result 
Acute	myeloid	
leukaemia	93 
Primary	human	
cells 
Fasudil Increased	apoptosis,	
reduced	viability 
Triple	negative	breast	
cancer	94 
Human	cell	line H-1152 Reduced	migration	and	
invasion 
Urothelial	cancer	95 Human	cell	line Fasudil Reduced	proliferation	and	
migration;	induced	
apoptosis 
Small	cell	lung	cancer	
96 
Human	cell	line Fasudil Reduced	growth,	
proliferation,	adhesion,	
migration	and	invasion;	
increased	apoptosis 
Glioblastoma	97 Human	cell	line	
&	in	vivo	
(murine	
xenograft) 
Fasudil Reduced	proliferation,	
migration,	invasion;	
increased	apoptosis.	
Reduced	invasion	and	
growth	in	vivo 
Prostate	cancer	98 Conditioned	
HUVECs 
Fasudil Reduced	endothelial	cell	
proliferation	and	
migration 
Adenocarcinoma	
lung	88 
Primary	human	
CAFs	&	human	
cell	line 
Y27632 Reduced	invasion 
Hepatocellular	
cancer	99 
Human	cell	line Y27632 Reduced	migration	and	
invasion 
Melanoma	100 Murine	and	
human	cell	lines	
&	in	vivo	 
Y27632 Reduced	invasion;	
reduced	tumour	volume 
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1.1.3 LIM	kinases	
1.1.3.1 LIM	kinase	expression	and	regulation	
There are two subtypes of the LIM kinase serine/threonine kinase protein family: 
LIM kinase 1 (LIMK1), encoded on chromosome 7q11.23, and LIM kinase 2 
(LIMK2), encoded on chromosome 22q12.2. As a result of alternative splicing, 
there are two LIMK1 mRNAs, one encoding the full-length protein, the other 
producing a truncated protein lacking the carboxyl-terminal kinase domain. 
Alternative splicing also produces three LIMK2 isoforms: 1 (the largest protein), 
2a and 2b. LIMK2a contains two LIM motifs, while LIMK2b contains 1.5 LIM 
motifs. A LIMK2a specific exon (exon 2) and a LIMK2b specific exon (exon 2b) at 
the 5’ region of the mouse Limk2 gene exist, implying that Limk2a and 2b are 
transcribed from a single Limk2 gene by alternative usage of exons 101 (Figure 1-
4). No functional differences between the isoforms have been identified, 
although there are indications that their expression may vary in different 
tissues. Both LIMK1 and 2 are expressed widely in all tissues, with particularly 
high expression of LIMK1 in the brain, kidney, stomach and testis 102,103. 
Both LIMK1 and 2 are phosphorylated by the Rho effector Rho kinase (ROCK) on 
conserved threonine residues (Thr-508 in LIMK1 and Thr-505 in LIMK2) leading to 
activation. In addition, PAK and MRCKα have been reported to phosphorylate and 
activate LIMK. Dephosphorylation and inactivation of LIMK1 is regulated by 
phosphatases including slingshot 1. Par-3, a polarity protein, appears to play a 
similar role in influencing the activity of LIMK2 40. 
The cofilin family, comprising cofilin 1, cofilin 2 and actin depolymerising factor 
(ADF) plays a key role in actin filament dynamics in cells 104. Cofilins sever 
Filamentous-actin (F-actin) filaments to generate barbed ends that can serve as 
de novo actin nucleation sites. In addition, cofilins have been shown to induce 
protrusion and influence the direction of cell migration 105. Cofilins are the most 
extensively characterised substrates of the LIM kinases, which act by 
phosphorylating cofilin on serine 3 and inactivating its F-actin severing activity. 
In addition to its role in regulation of the actin cytoskeleton, LIMK 1 has also 
been shown to play a role in modulating microtubule disassembly 106. 
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Figure 1-4 Schematic diagram of alternative exon usage near the 5’-terminal region of the 
mouse Limk2 gene 
Alternatively initiated Limk2a and Limk2b transcripts are indicated in the lower panels. Adapted 
from Ikebe et al 101. 
 
 
 
 
 
 
 
 
 
32 
 
1.1.3.2 LIM	Kinases	in	Cancer	
It has been proposed that the LIM kinases may play a role in cancer cell invasion 
and metastasis; the balance between phosphorylated and non-phosphorylated 
cofilin under the influence of LIMKs may prove to be a significant determinant of 
metastatic potential.  
Evidence suggests that LIMK 1 activity is important for cancer cell metastasis; 
the level and activity of LIMK 1 are higher in invasive breast and prostate cancer 
cell lines, leading to enhanced tumour angiogenesis and metastasis 107,108. LIMK 1 
activity was also shown to be necessary for invasiveness of breast cancer cell 
lines 109. In addition, work with pancreatic cancer cell lines has established a 
role for both LIMK 1 and 2 in metastasis and tumour cell-induced angiogenesis 
110. It is proposed that the LIM kinases likely have non-overlapping functions in 
the formation of metastasis, as a LIMK1/2 double knockdown is necessary to 
completely block metastatic behaviour in vivo. 
It has been shown that LIMK2 acts as a p53 target and is upregulated in response 
to DNA damage 111. This activation of LIMK2 is thought to have a pro-survival 
function. However, it appears that the isoforms of LIMK2 (LIMK2a and LIMK2b) 
behave differently in response to DNA damage. Certainly, there is differential 
regulation of LIMK2a and LIMK2b in different human cancers with, for example, 
marked reduction of LIMK2b and increase of LIMK2a in gastro-oesophageal 
cancers. It has been proposed that LIMK2b promotes DNA damage-induced G2/M 
cell cycle arrest, contributing to checkpoint regulation. Depletion of LIMK2b was 
reported to impair G2/M arrest, while reduction of LIMK2a did not appear to 
have this effect, again indicating their apparent functional differences 112. 
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1.2 Colorectal	cancer	
Colorectal cancer (CRC) is the 4th commonest type of cancer diagnosed in the 
UK, and the 2nd commonest cause of cancer death (Office for National 
Statistics). The lifetime risk of developing CRC is approximately 6% (Cancer 
Research UK, http://www.cancerresearchuk.org/health-professional/cancer-
statistics/risk/lifetime-risk#heading-One, accessed February 2016). CRC survival 
is dependent on the stage of disease at diagnosis; staging follows two 
conventional systems: Duke’s (Table 1-1) and TNM (Table 1-2). In addition, a 
number of factors are used to determine the prognostic outlook of an individual, 
including the tumour grade (i.e. the degree of differentiation) and the presence 
or absence of cancer cells within the vasculature around the tumour. In those 
patients presenting with early stage disease, curative surgery is usually possible, 
with consequent 5-year survival rates of 93.2% (NCIN 1996 – 2002). However, the 
majority of patients present with more advanced disease, necessitating more 
aggressive management strategies in the form of surgery, and adjuvant systemic 
treatments such as chemotherapy and biological agents. Despite developments 
in the treatment of CRC, survival rates progressively decline as the stage of 
disease at diagnosis advances. 
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 Depth	of	
invasion 
Lymph	node	
metastases	
present 
Distant	
metastases	
present 
%	of	cases %	5-year	
survival 
Duke’s	A Into,	but	not	
through,	
bowel	wall 
No No 8.7 93.2 
Duke’s	B Penetrates	
muscularis	
propria 
No No 24.2 77.0 
Duke’s	C Any Yes No 23.6 47.7 
Duke’s	D Any Yes	or	no Yes 9.2 6.6 
Unknown - - - 34.3 35.4 
 
Table 1-2 Duke’s staging of colon cancer 
Disease stage is determined by the depth of invasion of the primary tumour and the presence or 
absence of regional lymph node or distant metastatic deposits. The 5-year survival progressively 
declines as the stage of disease at diagnosis increases. Data from the National Cancer 
Intelligence Network 1996 – 2002. 
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Stage T N M 
0 Tis N0 M0 
I T1 
T2 
N0 
N0 
M0 
M0 
IIA 
IIB 
IIC 
T3 
T4a 
T4b 
N0 
N0 
N0 
M0 
M0 
M0 
IIIA 
IIIB 
IIIC 
T1	–	T2 
T1 
T3	–	T4a 
T2	–	T3 
T1	–	T2 
T4a 
T3	–	T4a 
T4b 
N1 
N2a 
N1 
N2a 
N2b 
N2a 
N2b 
N1	–	N2 
M0 
M0 
M0 
M0 
M0 
M0 
M0 
M0 
IVA 
IVB 
Any	T 
Any	T 
Any	N 
Any	N 
M1a 
M1b 
 
Table 1-3 TNM staging of colon cancer 
TNM staging assigns a group depending on the depth of primary tumour invasion (“T”), the 
extent of lymph node involvement (“N”) and the degree of metastasis (“M”). Tis = carcinoma in 
situ; T1 = tumour invades submucosa; T2 = tumour invades muscularis propria; T3 = tumour 
invades through muscularis propria and into the pericolonic tissues; T4a = tumour penetrates to 
the surface of the visceral peritoneum; T4b = tumour directly invades or is adherent to other 
organs/structures. N0 = no regional lymph node metastases; N1 = metastasis in 1–3 regional 
lymph nodes; N2a = metastasis in 4-6 regional lymph nodes; N2b = metastasis in 7 or more 
regional lymph nodes. M0 = no distant metastasis; M1a = metastasis confirmed to one organ or 
site; M1b = metastases in more than one organ or site. Adapted from the American Joint 
Committee on Cancer colon cancer staging, 7th edition 2009.  
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Colon cancers tend to arise from non-malignant adenomas, with subsequent 
acquisition of a series of genetic mutations permitting tumour progression 113 
(Figure 1-5). The alterations observed are dependent on the degree of 
chromosomal and microsatellite instability inherent to the tumour. In 
chromosomally unstable CRCs 114, loss of APC appears to be the triggering event 
for adenoma formation 115 . Subsequent mutations are acquired in KRAS 116, 
followed by loss of SMAD4 (due to chromosome 18 deletion) 117, and mutations in 
TP53 118. In contrast, CRCs displaying microsatellite instability (MSI) are deficient 
in the mismatch repair system (MMR), leading to an inability to maintain 
genomic stability 119. This primarily occurs through downregulation of MLH1 
secondary to promoter hypermethylation 120. In these tumours, adenoma 
formation secondary to alterations in Wnt signalling 121, followed by mutations in 
BRAF (and, in a minority, KRAS) more commonly occurs 116. Thereafter, positive 
selection of cells with microsatellite mutations in MSH2, MSH6 122, TGFβ 
receptor 2 123, insulin-like growth factor receptor 2 124, and BAX2 125 enables a 
TP53-independent mechanism of progression. 
 
Parallel to these genetic alterations, it is increasingly recognised that epigenetic 
changes play a key role in CRC carcinogenesis. There is a mounting body of 
evidence to suggest that many more genes within the CRC genome are affected 
by epigenetic aberrations than genetic mutations, with consequent 
transcriptional silencing of tumour suppressor genes and gain of function in 
oncogenes 126. 
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Figure 1-5 Sequence of events in the transition from adenoma to carcinoma 
The observed clinicopathological alterations in CRC can be aligned with genetic events initiating 
and promoting the disease. Differences exist between the pathways activated in tumours 
exhibiting chromosomal instability and those in which microsatellite instability predominates, 
but a degree of overlap also exists. Adapted from Walther et al 127. 
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1.2.1 Aetiology	of	colorectal	cancer	
In the vast majority of CRC cases (over 90%), no single causative agent is 
apparent. These cases are predominantly attributed to a diet high in red meat 
and processed foods, and high levels of physical inactivity and obesity. The 
remainder of CRCs are caused by inherited conditions or predisposing diseases 
128. 
1.2.1.1 Hereditary	non-polyposis	colon	cancer	
Hereditary non-polyposis colon cancer (HNPCC or Lynch syndrome) is the most 
frequently encountered cause of CRC in those cases deemed not due to the 
“Western lifestyle”, and is thought to be responsible for 2-7% of CRC diagnoses 
129 . Presentation with an HNPCC-related CRC occurs at an average age of 44 
years, in contrast to an average age at diagnosis of 64 years in non-HNPCC CRC. 
HNPCC is a genetic condition usually inherited in an autosomal dominant fashion, 
although it can also arise de novo. Faulty DNA mismatch repair leading to 
microsatellite instability is the hallmark of HNPCC; this can occur as a 
consequence of mutations in a number of genes involved in the DNA MMR 
pathway: MSH2, MLH1, MSH6, PMS2, PMS1, TGFβR2, and MLH3 130. Affected 
individuals are at increased risk of CRC, and other cancer types including 
endometrial, urothelial, small bowel, gastric and glioblastoma 131. The lifetime 
risk of CRC in a patient with HNPCC is approximately 80%. In order to identify 
patients at risk of HNPCC, the International Study Group on HNPCC developed 
the Amsterdam Criteria II 132: 
• Three or more family members with HNPCC-related cancers, one of 
whom is a first-degree relative of the other two 
• Two successive affected generations 
• One or more of the HNPCC-related cancers diagnosed at age less than 50 
years 
• Familial adenosis polyposis (FAP) has been excluded 
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1.2.1.2 Familial	Adenomatous	Polyposis	
Familial adenomatous polyposis (FAP) is an unusual inherited condition, with an 
incidence of 1 in 10,000 to 1 in 15,000. It is characterised by the formation of 
multiple adenomatous polyps in the large intestine 133. There are 3 subtypes of 
FAP: 
• “Classic” FAP, in which there is an inactivating mutation of the tumour 
suppressor gene APC 134, leading to the development of 100s – 1000s of 
polyps, with a 93% risk of malignant conversion by the age of 50 years 135.  
• Attenuated FAP, a less penetrant subtype 136, usually with truncating 
mutations in the 5’ region of the APC gene , manifested by fewer polyps 
and a lower lifetime risk of cancer (70%) . 
• Autosomal recessive FAP, in which there are mutations in the MUTYH gene 
encoding the base excision repair enzyme MYH glycosylase 137 . This 
generally results in a milder phenotype than classic or attenuated FAP. 
1.2.1.3 Colitis-related	colorectal	cancer	
Inflammatory bowel disease (IBD) is a blanket term for 2 distinct conditions: 
Crohn’s disease (in which inflammation can affect any part of the 
gastrointestinal tract) 138 and ulcerative colitis (in which inflammation is limited 
to the colon). Both are autoimmune diseases with a degree of genetic 
predisposition 139, characterised by disproportionate T-cell responses to some 
types of commensal bacteria 140 , leading to inflammatory cell infiltration, 
ulceration, oedema and fibrosis of the bowel wall. In patients with ulcerative 
colitis, the incidence of CRC increases 8 – 10 years after the initial diagnosis  , 
reaching 18% after 30 years 141; furthermore, the severity of inflammation is 
correlated with the risk of developing CRC 142. While the majority of sporadic 
CRCs appear to arise from adenomatous polyps, colitis-associated CRCs tend to 
evolve from regions of epithelial dysplasia 143. Affected patients are generally 
younger than those with sporadic cancers, and a higher proportion of patients 
present with 2 or more synchronous primary tumours 144. 
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A number of possible mechanisms of tumorigenesis specific to colitis-associated 
CRC have been proposed, including (1) The overexpression of Toll-like receptor 4 
(TLR4), which appears to increase EGFR-2 signalling 145; (2) Oxidative stress in 
inflamed tissue mediating DNA damage through reactive nitrogen species 146; and 
(3) Release of inflammatory cytokines and growth factors such as Interleukin-6 
and interleukin-23, causing the induction of anti-apoptotic genes such as BCL-XL 
147 .  
CRC as a consequence of IBD is relatively uncommon, accounting for less than 1% 
of all CRC diagnoses 128. 
1.2.2 Disordered	signalling	pathways	in	colorectal	cancer	
1.2.2.1 Genetic	aberrations	
Two differing types of genomic instability are regarded as mechanisms of CRC 
tumorigenesis. Chromosomal instability (CIN) is found in approximately 70% of 
CRCs, and constitutes the duplication or deletion of fragments of chromosomes 
or entire chromosomes, resulting in heterogeneous chromosomal abnormalities 
148 . Microsatellite instability (MSI) is observed in about 15% of CRCs and results 
from DNA mismatch repair, leading to the accumulation of DNA sequence errors 
149 . This generates novel “microsatellite” fragments. Tumours displaying 
microsatellite instability have less propensity to metastasise, and can be 
regarded as less sensitive to chemotherapeutic agents 150. Microsatellite 
instability is assessed through the analysis of five microsatellite markers, 
permitting identification of “high MSI” (>30% MSI in standard markers), “low MSI” 
(<30%) and microsatellite stable tumours (demonstrating absence of 
microsatellite alterations). High MSI tumours tend to be more proximal, poorly 
differentiated, mucinous lesions, with marked lymphocyte infiltration 151. A 
systematic review of patients with MSI CRCs revealed that MSI high tumours are 
associated with a significantly better prognosis when compared to microsatellite 
stable (MSS) tumours 152. A pooled survival analysis has found that patients with 
MSS tumours are more likely to derive benefit from 5-fluorouracil-based 
chemotherapy than those with MSI high tumours, although the mechanism 
underlying this remains unclear 153. The genetic alterations which are 
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encountered in CIN and MSI cancers, while sharing some common pathways, also 
demonstrate a number of differences. 
Further to the germline mutations in the APC gene that are responsible for the 
majority of cases of FAP, most sporadic CRCs are also observed to harbour 
somatic APC mutations. APC is a tumour suppressor gene, and its inactivation 
through chromosomal instability is deemed to be the triggering event in most 
CRCs 113 . Loss of APC function leads to the accumulation and nuclear-
localisation of β-catenin, resulting in constitutively active Wnt signalling 154. This 
in turn promotes cell signalling, proliferation and epithelial-mesenchymal 
transition through downstream effectors including the TCF/LEF family of 
transcription factors 155. It has been shown that, via Wnt activation, loss of APC 
in an animal model (Cre+Apcfl/fl) induced with napthoflavone resulted in 
abnormal intestinal crypt morphology, changes in ECM proteins, and increased 
proliferation and apoptosis 156. When a Wnt stimulus is absent a destruction 
complex, composed of tumour suppressors AXIN and APC, GSK-3 and CK1 
(serine/threonine kinases), protein phosphatase 2A and the E3-ubiquitin ligase β-
TrCP, degrades β-catenin. The role that APC plays in this process appears 
complex 157. APC proteins bear multiple binding sites for β-catenin; it is thought 
that APC may promote β-catenin phosphorylation by AXIN-bound kinases. It has 
also been postulated that CK1 and GSK-3 may phosphorylate APC after 
phosphorylating β-catenin, thus displacing β-catenin from AXIN and enabling 
AXIN to interact with a new β-catenin molecule 158. Furthermore, APC may 
function in promoting β-catenin ubiquitination, thus tagging it for proteosomal 
degradation 159.  
In contrast, in those tumours in which microsatellite instability is predominant, 
the Wnt signalling pathway appears to be disordered through mutations of AXIN1 
and AXIN2 160. 
KRAS mutations in colonic epithelium are not sufficient to initiate tumorigenesis; 
however, occurring on a background of APC mutation, KRAS mutation results in a 
clonal expansion that can develop into cancer. KRAS mutations are present in 
approximately 30-50% of CRCs, and occur early in the sequence of transition 
from adenoma to carcinoma 113. The majority of mutations are in exon 2 codon 
12, with the remainder predominantly located in exon 2 codon 13 and exon 3 
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codon 61; they lead to inhibition of the GTPase activity of RAS, thus preventing 
hydrolysis of GTP on RAS via GTPase activating proteins (GAPs) and resulting in 
the accumulation of RAS in the active GTP-bound form 161. Constitutively active 
KRAS activates the RAF/MAPK and PI3K/AKT pathways, driving cell proliferation 
and survival. BRAF mutations are less frequently encountered than KRAS, and 
are unlikely to co-exist with KRAS mutations 116. However, mutations in BRAF are 
more common in microsatellite unstable tumours 162. The presence of mutations 
in KRAS and/or BRAF is predictive of lack of response to EGFR-inhibitory agents 
such as cetuximab and panitumumab, and confers a worse prognosis on patients 
163 . 
The most commonly detected cytogenetic abnormality in CRC is deletion of the 
long arm of chromosome 18 113 . This is encountered in instances of CIN and MSI 
164. Loss of heterozygosity of 18q leads to loss of DCC (deleted in colorectal 
cancer), which is located in region 18q21 165. DCC functions as a receptor for 
netrin-1 and, when bound to netrin-1, activates the CDC42-RAC and MAPK 
pathways, promoting tumour development. However, when DCC and netrin-1 are 
not associated, DCC is a tumour suppressor with a pro-apoptotic function 166. 
SMAD4 is also located on 18q, and is a participant in the TGFβ signalling pathway 
167 . High levels of SMAD4 expression in colorectal tumours are associated with 
significantly better survival outcomes 168, while loss of SMAD4 has been found to 
upregulate VEGF expression in CRC cell lines and is predictive of early CRC 
recurrence 169 . 
In tumours displaying CIN, an event which occurs relatively late in the 
progression from adenoma to carcinoma is TP53 inactivation, either through loss 
of heterozygosity of chromosome 17, or acquisition of loss of function mutations 
118,170. p53 inactivation is frequently linked with chromosomal instability, 
although each can exist independently 171. Loss of p53 function can lead to 
aberrant cell growth; however, there is not a clear negative correlation between 
low p53 expression and clinical outcome 172. In contrast, tumours which display 
MSI are more inclined to develop through p53-independent mechanisms, such as 
mutations in bcl-2-associated X protein (BAX), a pro-apoptotic gene 125, and 
insulin-like growth factor 2 receptor (IGF2R), a participant in TGFβ signalling 124. 
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Inactivation of the TGFβ signalling pathway is a key event during CRC 
progression in a proportion of tumours 173; this is observed in CIN cancers 
through loss of SMAD4 174, and in MSI cancers through mutations in the TGFβ type 
II receptor 123. However, the role of TGFβ in CRC is not clearly delineated, as 
elevations in TGFβ both in the primary tumour and in the stromal compartment 
are strongly correlated with risk of relapse 175-177. 
1.2.2.2 Epigenetic	alterations	
Epigenetic modifications are heritable changes in the genome, with no change in 
the DNA sequence. Methylation is one such modification, and is the outcome of 
the covalent addition of a methyl group to the cytosines within CpG 
dinucleotides. CpG islands consist of clusters of CpG subunits, and are observed 
in the promoter regulatory regions of many genes. Alterations in the methylation 
status of CpG islands can lead to reduced gene transcription through effective 
silencing of genes, including tumour suppressor genes 178.  
Approximately 30-40% of proximal colon cancers display a disproportionately 
high frequency of CpG island methylation; this group has been labelled “CpG 
island methylated phenotype” (CIMP) , and is found to have a strong association 
with MSI and BRAF mutation 179. CIMP-associated hypermethylation of the MMR 
gene MLH1 appears to be the primary mechanism driving the development of 
sporadic CRC with MSI 120. Furthermore, cancer-specific CpG hypermethylation 
has been shown to affect gene expression in colorectal tumours, with 
consequent down-regulation of a number of genes that may function as tumour 
suppressor genes 180.  
Global hypomethylation is also commonly encountered in CRC, potentially 
resulting in the upregulation of previously silenced genes and loss of genomic 
stability 181. 
1.2.2.3 Colorectal	cancer	cell	of	origin	
The identification of cancer stem cells 182 indicates that a subset of progenitor 
cells exists within the intestinal mucosal epithelium 183, and transformation of 
these cells (classically through the loss of APC) causes initiation of intestinal 
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adenomas 184. CRC cancer stem cells are regulated through a number of 
mechanisms, outlined below.   
Wnt-mediated regulation of CRC cancer stem cells 
 
The canonical Wnt pathway is perhaps the most clearly defined regulator of 
colon cancer stem cells 185. Investigations using Wnt reporter expression have 
revealed that Wnt signalling correlates inversely with expression of 
differentiation markers such as mucin 2 (MUC2) and cytokeratin 20 (CK20). In 
those cells with the highest levels of Wnt, an increase in vitro clonogenicity was 
detected; furthermore, these cells expressed the stem cell marker CD133. 
Achaete scute-like 2 (ASCL2) is a Wnt target transcription factor 186, and is 
upregulated at an early point in colon tumorigenesis through activation of the 
Wnt signalling pathway 187. The function of ASCL2 in the context of CRC remains 
somewhat undefined, but evidence suggests that loss of ASCL2 leads to reduced 
cell proliferation and invasion, and loss of the stem cell phenotype, possibly 
through miRNA-mediated mechanisms 188 .  
Another marker of intestinal stem cells is Ephrin receptor B2 (EPHB2) 189; EPHB2 
is also a Wnt target gene, and again high expression levels of EPHB2 are found in 
a subset of cells within colon tumours 190; these cells display a high degree of 
clonogenicity and tumour-initiating capacity, and low levels of differentiation 
markers. 
In addition, Lgr5 has been found to serve as a stem cell marker of the intestinal 
epithelium. It is also a Wnt target gene, and is solely expressed in cycling crypt 
base columnar cells 184. 
Notch-signalling in CRC cancer stem cells 
 
Notch signalling has been observed to inhibit cell differentiation 191; in addition, 
interactions between the Notch and Wnt pathways have been documented 192, 
indicating that Notch also functions in CRC cancer stem cell regulation. Notch 
knock-down in CRC cell lines results in increased levels of apoptosis and reduced 
cell proliferation, while Notch over-expression promotes colony formation and 
proliferation 193. 
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Bone morphogenic proteins 
 
The bone morphogenic proteins (BMPs) belong to the TGFβ superfamily, and are 
also thought to participate in cancer stem cell regulation. Expression of a 
number of BMP components is elevated in the upper levels of colon crypts, 
corresponding to the greatest degree of cellular differentiation 194. Furthermore, 
several BMP inhibitors, including Gremlin-1, are more highly expressed at the 
crypt base, implying that BMP signalling exerts a degree of control over 
intestinal differentiation. Exogenous BMP4 has been found to lead to 
downregulation of Wnt, thus inducing differentiation in CRC cancer stem cells 
195; it has been proposed that the inverse may also be the case, with Wnt 
activation inhibiting BMP activity in cancer stem cells 196. 
Tumour microenvironment 
 
The microenvironment, comprising stromal cells and extracellular matrix, is also 
believed to impact on the regulation of CRC cancer stem cells, in part through 
creating a stem cell niche that maintains the stem cell compartment 197, and 
also through production of signalling molecules 194 and cytokines 198 . 
A hypoxic environment is also likely to influence the degree of differentiation of 
cancer stem cells, with CRC cell lines grown in < 5% O2 displaying greater 
clonogenicity and reduced expression of transcription factors associated with 
differentiation such as CDX1 199. Additionally, hypoxia-inducible factor 1 (HIF1) 
has been found to induce expression of multiple stem cell markers, including 
OCT4, in CRC cells 200. 
Methylation-mediated regulation of CRC cancer stem cells 
 
Many Wnt target and non-Wnt target genes are affected by aberrant CpG island 
methylation 201 , possibly silencing genes with a role in differentiation and thus 
maintaining the “stemness” of colorectal tumours.  Furthermore, methylation-
prone loci are generally found to lack specific transcription factor sequences, 
including specificity protein 1 (Sp1), yin yang 1 (YY1) and nuclear respiratory 
factor 1 (NRF1), which are thought to be protective against methylation in 
cancer 202 . 
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1.2.3 The	actin	cytoskeleton	in	colorectal	cancer	
The ability of cancer cells to migrate is recognised as the major determinant of 
the development of metastatic disease. Dysregulation of components of the 
actin cytoskeleton is a vital step in the development and progression of CRC; this 
is mediated through a number of mechanisms. 
Reductions in cell-cell adhesion and alterations in cytoskeletal organisation are 
characteristics of the acquisition of a malignant phenotype. In physiological 
conditions, the adherens junction is connected to the actin cytoskeleton, 
maintaining cell polarity and tissue architecture. Epithelial cadherin (E-
cadherin) is the primary functional component of adherens junctions of colonic 
epithelial cells, and is bound to cytoskeletal actin by catenins (α, β, ɣ, and p 
120). As previously described, in CRC β-catenin accumulates in the nucleus 
following loss of APC function. As a consequence of this, the E-cadherin-catenin 
complex is disassembled, leading to disruption of the normal cell adhesion 
processes 155,203 . Loss of adhesion can act to promote tumour cell detachment 
from the primary site, direct invasion of adjacent tissue, and dissemination to 
distant sites. In several tumour types, including CRC, loss of membranous E-
cadherin expression is observed to be associated with reduced levels of tumour 
differentiation; furthermore, reduced expression correlates with increased risk 
of metastasis 204. The importance of E-cadherin loss in the development of 
metastatic disease is highlighted by the finding that expression levels are higher 
in primary tumours when compared with metastatic deposits, indicating that the 
ability of tumour cells to disseminate relies upon loss of the adhesion complex 
205. 
Loss of APC is a common feature in CRC tumorigenesis. In addition to the 
alterations in Wnt signalling that occur as a consequence of this, APC also plays 
a key role in regulation of the actin cytoskeleton, through binding to and 
stabilising microtubules 206. Furthermore, APC has been observed to localise to 
the cortical actin cytoskeleton in confluent cultured cells 207. Indirect effects on 
the actin cytoskeleton can be mediated through APC interactions with IQGAP (a 
scaffold protein that activates Cdc42), ARHGEF4 (a Rho GTPase), and mDia1 (a 
Rho GTPase effector protein involved in stress fibre formation) 208-210. 
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The integrins are a group of transmembrane receptors that serve to mediate 
cell-cell and cell-extracellular matrix interactions 211. Integrin-mediated signal 
transduction occurs via intermediary proteins, including talin, vinculin 212 and α-
actinin 213, which link integrins to actin cytoskeleton components. A 
consequence of these interactions is activation of the focal adhesion-linked 
protein tyrosine kinases Src and FAK, with subsequent alterations in the actin 
cytoskeleton promoting cell migration 214 . An association has been observed 
between increased integrin αv expression and malignant angiogenesis and 
tumour progression in several cancer types 215. In CRC, a link between increased 
integrin αv expression and (i) advanced disease stage 216, and (ii) the presence of 
hepatic metastases 217 has been found. Furthermore, overexpression of integrin 
αv as determined by IHC on patient samples is an independent predictor of 
poorer survival outcomes 218.  
1.2.4 The	Rho/ROCK	pathway	in	colorectal	cancer	
In several cancer types, including breast cancer 75 , activation of the ROCK 
pathway appears to promote tumour progression 219 . However, the impact of 
dysregulation of the Rho/ROCK pathway in the context of CRC is less clearly 
defined. There is increasing evidence to suggest that, contrary to the oncogenic 
role of Rho/ROCK activation in other tumour types, loss of RhoA can accelerate 
CRC progression 220. This is thought to occur through a number of mechanisms 
221: 
• RhoA signalling is essential to maintain adherens junctions, both in 
normal intestinal epithelium and in CRC cells 63,222; inactivation of RhoA 
in CRC cells results in reduced E-cadherin bound β-catenin, with 
consequent increased Wnt pathway activation  
• RhoA inactivation leads to increased TCF4/β-catenin activity, also 
promoting Wnt signalling and leading to upregulation of mitogenic 
proteins such as c-MYC and cyclin D1  
• Loss of RhoA activity appears to prevent differentiation of CRC cells, 
through mechanisms that are not yet clearly defined. 
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Furthermore, pharmacological inhibition of ROCK has been shown to facilitate 
the culture of CRC organoids with cancer stem cell properties through induction 
of CD44 220. 
Another component of the Rho/ROCK pathway, LIM kinase, is also frequently 
found to be upregulated in certain cancer types, including breast 107,109 and 
prostate 108 cancers, and is thought to promote tumour progression, 
predominantly through the acquisition of a motile phenotype. LIMK inhibition is 
found to reduce cell motility, and thus reduce the capacity of cancer cells to 
invade and metastasise 223.  
LIMK is also known to function as a p53 target, upregulated by DNA damage 
111,112. Knockdown or inhibition of LIMK appears to increase the sensitivity of 
cells to apoptosis following exposure to ionising radiation or chemotherapeutic 
agents, suggesting that LIMK functions in a pro-survival manner. Thus it can be 
determined that LIMK serves additional functions besides regulation of the actin 
cytoskeleton, and that selective pressure may exist in the context of some 
cancer types. 
The pattern of LIMK2 expression was studied in CRC 224, and it was discovered 
that LIMK2 levels in a human CRC TMA progressively decreased with advancing 
stage of disease. In addition, a correlation between LIMK2 level and overall 
survival was discovered. The mechanism governing the relationship between 
reduction in LIMK2 expression and CRC was examined further by using Drosophila 
melanogaster, as the posterior midgut is representative of the mammalian 
intestine. An RNA interference approach was used to reduce dLIMK expression, 
and a consequent increase in stem cell proliferation was detected. This was 
recapitulated in a murine Limk2 knockout model, with an increase in the number 
of stem cells seen in Limk2 knockout intestinal crypt organoids relative to wild 
type. The conclusion drawn from this work was that the presence of LIMK2 limits 
the proliferation of intestinal stem cells, and thus a reduction in LIMK2 permits 
their propagation. 
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1.3 Squamous	cell	skin	cancer	
Non-melanoma skin cancer is the commonest cancer diagnosis in the UK, making 
up 20% of all diagnoses of malignancy. Basal cell carcinoma, originating from the 
basal cells of the epidermis, represents 74% of non-melanoma skin cancers. 
Cutaneous squamous skin cancer accounts for approximately 23% of non-
melanoma skin cancers. Squamous cell carcinoma (SCC) arises through the 
malignant transformation of stratifying epithelium, the epithelial subtype 
present in tissues that serve a barrier function against the environment (e.g. the 
skin, cervix, and upper aero-digestive tract).  
1.3.1 Pathogenesis	of	cutaneous	squamous	skin	cancer	
The most commonly encountered precursor lesion of cutaneous squamous skin 
cancer is actinic keratosis, characterised by dysplasia, with keratinocytes 
displaying atypical, hyper-pigmented, pleomorphic nuclei. The normal 
differentiation process is partially disrupted, resulting in epidermal atypia 225. 
TP53 mutations are frequently observed in actinic keratosis, indicating that 
dysplastic lesions have acquired triggering genetic mutations before developing 
into cutaneous squamous cell cancers 226,227. Following a route of stepwise 
progression, actinic keratosis can develop into cutaneous squamous cell cancer 
in situ, with a more complete disruption of differentiation. 40% of in situ lesions 
have p53 mutations, again suggesting that this is an early event occurring before 
the development of an invasive phenotype 228. In the cutaneous context, loss of 
p53 function is thought to occur due to UVB-induced inactivation 229 and is 
widely encountered in pre-malignant and malignant squamous lesions 226,230. 
Aberrant Ras activation has also been noted in cutaneous SCC (cSCC) 231,232 and, 
in its role as an activator of the Raf/Mek/Erk pathway, can promote cSCC 
formation 233. However, Ras activation in isolation is insufficient to trigger cSCC 
formation 234; simultaneous alterations in pathways including NFκB or activation 
of CDK4 (a cell cycle progression mediator) are necessary 235,236. 
Notch signalling has also been found to participate in the development of cSCC 
237. Notch signalling decreases keratinocyte proliferation and enhances 
differentiation via p21 (a cell cycle inhibitor), caspase 3 and PKC-δ (a regulator 
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of UVB-induced apoptosis) activation 238. NOTCH1 expression is reduced in cSCC 
relative to healthy epidermal controls 239, possibly as a consequence of p53 
downregulation. Furthermore, NOTCH1 mutations appear to be early events in 
the carcinogenesis of cSCC and evidence indicates that NOTCH1 serves a tumour 
suppressor function in the epidermis 240,241. Interestingly, Notch activation 
appears to suppress Rho/ROCK signalling, while loss of Notch signalling is 
accompanied by an increase in Rho/ROCK activity in cSCC 239. 
1.3.2 Tumour	microenvironment	
The tumour microenvironment also plays a key role in the initiation and 
progression of cSCC.  
1.3.2.1 cSCC	arising	in	scar	tissue	
Chronic wounds/scars have the capacity to undergo malignant transformation; of 
cancers arising on a background of scar tissue, cSCC is the most common subtype 
242. The pathways involved in this process have not been fully elucidated, but it 
has been suggested that increased cell proliferation secondary to chronic 
inflammation, exposure of tissue to environmental toxins and carcinogens 
through loss of barrier function, and impaired immunological responses as a 
result of inadequate vascularisation of scar tissue may all play roles 242,243. 
1.3.2.2 Inflammation	
Tumour stroma in general has been shown to attract infiltrating immune cells 
that produce interleukins, cytokines and growth factors that permit evasion of 
the host immune responses 244. 
In a mouse model of cSCC, cancer associated fibroblasts mediated tumour-
promoting inflammation through a gene expression signature that recruited 
macrophages, and enhanced tumour growth and neoangiogenesis 245. 
1.3.2.3 Adhesion	
Fluctuations are observed in the type and number of adhesion molecules 
detected in different cancer contexts, as cells encounter altering environments 
through the processes of invasion and metastasis. 
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A more aggressive subtype of cSCC, acantholytic SCC, displays lower levels of 
intercellular adhesion proteins, such as E-cadherin and Syndecan-1, than those 
observed in non-acantholytic SCCs 246; this is thought to contribute to the more 
invasive nature of this variant. 
The dysregulated function of adhesion molecules may also impact on treatment 
outcomes in SCC: following radiotherapy treatment to head and neck SCC, 
intercellular adhesion molecule 2 (ICAM2) appears to activate PI3K/AKT 
signalling, thus blocking apoptosis and enhancing survival 247. 
1.3.2.4 Stromal	fibroblasts	
Cancer-associated fibroblasts are able to remodel the microenvironment, 
forming tracks that permit the collective invasion of SCC cells 86. This appears to 
be both force-mediated, through Rho-regulated actin cytoskeleton alterations in 
CAFs, and protease-mediated, e.g. via matrix metalloproteinases 248. The SCC 
cells that follow the tracks created by the leading CAFs do so in a MRCK and 
Cdc42-dependent fashion 86. 
1.3.2.5 The	extracellular	matrix	
Extracellular matrix components 
Laminins are a group of large extracellular glycoproteins that function in tissue 
development, wound repair and tumorigenesis 249. Laminin 332 plays an integral 
role in epidermal adhesion in normal conditions 250. However, laminin 332 has 
been shown to be over-expressed in several types of SCC, including cutaneous, 
oral, laryngeal, oesophageal and cervical cancers, and expression levels 
correlate with increased invasiveness and adverse clinical outcome 251. In SCC, 
laminin 332 tends to localise at the interface between tumour and stroma 252. In 
the context of cSCC, laminin 332 appears to promote tumour progression through 
an interaction with collage VII, which triggers phosphoinositol-3-kinase signalling 
and thus cell proliferation 253. Co-deposition of laminin 332 and other 
extracellular matrix components, including TNC, has been documented 254 ; this 
is thought to serve a supportive role permitting tumour cell invasion. 
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Tension within the extracellular matrix 
Mechanotransduction signalling within the tumour microenvironment has also 
been shown to play a pivotal role in the progression of cSCC. A murine model of 
cSCC, utilising a 2-stage chemical carcinogenesis protocol in FVB/N mice (one 
application of the mutagen dimethylbenz[a]anthracene followed by multiple 
applications of 12-O-tetradecanoylphorbol-13-acetate 255) was used to induce 
papillomas, with conversion to invasive tumours resembling human cSCC 
observed in a subset of these lesions. Only a cohort of animals in which ROCK 
activation within the epidermal keratinocytes was achieved (through the K14 
ROCK:ER transgene system) demonstrated progression to invasive cSCC within 15 
weeks, indicating the importance of cellular tension in cancer progression. The 
changes observed in this model included an increase in nuclear and total β-
catenin and an increase in collagen deposition within the extracellular matrix, 
with a consequent elevation in the level of stiffness within the ECM 83. 
Subsequent studies have confirmed that levels of ROCK 1 and ROCK 2 activation 
are increased in human cSCC relative to normal skin, and that integrin-mediated 
FAK signalling appears to be driven by increased ECM density 84. 
1.4 Epigenetics	
1.4.1 Mechanisms	of	protein	level	regulation	
Earlier work in the lab had determined that LIMK2 expression was downregulated 
at a protein level in CRC. There are a number of mechanisms by which protein 
level regulation occurs: 
1.4.1.1 Transcriptional	regulation	
Through binding enhancer elements, and the recruitment of co-factors and RNA 
polymerase II, transcription factors can regulate gene expression 256-258. Each 
individual cell type expresses a specific set of transcription factors, and 
therefore controls the selective transcription of a subset of genes by RNA 
polymerase II, and consequently determines the gene expression programme of 
the cell 259. Mutations in transcription factors are known to contribute to 
tumorigenesis, often as a result of overexpression of oncogenic transcription 
factors such as c-MYC 260. However, it has also been shown that long non-coding 
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RNAs can be misregulated, leading to silencing of tumour suppressor genes and 
consequently promoting cancer progression 261.  
1.4.1.2 MicroRNAs	
MicroRNAs (miRNAs) are short non-coding RNAs that are often present in reduced 
levels in tumours 262. This can occur secondary to genetic loss 263, epigenetic 
silencing 264, or transcriptional repression via loss of tumour suppressor 
transcription factors such as p53 265. miRNAs regulate the protein synthesis of 
messenger RNAs by deadenylation or translational repression 266. 
1.4.1.3 Protein	degradation	
Through ubiquitin labelling, proteins are tagged for degradation via proteolysis 
267. The tumour suppressor gene p53 can be targeted by Mdm2 for ubiquitination 
and proteasomal degradation 268, leading to loss of p53 expression. This 
mechanism may also apply to destruction of the protein products of other 
tumour suppressor genes. 
The knowledge that a significant proportion of colorectal tumours are 
characterised by a CpG island methylated phenotype indicated that epigenetic 
silencing may be the mechanism by which LIMK2 expression is reduced in this 
context, and therefore my work focused on epigenetic regulation.  
1.4.2 Epigenetic	regulation	
Mutations, whether inherited through the germ line or arising in somatic cells, 
can cause cancer 269. This can occur through oncogenes, in which mutations lead 
to enhanced cell proliferation, or via the loss of function of tumour suppressor 
genes. However, it is increasingly evident that epigenetic factors are also at 
play, with heritable alterations in gene expression that are not mediated by 
changes in the gene’s nucleotide sequence 270 leading to silencing of genes in 
cancer cells 271-273.  
The changes in gene expression that are mediated by epigenetic alterations are 
a consequence of methylation of DNA in promoter regions, where transcription 
takes place. DNA methylation involves the modification of post-replicative DNA, 
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with the addition of a methyl group to the cytosine ring to generate methyl 
cytosine. S-adenosyl-methionine (SAM) is the methyl group donor, and the 
reaction is catalysed by DNA methyltransferases (DNMTs) (Figure 1-6). In 
mammals, methyl cytosine modification only occurs in cytosines that 
immediately precede a guanosine in the nucleotide sequence. This is known as a 
CpG dinucleotide; these are observed relatively infrequently in the genome, in 
likelihood due to progressive CpG depletion through DNA methylation. Depletion 
occurs as a consequence of the tendency for methylated cytosine to deaminate, 
thus forming thymidine 274. 
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Figure 1-6 Conversion of cytosine to 5-methylcytosine 
DNMT catalyses the donation of a methyl group from SAM to the 5-carbon position of cytosine. 
Adapted from Gibney and Nolan 275. 
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1.4.3 The	physiological	role	of	DNA	methylation	
1.4.3.1 Maintenance	of	non-coding	DNA	
Several studies have linked the state of DNA methylation to gene expression, 
with a direct correlation observed between promoter region methylation and 
transcriptional silencing 270-273. Hypermethylated DNA replicates at a later time 
point than unmethylated DNA 276, ensuring the majority of the genome 
undergoes delayed replication. Inactive chromatin is generated during late 
replication, facilitating transcriptional silencing of non-coding sequences 277. 
Through this mechanism, potentially harmful DNA sequences such as 
transposons, repeat elements, and inserted viral sequences are repressed 278. 
1.4.3.2 CpG	islands	
While CpG dinucleotides are fairly scarce throughout the genome, they are seen 
grouped within short DNA sequences, often in promoter regions 270. These CpG 
clusters are termed CpG islands, and are found in nearly 50% of genes in the 
genome. The majority of CpG dinucleotides that exist out-with the confines of a 
CpG island are methylated; however, the CpG dinucleotides within CpG islands 
tend to be unmethylated, irrespective of whether the gene is undergoing 
transcription 270. There are physiological instances in which CpG islands within 
gene promoter regions are heavily methylated, for example in association with 
transcriptionally silent genes on the inactive X chromosome of females 270. 
1.4.4 DNA	methylation	in	cancer	
It has long been recognised that aberrant DNA methylation patterns are observed 
in cancer cells (Figure 1-7). 
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Figure 1-7 Two mechanisms by which epigenetic mechanisms contribute to carcinogenesis 
A) Methylation of a tumour suppressor gene prevents transcription factors (TF) binding to the 
promoter region; the gene is therefore not expressed, and damaged cells proliferate and become 
malignant. B) Demethylation of a proto-oncogene allows TFs to initiate transcription and genes 
to express the protein product. Uncontrolled cell proliferation follows. Adapted from 
Nelson, S. (2008) Comparative methylation hybridization. Nature Education 1(1):55 . 
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1.4.4.1 Increased	DNA	methylation	
Loss of function of tumour suppressor genes is an important factor in 
tumorigenesis; this occurs through germ-line or somatic mutations 279, but can 
also be caused by hypermethylation of gene promoters, leading to 
transcriptional silencing 280. The loss of gene function that results from 
hypermethylation of the promoter and from mutations in the coding region has a 
similar biological impact 273. This is illustrated by the fact that microsatellite 
instability in colon cancer can result from mutation or hypermethylation of MLH1 
281.		
Patterns of DNA methylation have been assessed as diagnostic, prognostic and 
predictive biomarkers in a number of cancer types, including prostate cancer 282. 
Furthermore, hypermethylation, and consequent tumour suppressor gene 
silencing, has been found to be reversible through the use of demethylating 
agents 283, permitting re-expression of functional genes in cancer cell lines. 
These agents include DNMT inhibitors such as 5-azacytidine, which has gained 
approval for use in some haematological malignancies 284. Thus, it is evident that 
the identification of tumour suppressor genes that undergo methylation-
mediated silencing during tumorigenesis is important for developing future 
clinical management strategies. 
1.4.4.2 Reduced	DNA	methylation	
Loss of DNA methylation is thought to play a role in tumorigenesis through a 
decrease in transcriptional repression of normally silent regions of the genome, 
potentially leading to expression of harmful elements and/or genes that would 
usually be silent 285. Furthermore, a reduction in methylation can also impact on 
nuclear structures, e.g. pericentromeric regions of the chromosome, resulting in 
instability and incongruous DNA replication 286. The degree of hypomethylation 
of DNA correlates with tumour progression and/or grade in some tumour types, 
including epithelial ovarian cancer 287; in addition, hypomethylation of 
centromeric satellite DNA has been identified as a marker predictive of relapse 
in ovarian cancer 288. 
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1.4.5 Determining	methylation	status	
Most of the methods utilised to determine the methylation status of a DNA 
sequence rely on the principle of bisulphite conversion: bisulphite treatment of 
DNA converts cytosine residues to uracil, but does not alter 5-methylcytosine 
residues 289 (Figure 1-8). DNA must be denatured prior to bisulphite modification, 
as only methylcytosines on single strands are vulnerable to bisulphite treatment 
290. DNA degradation can occur during bisulphite treatment, but can be 
minimised by maintaining an optimum bisulphite concentration, and thus 
reducing the time required to complete the reaction 291.		
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Figure 1-8 Bisulphite conversion 
Following treatment with bisulphite, cytosines undergo conversion to uracil. In contrast, 5-
methylcytosines are resistant to conversion and remain unaltered. 
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1.4.5.1 Methylation-specific	PCR	
Methylation-specific (MSP) PCR is one common method used to assess 
methylation status; it requires primer design that is customised to detect both 
unmethylated and methylated sequences 292. Methylation is determined by the 
capacity of the specific primer pair (unmethylated or methylated) to achieve 
amplification. It does not permit resolution at the nucleotide level, and is 
therefore a non-quantitative measure.  
1.4.5.2 Bisulphite	sequencing	
Bisulphite sequencing relies on PCR amplification of bisulphite treated DNA, with 
primers that flank but do not involve the methylation site of interest 293. This 
permits amplification of both methylated and unmethylated sequences. The PCR 
product is subsequently cloned into plasmid vectors, and the individual clones 
are sequenced; this permits the generation of methylation maps of individual 
DNA molecules (Figure 1-9). All unmethylated cytosines are displayed as 
thymines in the sequence. 
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Figure 1-9 Schematic illustrating the process of bisulphite sequencing.  
Bisulphite conversion of gDNA results in conversion of unmethylated CpG dinucleotides to uracil. 
Methylated CpG dinucleotides remain resistant to conversion. Following amplification, gDNA is 
cloned and sequenced, and the CpG dinucleotides analysed to produce a map of methylation 
status. 
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1.5 Tissue	mechanics	
Solid tumours consist of a mass of cancer cells, host cells (including immune 
cells), and blood and lymphatic vessels, embedded within an ECM 294. As tumours 
progress and grow, they become detectably stiffer than the surrounding tissue 
due to an increase in the structural components of the tumour. This process 
inevitably involves the generation of mechanical forces, both within the tumour, 
and between the tumour and its microenvironment. The increase in rigidity 
observed in tumours is due in part to: 
• Elevations in the elastic modulus as a consequence of changes in the cell 
architecture 295 
• Stiffening of the ECM through pro-fibrotic mechanisms 296 
• Increases in interstitial tissue pressure as a result of alterations in the 
tumour vasculature 297. 
As the tumour and its surroundings become stiffer, the capacity for tumour cell 
survival, proliferation and progression is enhanced 298,299.  
1.5.1 Non-malignant	fibrosis		
Alterations in mechanical force can directly affect the morphological features of 
cells; these changes are mediated through the Rho GTPases, regulatory hubs 
that determine the cytoskeletal response to changes in extracellular tension 300. 
An increase in external force is coupled with cytoskeletal Rho/ROCK activation, 
a response that serves to increase cellular tension and returns the cell to a state 
of tension balance with its environment 301 . Simultaneously, ECM components 
are manufactured in response to alterations in mechanical force to ensure that 
equilibrium is maintained between the internal and external cellular 
environments 302 .  
Fibrosis is initiated during physiological wound healing; however, when these 
mechanisms are dysregulated, pathological fibrosis occurs 303. This is 
characterised by the deposition of excessive amounts of ECM components, 
including fibrillar collagen and hyaluronan. The myofibroblast is the cell type 
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primarily responsible for the synthesis and deposition of ECM components in this 
setting. Myofibroblasts are essentially activated fibroblasts that express α 
smooth muscle actin, permitting a contractile phenotype 304. Fibrotic tissue is 
stiffer than comparative healthy tissue 305; the dermis is estimated to have a 
Young’s elastic modulus of 1-5 kPa, while fibrosed dermis measures 20-100 kPa. 
During the generation of a fibrotic scar, myofibroblast precursors are recruited, 
attain contractile features and thus contribute to the development of fibrosis 
304. Mechanical stress generated by the stiff, fibrotic ECM accelerates the 
expression of αSMA in fibroblasts 306 and promotes the survival of myofibroblasts 
in granulation tissue, leading to the formation of hypertrophic scar tissue 307. 
Myofibroblast contraction can also bring about the release of active TGFβ from 
its stored, latent form within the ECM 308. This is thought to occur through 
myofibroblast integrins mediating opening of the latent complex through stress 
fibre contraction. TGFβ is the primary pro-fibrotic factor and its release 
compounds the cycle of increasing ECM stiffness leading to myofibroblast 
activation, in part through enabling myofibroblasts to resist apoptosis 309.  
1.5.2 Fibrosis	of	the	tumour	stroma	
Several tumour types are known to arise on a background of pre-existing fibrosis, 
such as hepatocellular cancer as a consequence of chronic hepatitis 310, and lung 
cancer occurring in the context of interstitial lung diseases such as idiopathic 
pulmonary fibrosis 311. Tumours arising within fibrotic lesions are thought to 
develop through dysregulation of cell polarity, cell proliferation, and 
myofibroblast-stimulated inflammation and neo-angiogenesis 312. 
In addition to fibrosis observed in the context of wound healing, scar formation, 
and benign pathological processes, similar changes are observed in the fibrotic 
stroma that surrounds some tumours. The same pathways that activate 
fibroblasts, leading to deposition of ECM components and increased levels of 
contractility are at play within the reactive tumour stroma. Furthermore, 
myofibroblasts are present at the invading front of a number of different tumour 
types, including lung 313, liver 314, breast 312 and gastric 315 cancers. In this 
context, myofibroblasts are termed cancer associated fibroblasts (CAFs); they 
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are thought to contribute to cancer progression through the secretion of pro-
invasive cytokines and proteases 316-319. 
1.5.3 Cancer	associated	fibroblasts	
The primary difference between CAFs and myofibroblasts is the resistance to 
apoptosis displayed by the former; as a result of this, CAFs tend to persist for 
significantly longer, and their activation is irreversible 320. They are derived from 
a number of cell types, including resident fibroblasts 321, bone marrow-derived 
mesenchymal stem cells 322, and epithelial cells, the latter conversion occurring 
through the process of EMT 312 (Figure 1-10). 
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Figure 1-10 Origins of CAFs within the tumour microenvironment 
CAFs can develop through differentiation of dormant resident fibroblasts or pericytes via 
mesenchymal mesenchymal transition (MMT). They can also arise from bone marrow 
mesenchymal stem cells and from normal or malignant epithelial cells via EMT or from 
endothelial cells via endothelial to mesenchymal transition (EndMT). Adapted from Cirri and 
Chiarugi 320. 
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1.5.3.1 The	role	of	CAFs	in	tumour	initiation	
It has been shown that dermal fibroblasts isolated from patients with several 
types of cancer, including breast, melanoma and colon, display an increased 
proliferation rate in vitro, suggesting that changes in fibroblast phenotype may 
play a role in cancer initiation 323. Studies involving murine models of genetically 
modified fibroblasts have also indicated that fibroblasts participate in the 
initiation of tumours, with overexpression of growth factors such as TGFβ and 
HGF within fibroblasts promoting malignant transformation of mammary 324 and 
prostate epithelium 325.		
1.5.3.2 The	role	of	CAFs	in	tumour	progression	
CAFs produce several growth factors, permitting direct stimulation of tumour 
cell proliferation, and thus enabling tumour progression. For example, CAFs 
isolated from lung tumours secrete hepatocyte growth factor (HGF), activating 
c-MET signalling in cancer cells 326. In addition to growth factors, stromal CAFs 
produce cytokines, which promote immune cell infiltration and consequent 
vascularisation and metastasis 327, and MMPs, which can both degrade the 
adjacent ECM, allowing tumour expansion, and activate growth factors through 
cleavage 328,329. CAFs also play a role in determining cancer cell motility, mainly 
through the induction of EMT in cancer cells 330. Growth factors produced by 
cancer cells are also able to act on CAFs, leading to a pro-tumorigenic interplay 
between the tumour and stroma 331 (Figure 1-11). 
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Figure 1-11 Dialogue between CAFs and cancer cells 
Tumour progression depends on the interplay between CAFs and cancer cells. Cancer cells 
stimulate and maintain the activated fibroblast phenotype via growth factors (including TGFβ) 
and cytokines. In turn, fibroblasts produce PDGF, VEGF, MMPs and cytokines, promoting ECM 
remodelling, EMT, proliferation and angiogenesis, and thus tumour progression. Adapted from 
Cirri and Chiarugi 320. 
 
 
 
 
 
 
 
 
 
69 
 
The architecture of the tumour microenvironment is also subject to regulation 
by CAFs, as the components of the ECM are produced by activated fibroblasts. 
The density and constituents of the ECM impact on the stiffness of the 
microenvironment, and consequently alter cell morphology, cell signalling and 
cytoskeletal organisation 332 . Within the ECM around a tumour, fibrillar 
collagens display enhanced maturation, with increased cross-linking, catalysed 
by lysyl oxidase (LOX). LOX is expressed in fibroblasts during the initial phase of 
breast tumorigenesis; the cross-linked collagen fibres that develop as a 
consequence of this promote cancer cell migration and invasion. Treatment with 
LOX inhibitors reduces collagen cross-links and thus inhibits tissue stiffening and 
cancer progression 333. In addition to the action of LOX on collagen, increased 
ECM stiffness occurs through integrin signalling and discoidin domain receptor-1 
activation, and consequently leads to enhanced growth factor-mediated cell 
migration 334.  
In addition to collagen, CAFs also produce fibronectin, hyaluronan and tenascin 
C (TNC). Fibronectin participates in numerous cellular interactions with the ECM, 
mediating cell adhesion, migration and proliferation 335; its presence in stroma is 
positively correlated with metastatic potential and MMP production 336. 
Expression of hyaluronan by CAFs has been shown to enhance recruitment of 
tumour-associated macrophages, thus promoting tumour progression 337. 
Myofibroblast-derived TNC has been shown to stimulate colon cancer cell 
invasion through promotion of a migratory phenotype 338. 
Fibronectin and collagen bind to cells via integrins; however, hyaluronan 
functions through binding to a range of cellular receptors, including CD44, and 
the receptor for hyaluronan-mediated motility (RHAMM) 339.  
Increased stromal stiffness as a result of the accumulation of types I and III 
collagens, with concurrent increased breakdown of collagen type IV, results in 
the fibrotic condition termed desmoplasia 340 (Figure 1-12). Desmoplastic stroma 
is associated with a poor clinical outcome in a number of cancer types, including 
breast 341 and pancreatic 80,82; in part, this is due to the pro-invasive components 
of the ECM, and in part to the fact that fibrotic stroma impacts intra-tumoral 
drug delivery, rendering pancreatic cancer in particular relatively chemo-
insensitive 342. 
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Figure 1-12 The stages of stromal ECM remodelling 
In normal conditions, stromal collagen fibrils are wavy. In the pre-invasive stage, collagen fibres 
straighten and align around the tumour. In the invasive stage, collagen fibres are arranged 
parallel to the tumour border. Adapted from Malik et al 343. 
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1.5.4 Increased	cellular	tension	
In addition to the increased stiffness observed within the microenvironment, 
tumour cells themselves are frequently found to demonstrate higher levels of 
tension through over-expression of Rho GTPases 344. Furthermore, ROCK 
activation appears to promote tumour cell invasion 345. The increase in 
cytoskeletal tension that is generated by Rho-ROCK activation induces F actin 
assembly and promotes cell proliferation 346.	 The forces generated by 
cytoskeletal contraction also promote focal adhesion maturation 347.	The balance 
of mechanical stress can shift, either through interactions with other cells 348, or 
due to distortion of the cell membrane as an adaptation to changes in force in 
the environment 349. As a consequence, rearrangement of the cytoskeleton, 
proliferation and morphogenesis occur 350. 
1.6 Tenascins	
Using an RNA microarray approach, I found that ROCK activation in primary cells 
led to an increase in Tenascin C gene transcripts and protein level. It had 
previously been shown in the group that ECM components such as collagen are 
deposited in higher quantities in murine epidermis following ROCK activation 83. I 
hypothesised that TNC may be a constituent part of the dense, stiff ECM 
observed following ROCK activation, and opted to investigate this further. 
Tenascins are a family of oligomeric glycoproteins, located in the extracellular 
matrix 351; four members exist, denoted tenascin C, R, X and W. Of these, 
tenascin C (TNC) is the most extensively studied. All subtypes of tenascin share 
the same basic structure: amino-terminal heptad repeats, epidermal growth 
factor (EGF)-like repeats, fibronectin type III domain repeats, and a carboxyl-
terminal fibronectin-like globular domain. Individual subunits are able to 
assemble into trimers or hexamers due to heptad repeats lying in a highly 
conserved amino-terminal oligomerisation region. Each member of the family 
displays a different number of EGF-like and fibronectin type III repeats. TNC is 
the member of the family that I found to be upregulated in response to ROCK 
activation, and thus has been the focus of this section of my research. .  
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1.6.1 TNC	structure	and	expression	
The human TNC gene is found on chromosome 9q33 352. The 8150bp transcript 
encodes a protein 180-250 kDa in size 353. TNC is conventionally assembled into 
hexamers, and indeed is also known as hexabrachion. The protein subunits of 
TNC typically possess 14.5 EGF-like repeats, and 8 fibronectin type III repeats 
(Figure 1-13). A significant number of splice variants exists, due to alternative 
splicing of an additional 9 repeats that can be individually incorporated in the 
TNC structure 354 . Numerous TNC binding partners have been identified, 
including integrins 355, annexin II 356 , heparin 357, and fibronectin 358. The 
majority of binding sites are found in the fibronectin type III repeats or the 
fibrinogen globe; however, the EGF-like repeats are also thought to behave as 
ligands for EGF receptors (albeit with low affinity) 359.  
During embryogenesis, TNC is expressed at high levels in neural, vascular and 
skeletal tissues 360. In adults, low level expression persists only in tissues subject 
to mechanical loading (e.g. tendinous tissue 361; however, significant TNC 
upregulation occurs during wound healing 362,363, and in pathological conditions 
involving tissue remodelling such as inflammation, tumorigenesis 364 and 
hyperproliferative conditions (e.g. psoriasis 365). 
1.6.2 TNC	in	wound	healing	
Tissue injury prompts a well-recognised series of processes: inflammation, tissue 
rebuilding, and tissue remodelling 366 (Figure 1-14).  
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Figure 1-13 Structure of TNC 
The assembly domain (AD) at the N-terminus mediates the oligomerisation of the protein, where 
2 trimers form a hexamer. The fibronectin repeats are between the EGF-like repeats and the 
carboxy terminal fibrinogen globe. In humans, 9 of the 17 fibronectin repeats are alternatively 
spliced. Adapted from Lowy and Oskarsson 367. 
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Figure 1-14 TNC in tissue repair 
TNC interacts with disparate cell types during the different phases of wound healing. Adapted 
from Midwood and Orend 363. 
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1.6.2.1 Inflammation	
Upon tissue injury, TNC expression is rapidly induced. It appears to modulate 
inflammatory responses by stimulating the production of pro-inflammatory 
cytokines including TNFα, IL-6 and IL-8 368. Furthermore, during the acute 
inflammatory phase, TNC co-localises with polymorphonuclear lymphocyte 
infiltration in the dermis 369. TNC also appears to directly regulate T cell 
behaviour, with both anti-adhesive effects mediated by fibronectin binding 370 
and pro-adhesive effects through support of lymphocyte rolling 371. The differing 
roles are likely to be both context- and splice variant-dependent 372. TNC 
expression is observed at sites of inflammation secondary to e.g. incisional 
wounding 373 but also in states of pathological inflammation such as pulmonary 
tuberculosis 374 and autoimmune myocarditis 375, suggesting that TNC 
upregulation is an aspect of a non-specific inflammatory response. 
1.6.2.2 Tissue	rebuilding	
Re-epithelialisation 
Early wound closure is achieved by the proliferation and migration of 
keratinocytes through the fibrin clot. Within 24 hours of wounding, TNC 
expression is detected at the dermal/epidermal junction beneath the 
proliferating and migrating keratinocytes 362,373. Keratinocytes are the primary 
source of TNC in this context 376. Pathological skin conditions in which hyper-
proliferation of the epidermis is a feature, such as psoriasis 377 and bullous 
conditions 378 also display high levels of TNC expression under the epidermis. 
There is evidence to suggest that TNC may promote differentiation of epithelial 
cells during wound healing: in one study, TNC was discovered to provide a signal 
that drives differentiation via androgen receptor upregulation in the developing 
prostate gland 379. Furthermore, primary human epidermal keratinocytes display 
a rounded morphology when cultured on TNC substrates (containing TNC purified 
from the culture medium of glioblastoma cell lines), indicating that TNC may 
play a pro-adhesion, pro-migration role during re-epithelialisation376. 
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Fibroblast proliferation and migration 
Following wounding of the dermis fibroblasts infiltrate into the fibrin and 
fibronectin matrix-covered wound bed 380. The presence of TNC within the 
fibrin-fibronectin scaffold enhances fibroblast migration 381; one region of 
fibronectin type III-like repeats appears to be the critical domain of TNC in the 
promotion of migration. In contrast, another region of these repeats inhibits 
migration, indicating that differential proteolysis of TNC may dictate the 
termination of the wound healing process versus the prolonged, unwarranted 
fibroblast migration seen in pathological fibrosis.		
The EGF-like domain of TNC also regulates fibroblast proliferation and migration; 
the EGF-like repeats phosphorylate EGFR, thus activating the MAP kinase 
pathway in the NR6 fibroblast cell line 359.  
ECM synthesis 
In order to restore normal tissue architecture, new ECM must be deposited on 
the wound bed 382. TNC increases pro-collagen synthesis, promoting matrix 
deposition. It is difficult to determine if this is mediated via pro-inflammatory 
pathways leading to recruitment of collagen-synthesising cells or if TNC has 
direct effects on ECM deposition. In Tnc-null mice, collagen production was 
reduced in a model of immune-mediated hepatitis 383; however, the model 
involved intravenous injections of a pro-inflammatory compound (concanavalin 
A). In this context, Tnc-null mice exhibit attenuated inflammatory responses, 
potentially leading to a failure to recruit myofibroblasts and collagen-producing 
cells. 
Independent of its effects on inflammation, TNC does appear to impact growth 
factor production and myofibroblast activity. In a model of glomerulonephritis 
induced by snake venom 384, the inflammatory infiltrate seen in WT and Tnc-null 
mice was equivalent; however, the number of mesangial cells, which are 
responsible for tissue regeneration, was significantly lower in the Tnc-null mice, 
leading to irreversible, persistent kidney damage. In addition, platelet-derived 
growth factor (PDGF) expression was reduced, and TGFβ1, collagen type VI, and 
fibronectin induction were delayed in Tnc-null mice, while mesangial cells 
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isolated from these mice did not proliferate when stimulated with PDGF or 
TGFβ, indicating that the response to these growth factors is affected by the 
presence or absence of TNC. 
The functional subunit of TNC in this context appears to be TNIIIA2, a 
fibronectin-like repeat peptide that induces β1 integrin activation through 
syndecan-4 binding 357. Fibroblasts induced by TNC and the active peptide 
TNIIIA2 display enhanced integrin αvβ1 activation, resulting in hyper-stimulation 
of PDGF-dependent proliferation and attenuation of contact inhibition 385. 
There is also evidence that the addition of TNC to culture medium enhances 
EGF-induced proliferation of murine 3T3 fibroblasts 386. These data suggest that 
TNC regulates the synthesis of ECM components through regulation of cell 
migration and proliferation, and controlling the level of and cellular response to 
growth factors.  
ECM assembly 
TNC is known to directly interact with several ECM components: it is observed to 
co-localise with fibronectin fibrils and to areas of fibronectin accumulation 387. 
The assembly of a TNC matrix appears to depend on the existence of a 
fibronectin template 388. TNC can also bind to fibrillar collagen types I – VI and IX 
389, to periostin, forming a bridge between TNC and the ECM 390 and to 
proteoglycans including versican, aggrecan and neurocan 391. These data appear 
to support the theory that TNC can function as a matrix template, facilitating 
assembly of ECM components during the wound healing process.  
Neo-angiogenesis 
To enable new tissue to form and repair wounds, new blood vessel formation 
must take place. A strong association between TNC expression and sites of 
vascular remodelling during wound healing has been documented 362,373,392 . 
Endothelial cells are activated during the process of new blood vessel 
development, adopting a migratory phenotype 393. TNC expression appears to be 
increased preferentially in active endothelial cells as opposed to non-migratory 
endothelial cells 394 . Furthermore, the addition of TNC promotes endothelial 
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cell migration and reduces endothelial cell focal adhesions 356. These changes in 
the interface between endothelial cells and the ECM are accompanied by 
alterations in growth factors including vascular endothelial growth factor (VEGF) 
and basic fibroblast growth factor (bFGF) 395. TNC has been observed to regulate 
the levels of and the manner in which cells respond to these growth factors; 
absence of TNC leads to suppression of VEGF expression and a resultant 
reduction in neovascularisation 396. TNC also co-localises with endothelial 
progenitor cells at sites of angiogenic induction 397. Dual stimulation with bFGF 
and TNC also enhances endothelial cell proliferation 356. These data indicate that 
TNC plays a crucial role in vascular remodelling during tissue repair. 
Tissue remodelling 
In the final stages of wound healing, closure is facilitated by myofibroblast-
mediated wound contraction 398. Following contraction, myofibroblasts and 
vascular cells undergo apoptosis, reducing the cellularity of the region and 
permitting the transition from granulation tissue to scar 399. Upon completion of 
normal wound repair, TNC is no longer expressed 362,373,400 .  
Keloid scars are the consequence of excessive deposition of fibrotic tissue rich in 
fibrillar collagen 401; they extend outwith the borders of the original wound and 
are persistent, recurring after re-excision 402. TNC expression is elevated in 
keloid scars in vivo, and in fibroblasts isolated from keloid tissue, indicating that 
a failure to down regulate TNC expression at the end of the wound healing 
process may lead to inappropriate dermal fibrosis 403. Tumours have been 
thought of as wounds that do not heal 404; the clear role of TNC in the wound 
healing process has prompted further investigation into the part played by TNC 
in tumorigenesis and cancer progression. 
1.6.3 TNC	in	cancer	
The tumour stroma consists of immune cells, fibroblasts, blood vessels, and 
extracellular matrix components 405; the interplay between the “reactive” 
stroma and the tumour cells is increasingly recognised as an integral aspect of 
tumorigenesis. TNC is highly expressed in the stroma of most types of solid 
tumour 406, and has been found to facilitate the acquisition of a pro-invasive 
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phenotype by cancer cells through a number of mechanisms (Figure 1-15). Its 
expression is positively correlated with a poor clinical outcome in a number of 
tumour types, including glioma, breast, colon and lung cancers. 
The presence of several cytokines and growth factors in a tumour can induce 
TNC expression; these include TNFα, IFNɣ, interleukins 1, 4, 6, 8 and 13 407, and 
EGF, TGFβ 408, and CTGF. Within the stromal compartment, NFκB 409, ROS 410, 
hypoxia 411 and mechanical tension 302,412,413 are also capable of inducing TNC.  
Matrix metalloproteinases (MMPs) secreted by tumour and stromal cells can 
cleave TNC from the ECM, thus freeing it to participate in pro-tumorigenic 
signalling pathways 414,415 .	 Cleavage by MMP2 causes the release of a peptide 
that contains FNIIIA, a pro-adhesive site that enhances PDGF-mediated 
proliferation and resistance to anoikis 385. In the context of non-small cell lung 
cancer, TNC fragmentation is observed 416 and appears to be linked with poor 
clinical outcomes 417. 
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Figure 1-15 TNC in cancer 
TNC impacts on several cell types within the tumour and the tumour microenvironment. TNC 
promotes cell proliferation, migration, invasion, angiogenesis and metastasis, and inhibits cell 
adhesion. Adapted from Midwood and Orend 363. 
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1.6.3.1 Cell	proliferation	
The addition of TNC to tumour cell culture has been found to enhance cell 
proliferation 406,418. Furthermore, glioblastoma and breast carcinoma cells 
cultured on composite fibronectin/TNC substrates display a more proliferative 
phenotype and reduced adhesion 418. Increased proliferation has also been 
observed in 3-dimensional reconstructions of mammary epithelial tissues in vitro 
419. In addition, proliferation of cells in 3-D melanoma spheres is significantly 
attenuated by loss of TNC 420. An association has also been noted between the 
expression of TNC and the proliferation marker Ki67 in many solid tumours 421 .  
TNC appears to function in the stem cell niche, supporting cell proliferation and 
differentiation 422. This is the case with neural stem cells 423; studies illustrating 
a link between increasing TNC expression and advancing grade of glioblastoma 
indicate that TNC may also facilitate cancer stem cell proliferation 424. TNC is 
also detected in the haematopoietic stem cell niche 425, where it may facilitate 
stem cell recruitment, as evidenced by the attenuation in haematopoiesis seen 
in TNC null mice 426. 
TNC has also been noted to increase the stability and nuclear accumulation of β-
catenin in glioblastoma cells, with consequent induction of Wnt signalling and 
enhanced proliferation 427. Furthermore, the EGF-like repeats within TNC possess 
a significant, albeit low, affinity to EGFR, enabling them to bind the receptor 
and stimulate proliferation 359.   
1.6.3.2 Metastasis	
Cell adhesion 
Cell adhesion to ECM components causes engagement of integrins and syndecan-
4, in turn bringing about cell spreading. The initiation of integrin signalling leads 
to the formation of focal adhesions, facilitating cell-cell and cell-ECM 
interactions. The presence of TNC during cell adhesion impacts on how cells 
interact with the ECM; this relationship depends on the cell type, and whether 
entire TNC molecules or sub-fragments are available 428. Syndecan-4 is a co-
receptor that initiates integrin signalling when cells bind to fibronectin 429; in 
fibroblasts 430 and several tumour cell lines 418, TNC binds competitively to a 
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fibronectin type III repeat and prevents syndecan-4 activation. This is one 
mechanism by which TNC inhibits cell adhesion to fibronectin substrates. 
In addition, TNC appears to prevent the assembly of fibronectin matrices in cells 
cultured on mixed, fibrin-based fibronectin/TNC substrates 431. The absence of a 
fibronectin matrix has been observed as a characteristic of some tumour types 
432. Fibronectin matrix construction requires integrin activation, and also relies 
on cells adhering to fibronectin, which is inhibited by the action of TNC on 
syndecan-4. 
Epithelial-mesenchymal transition 
Epithelial-mesenchymal transition (EMT) is a process in which cells display 
reduced adhesion, increased cell motility, and loss of E-cadherin expression. 
TNC may play a role in EMT, as breast cancer cells undergoing TGFβ-mediated 
EMT produce TNC 433. Studies in colon cancer found that TNC derived from 
cancer cells was associated with the expression of genes comprising the EMT 
signature 434. Furthermore, adding TNC to the culture medium of breast cancer 
cells induced EMT-like change 435. 
Cell migration 
Cells adhere to a TNC matrix in a fashion labelled “intermediate”, i.e. the links 
between the cell and the ECM are not strong to the point of preventing 
detachment, but are sufficiently strong to permit the generation of contractile 
forces 436,437 . This facilitates cell motility and invasion in a number of malignant 
cell types, including colon cancer 338, ovarian cancer 438, laryngeal cancer 439 and 
glioma 440. TNC expression tends to be highest at the invasive front of solid 
tumours 364; an association between the presence of TNC at the invading front 
and poor clinical outcome is observed in a number of cancer types, including, 
prostate 441, mesothelioma 442, melanoma 443, and cholangiocarcinoma 444. 
A significant increase in the capacity of breast cancer cells to migrate has been 
observed following the over-expression of TNC splice variants, through both 
MMP-dependent and MMP-independent means 445. 
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Dissemination 
As cancer cells become non-adherent and develop migratory characteristics, 
they gain the ability to invade local structures and metastasise to distant 
locations. Cancer cells with the capacity to produce factors that support survival 
under stress have a distinct advantage over those cells that require factors 
produced by the metastatic “soil”. Breast cancer cells that express TNC 
demonstrate increased survival during the initial phases of colonisation, prior to 
the activation of stromal fibroblasts 446. As the micrometastatic deposit becomes 
established, the microenvironment becomes reactive, and subsequently 
produces TNC that contributes to maintaining the viability of the cancer cells 
446,447. Thereafter, upon settling within the metastatic niche, TNC engages the 
Wnt and Notch pathways 448, with a consequent impact on stem/progenitor cell 
signalling. 
TNC is consistently present in gene expression profiles predictive of metastatic 
disease in breast cancer 449,450; in addition, TNC expression levels are higher in 
cases of recurrent non-small cell lung cancer compared with the primary tumour 
451, and high expression is linked to the development of early metastatic disease 
in laryngeal and hypopharyngeal cancers 452.  
1.6.3.3 Promotion	of	angiogenesis	
In physiological conditions in adult vasculature, TNC expression is minimal; 
however, it is induced when blood vessels sustain damage, and is also evident 
during pathological angiogenesis in a number of conditions, including diabetes, 
inflammatory bowel disease and cancer 453. In a Tnc knock-out mouse model, 
tumours formed following the injection of melanoma cells displayed a significant 
decrease in angiogenesis, indicating that TNC is necessary for the development 
of new vasculature 454. It has been proposed that TNC may encourage a sprouting 
phenotype in endothelial cells in culture 394; furthermore, TNC reduces focal 
adhesions and thus promotes endothelial cell migration 356. VEGF levels, among 
other factors known to drive angiogenesis, are noted to be secreted at lower 
levels when stromal-derived TNC is absent 454, but the mechanism behind this 
remains unclear. 
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1.6.4 Impact	of	tissue	mechanics	on	TNC	
A role for mechanical stress in the regulation of TNC is suggested by tissues 
subject to high mechanical loads (e.g. tendons) displaying high levels of TNC 
387,455 . Furthermore, upregulation of TNC expression is induced by tensile strain 
410,456-458. These findings are particularly of interest in the context of cancer, as 
an association has been noted between the rigidity of the tumour 
microenvironment and tumour progression 332,333. This raises the possibility that 
increased mechanical tension in the tumour stroma may prompt the production 
of TNC, both within the ECM and in cancer cells, thus driving cancer progression 
through the mechanisms previously outlined. 
1.6.5 Megakaryoblastic	leukaemia	1	
Mechanical strain has been shown to induce TNC expression458; this appears to 
occur in an MKL1-dependent manner. MKL1 (megakaryoblastic leukaemia 1) 
belongs to the myocardin-related transcription factor (MRTF) family, a group of 
transcription factors that function as co-activators of serum response factor 
(SRF). MKL1 (also known as MRTFA) is one of the most potent SRF inducers 459. 
SRF relays cytoskeletal signals to the nucleus and is in turn influenced by 
alterations in actin dynamics 460. However, it has been shown that MKL1 can 
mediate TNC transcription secondary to increased mechanical stress in an SRF-
independent manner 461. Furthermore, there is evidence that MKL1 switches 
between SRF-dependent and SRF-independent gene regulation, with those genes 
being induced in a non-SRF manner showing correlation with more aggressive 
breast cancer subtypes 450. The implication is thus that mechanical strain, MKL1, 
TNC and aggressive malignant phenotypes are inter-linked. 
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1.7 Project	aims	
Colorectal cancer is a complex, multi-stage process with, in the majority of 
cases, a gradual transition from benign adenoma to malignant tumour. 
Determining that loss of LIMK2 occurs as tumours become more invasive was an 
important first step in assessing the potential role of LIMK2 as a tumour 
suppressor gene. This led to the first aim of my project: 
1. To characterise the mechanism by which LIMK2 expression is reduced in 
colorectal cancer. 
Hypothesis: LIMK2 downregulation occurs via epigenetic silencing and is 
associated with worse clinical outcomes. 
Subsequently, I wished to investigate the impact of altering the mechanical 
tension of the microenvironment through modulation of the actin cytoskeleton. 
This generated the second aim: 
2. To determine the consequence of ROCK activation on the composition of 
the extracellular matrix of the epidermis and to investigate if similar 
effects could be recapitulated through altering the cellular environment. 
Hypothesis: ROCK activation leads to deposition of ECM components in 
addition to collagen, and that increased tension within the cellular 
environment would replicate/enhance the effects seen following ROCK 
activation. 
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2 Materials and methods 
2.1 Materials	
2.1.1 Reagents	and	chemicals	
Reagent/Chemical Supplier 
4-Hydroxytamoxifen Sigma 
5-Azacytidine Sigma 
Ampicillin sodium salt Sigma 
Agarose Melford 
β-mercaptoethanol Invitrogen 
Bicinchoninic acid solution Sigma 
Bovine pituitary extract Lonza 
Bovine serum albumin Sigma 
Calcium chloride Lonza 
Copper (II) sulphate solution Sigma 
Dimethylformamide Sigma 
Dispase II Roche 
DMEM (Dulbecco's Modified Eagle Medium) Gibco 
DMSO (dimethyl sulfoxide) Sigma 
dNTPs Zymo Research 
Donor calf serum Gibco 
E.coli DH5α cells Invitrogen 
Eco R1 Invitrogen 
Epidermal growth factor Lonza 
Epinephrine Lonza 
Ethidium bromide Sigma 
Fetal bovine serum Gibco 
Fibronectin from bovine plasma Sigma 
G1000A Lonza 
G418 Formedium 
Ham's F12 nutrient mixture Gibco 
Hepes Free Acid Sigma 
Hydrochloric acid Fisher Scientific 
Hydrocortisone Lonza 
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Hyperladder I Bioline 
Hyperladder IV Bioline 
Insulin Lonza 
Kanamycin sulphate Sigma 
Keratinocyte Growth Medium 2 Lonza 
L-glutamine (200mM) Gibco 
NuPAGE 4-12% Bis-Tris gels Invitrogen 
NuPAGE MES SDS running buffer Invitrogen 
NuPAGE MOPS SDS running buffer Invitrogen 
NuPAGE Transfer buffer Invitrogen 
Page ruler Pre-stained Protein Ladder Thermoscientific 
Paraformaldehyde 16% aqueous solution 
Electron Microscopy 
Sciences 
Penicillin/Streptomycin Life Technologies 
Precision Plus ProteinTM   all blue standards Bio-Rad 
PureCol Advanced BioMatrix 
React 3 Invitrogen 
RG108 Tocris 
RNase A Qiagen 
RNase free DNase set Qiagen 
S.O.C. medium (Super Optimal broth with 
Catabolite repression) Invitrogen 
Sodium hydroxide Fisher Scientific 
Transferrin Lonza 
Transforming growth factor β (recombinant) Peprotech 
Trypsin EDTA (0.05%) Gibco 
Trypsin EDTA (2.5%) Gibco 
Vectashield mounting medium with DAPI Vector Laboratories 
ZymoTaq polymerase Zymo Research 
Table 2-1 List of reagents and chemicals 
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2.1.2 Kits	
Kit Supplier 
DyNamo Hot Start SYBR Green q PCR kit  Thermoscientific 
EZ DNA Methylation Gold Kit Zymo Research 
Luciferase Assay System with Reporter Lysis Buffer Promega 
QiaQuick Gel Extraction Kit Qiagen 
QiaQuick PCR Purification Kit Qiagen 
QiAmp Mini Kit Qiagen 
Quantitect Reverse Transcription Kit Qiagen 
RNeasy Mini Kit Qiagen 
TOPO TA Cloning Kit (pCR 2.1 TOPO vector with one 
shot top 10 chemically competent e.coli) Invitrogen 
Quantikine ELISA TGFβ1 R&D Systems 
SEAP Reporter Gene Assay, Chemiluminescent Roche 
pMet Luc Ready to Glow Luciferase Reporter Assay Clontech 
NE-PER Nuclear and Cytoplasmic Extraction Reagents Thermoscientific 
Table 2-2 List of kits 
 
2.1.3 Solutions	
Solution Recipe 
Agar plates 
85 mM NaCl, 1% (w/v) bacto trypton, 0.5% (w/v) yeast 
extract, 1.5% (w/v) agarose, antibiotic (100µg/ml 
ampicillin or 50µg/ml kanamycin) 
DNA loading 
buffer 
20 mM EDTA, 0.05% (w/v) bromophenol blue, 50% (v/v) 
glycerol 
L-broth 
85 mM NaCl, 1% (w/v) bacto trypton, 0.5% (w/v) yeast 
extract  
PBS 
170 mM NaCl, 3.3mM KCl, 1.8mM Na2HPO4, 10.6mM 
H2PO4 
SDS sample 
buffer 125 mM Tris-HCl pH 6.8, 6% (w/v) SDS, 30% glycerol,  
TBS 20 mM Tris-HCl pH 7.5, 136 mM NaCl 
TBST 21 mM Tris-HCl pH 7.5, 136 mM NaCl, 0.1% Tween 20 
Table 2-3 List of solutions 
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2.1.4 Antibodies	
Antigen Species Supplier Catalogue no. 
Alpha smooth muscle actin Mouse Abcam AB7817 
Alpha-tubulin Mouse Santa Cruz SC5286 
ER alpha Rabbit Santa Cruz SC543 
ERK2 Rabbit 
Cell 
signalling 9108S 
GAPDH Mouse Sigma G9295 
Lamin A/C Goat Santa Cruz SC6215 
Lamin B Goat Santa Cruz SC6217 
LIMK2 Rabbit Santa Cruz SC5577 
MKL1 (MRTF-A) Mouse Santa Cruz SC39867S 
Myosin light chain 2 Rabbit 
Cell 
signalling 3672 
Phospho myosin light chain (Thr 
18/Ser 19) Rabbit 
Cell 
signalling 3674S 
ROCK I/2 Rabbit Millipore 07-1458 
Tenascin C Mouse Sigma T3413 
Table 2-4 List of primary antibodies 
 
Antibody Supplier 
Catalogue 
number 
Alexa Fluor 680 goat anti-rabbit IgG Invitrogen  A21076 
Alexa Fluor 680 goat anti-mouse IgG Invitrogen  A21057 
DyLight 800 goat anti-rabbit IgG Thermo Scientific  35571 
DyLight 800 goat anti-mouse IgG Thermo Scientific  35521 
Donkey 800 anti-goat IgG Rockland 605-732-125 
Table 2-5 List of secondary antibodies 
All secondary antibodies were used at a concentration of 1:10000. 
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2.2 Cell	culture	techniques	
2.2.1 Origin,	maintenance	and	storage	of	cell	lines	
HCT116 and SW48 are adherent epithelial cell lines originally isolated from 
human colon adenocarcinomas. Both were grown in DMEM medium supplemented 
with 10% fetal bovine serum (FBS) and 2 mM L-glutamine. Cells were maintained 
at 37 °C, 5% CO2 in a humidified incubator and passaged every 3-4 days as 
follows: culture medium was removed; cells were washed once with PBS, and 
incubated in 0.05% trypsin for approximately 5 minutes. Cells were resuspended 
in culture medium, counted using a Casy® Innovatis cell counter, and an 
appropriate number of cells transferred to a new tissue culture dish with fresh 
medium. 
 
Human cell lines were authenticated by the Beatson Institute Molecular 
Technology Service using the Promega GenePrint 10 system.  
 
NIH 3T3 is an adherent mouse embryo fibroblast cell line. Cells were grown in 
DMEM medium supplemented with 10% donor calf serum. Cells were maintained 
and passaged as above, with the substitution of 0.25% trypsin. In addition to the 
parental cell line, NIH 3T3 cells stably expressing a conditionally active form of 
ROCK II (ROCK:ER, under the control of 4-hydroxytamoxifen), and a kinase dead 
(KD:ER) variant were also utilised. These had previously been generated in the 
laboratory, and were maintained in identical conditions to the parental cells. 
 
For long-term storage, all cell lines were frozen in liquid nitrogen vapour phase 
tanks. To prepare cells for freezing, healthy cells were harvested by 
trypsinisation as described above. They were then centrifuged at 1,200 rpm in 
an Eppendorf 5804R centrifuge for 5 minutes, and the cell pellet resuspended in 
DMEM medium supplemented with 10% FBS and 10% DMSO. 1 ml aliquots were 
transferred to cryogenic vials, and these were stored at -80 °C for 24 hours prior 
to placement in the liquid nitrogen tank. 
To thaw cells, cryogenic vials were transferred from the liquid nitrogen tank to a 
37 °C water bath; the contents were transferred to a new culture dish with fresh 
medium. 
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2.2.2 Treatment	of	cell	lines	with	DNMT	inhibitors	
5-Azacytidine (5-AZA) was prepared by dissolving 1.2 mg in 10 ml of DMEM to 
create a 500 µM stock solution. RG108 was prepared by dissolving 10 mg in 2990 
ml of DMSO to give a 1 mM stock solution. 24 hours after plating, culture medium 
was aspirated from HCT116 and SW48 cells and replaced with medium containing 
5-AZA (final concentration 10 µM), RG108 (final concentration 100 µM) or DMSO 
control (1%). Cells were cultured in treated medium for 48 hours before 
proceeding with RNA or protein lysate preparation.  
 
2.2.3 Culture	of	cell	lines	on	differing	substrates	
ExCellness® biomimetic culture surfaces were utilised to determine the impact 
of differing culture substrate stiffness on cells. Prior to use, the surface was 
washed with isopropanol, and subsequently coated with fibronectin (1 mg/ml) 
diluted in serum-free medium to a stock concentration of 2 µg of protein in 200 
µl of medium.  The coated plate was incubated at 37 °C for 16 hours, after 
which time the coating was aspirated from the plate prior to seeding cells. 
 
2.2.4 Plasmid	preparation	
SRE-SEAP and pMET LUC DNA constructs were a gift of Professor Chiquet-
Ehrismann (Friedrich Miescher Institute for Biomedical Research, Basel). 30 ng of 
DNA was added to a 50 µl aliquot of E.coli DH5α competent cells, and incubated 
on ice for 30 minutes. Following a 45 second heat-shock in a 42 °C water bath, 
the sample was incubated on ice for 2 minutes. 150 µl of SOC medium was 
added, and the sample was incubated in a polypropylene round-bottomed snap-
cap tube in a 37 °C shaking incubator for 1 hour.  
 
The transformation mixture was subsequently spread on an agar plate containing 
the appropriate antibiotic for selection, and incubated for 16 hours at 37 °C. 
Subsequently, 250 ml cultures of bacteria transformed with plasmid were grown 
at 37 °C in a shaking incubator for at least 16 hours. The culture was transferred 
to a 250 ml centrifuge tube, and centrifuged at 4000 rpm for 20 minutes at 4 °C 
in a Beckman-Coulter J6-M1 centrifuge. After removal of supernatant, DNA was 
isolated from the resulting pellet using the Invitrogen Purelink HiPure Plasmid 
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Filter Purification Kit following the manufacturer’s instructions. DNA isolation 
was performed by the Beatson Molecular Technology Services. 
 
2.2.5 Transfection	of	plasmid	DNA	
For promoter-reporter studies, NIH 3T3 ROCK:ER and KD:ER cells were 
transiently transfected with SRE-SEAP and pMET LUC plasmids as follows. Cells 
were seeded 24 hours prior to transfection at 4 x 104 cells per well in 24-well 
plates with complete DMEM. Lipofectamine 2000 transfection reagent, plasmid 
DNA and Optimem I Reduced Serum Medium (Optimem) were equilibrated to 
room temperature before commencing. SRE-SEAP plasmid DNA (5 µg) and pMET 
LUC plasmid DNA were diluted in 250 µl of Optimem, and 3 µl of Lipofectamine 
2000 was diluted in 50 µl of Optimem. 50 µl of diluted DNA was added to the 
diluted Lipofectamine 2000 and the mixture was incubated for 5 minutes at 
room temperature to permit transfection reagent/DNA complexes to form. 50 µl 
of the resulting mixture was added to the 500 µl of complete DMEM in each well, 
and the plate was incubated at 37 °C for 3-4 hours. Following this, the medium 
containing transfection complexes was removed and the cells were washed twice 
with complete DMEM, before fresh medium was added.    
 
2.2.6 Secreted	alkaline	phosphatase	assay	
To detect secreted alkaline phosphatase (SEAP), the Roche chemiluminescent 
SEAP reporter assay was used.  The plate of transfected cells was allowed to 
equilibrate to room temperature, and medium was transferred to 1.5 ml 
Eppendorf tubes. The medium was centrifuged at 13,200 rpm for 10 minutes; 50 
µl of medium was then added to 150 µl of dilution buffer in a clean tube, and 
incubated in a 65 °C water bath for 30 minutes to heat inactivate contaminating 
alkaline phosphatase activity. The samples were centrifuged at 13,200 rpm for 
30 seconds at room temperature, and transferred to ice. 50 µl of each sample 
was transferred to 1 well of a white 96 well plate, and 50 µl of inactivation 
buffer was added to each well and incubated for 5 minutes at room 
temperature. Substrate reagent was formed by adding 50 µl of alkaline 
phosphatase substrate to 950 µl of substrate buffer; 50 µl of the resulting 
mixture was added to each well of the plate, and the plate was gently rocked at 
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room temperature for 10 minutes. The plate was subsequently read on a Turner 
BioSystems Veritas ™ Microplate Luminometer. 
 
2.2.7 	Secreted	luciferase	assay	
To determine transfection efficiency, cells were transfected with pMET LUC 
plasmid. In order to detect secreted Metridia luciferase, the Clontech Ready-to-
Glow™ secreted reporter system was used. Following appropriate treatment of 
NIH 3T3 ROCK:ER and KD:ER cells, the culture plate was brought to room 
temperature, and 50 µl of medium was transferred to a white 96 well plate. 
Substrate/reaction buffer was formed by diluting lypophilized secreted 
luciferase substrate in substrate buffer and incubating at room temperature for 
15 minutes. This was further diluted 1:10 in reaction buffer, and 5 µl of 
substrate/reaction buffer was added to each sample. The plate was then read on 
a luminometer. 
 
2.3 Animal	studies	
2.3.1 Home	office	project	and	personal	licensing	
All animal work undertaken was reviewed and approved of in project and 
personal licenses issued by the UK Home Office. 
 
2.3.2 Animal	genotyping	
For routine genotyping, animals were ear-clipped at weaning and samples 
dispatched to Transnetyx molecular diagnostics for automated genotyping. 
 
2.3.3 Lifeact	GFP	mice	
The Lifeact GFP mouse was developed within the group by Dr Nicola Rath; GFP 
Lifeact was cloned into the pBigT plasmid and the animals were subsequently 
created by the Beatson transgenic facility. In order to achieve ubiquitous 
expression of Lifeact GFP, the mouse was crossed with a Deleter Cre mouse. GFP 
expression was verified by imaging the mouse using the IVIS® Spectrum in vivo 
imaging system. Thereafter, the mice were crossed with K14 KD:ER and K14 
ROCK:ER mice, and the offspring phenotyped using GFP goggles. GFP positive 
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mice were crossed to achieve homozygous KD or ROCK expression (confirmed by 
western blot following treatment of primary keratinocytes with 4-
hydroxytamoxifen). 
 
2.3.4 Isolation	of	primary	murine	keratinocytes	
Mice were euthanized either by cervical dislocation or by rising concentration of 
CO2, and the tail was subsequently removed near the base. The tail was washed 
with Povidone-Iodine solution, PBS-AF (PBS with fluconazole and streptomycin), 
and 70% ethanol, and the skin was peeled off and placed in a 10% Dispase II 
solution. Following 90 minutes incubation at 37 °C, the epidermis was separated 
from the dermis, washed in PBS and minced with a scalpel. The minced 
epidermis was transferred to a 50 ml Falcon tube containing 10 ml of 0.25% 
trypsin and incubated for 10 minutes at 37 °C, then agitated by pipetting up and 
down. Filtered FBS was added and the mixture was passed through a 70 µm then 
a 40 µm cell strainer. The resulting solution was centrifuged in an Eppendorf 
5804R centrifuge at 2,000 rpm for 5 minutes and the cell pellet was resuspended 
in PBS. Following further centrifugation, the cells were resuspended in 
Keratinocyte Growth Medium (KGM-2; 500 ml supplemented as below) and plated 
on PureCol-coated tissue culture dishes. The cells were maintained at 37 °C in a 
low (3%) O2 incubator. 
 
KGM-2 Supplement Volume 
Bovine pituitary extract 2 ml 
Human epidermal growth 
factor 
500 µl 
Insulin 500 µl 
Hydrocortisone 500 µl 
Transferrin 500 µl 
Epinephrine 500 µl 
Gentamicin (GA-1000) 500 µl 
Calcium chloride 83 µl 
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2.3.5 Treatment	of	primary	murine	keratinocytes	
Following 24 – 48 hours in fully supplemented KGM-2 medium, keratinocytes 
were washed twice with PBS then cultured in keratinocyte basal medium (KBM) 
with no growth factors or antibiotics. 4-hydroxytamoxifen (1 µM) or ethanol 
vehicle was added to medium, and cells were cultured at 37 °C for 16 hours 
before imaging, or preparation of RNA and protein lysates. 
 
2.3.6 Culturing	cells	in	hanging	drops	
In order to co-culture keratinocytes and fibroblasts, a technique of culturing 
both cell types in a suspended drop of medium was used. To do this, primary 
keratinocytes were isolated from K14 KD:ER and ROCK:ER animals as previously 
described, and grown in 6-well plates. On the 3rd day of culture, the cells were 
trypsinised with 500 µl of 0.25% trypsin, and transferred to a 14 ml Falcon tube 
with 3.5 ml of complete medium. Simultaneously, NIH3T3 fibroblasts stably 
expressing a TGFβ reporter were trypsinised in the same manner. The Falcons 
were centrifuged (at 2000 rpm for keratinocytes, 1200 rpm for fibroblasts) for 5 
minutes. The supernatant was removed, and the cells were resuspended in 8 ml 
of serum-free medium. After establishing the cell number with the Casy® 
Innovatis cell counter, both types of cell were centrifuged at 400 g for 5 
minutes. The supernatant was removed, and thereafter the cells were dyed 
using red (keratinocytes) and green (fibroblasts) fluorescent cell linker kits for 
general cell membrane labelling (Sigma). In summary, this was achieved by 
adding 500 µl of diluent C from the kit to the cell pellet and pipetting to mix 
gently. Dye solution was prepared by adding 2 µl of dye to 500 µl of diluent C; 
this was added to the cell suspension and mixed. The resulting suspension was 
incubated at room temperature for 3 minutes, then 1 ml of serum was added, 
followed by a further incubation at room temperature for 1 minute. 
Subsequently, the cells were centrifuged at 400 g for 10 minutes, and then 
centrifuged at 400 g for 5 minutes 6 times, with the supernatant being aspirated 
and the cells resuspended in complete medium at each step to ensure complete 
removal of the dye solution. After the final centrifuge, the cells were 
resuspended to a concentration of 6 x 105 cells/ml. 
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Meanwhile, a 10 cm tissue culture dish was filled with 20 ml of sterile water, 
and the lid was wiped with damp tissue to eliminate static. The lid of the plate 
was inverted and 10 µl drops of cell suspension (consisting of 5 µl of 
keratinocytes and 5 µl of fibroblasts) were placed on the lid. The lid was flipped 
over and placed on the plate over the sterile water with the drops hanging down 
from the lid. Thereafter, images of the drops were taken using the Olympus 
FV1000 confocal microscope. 
 
2.3.7 In	vivo	treatments	
2.3.7.1 Topical	tamoxifen	
K14 ROCK:ER and K14 KD:ER mice had topical 4-hydroxytamoxifen (4-HT) applied 
to both ears once daily for 21 days at a dose of 500 µg/ear. 4-HT was prepared 
by dissolving 50 mg in 2 ml of 100% ethanol. Animals were euthanized following 
the final application of 4-HT and ears were collected for histology. 
 
2.3.7.2 Tamoxifen	diet	
Baseline weight was recorded for K14 ROCK:ER and K14 KD:ER mice, and normal 
diet was replaced with tamoxifen  diet. The weight of the animals was 
rechecked 3 times per week to ensure <10% weight loss and the animals were 
euthanized on day 36. Dorsal skin was shaved, dissected, placed in formalin and 
submitted to histology. 
 
2.4 Epigenetics	studies	
2.4.1 Preparation	of	genomic	DNA	from	tissue	and	cell	lines	
2.4.1.1 Preparation	of	genomic	DNA	from	cell	lines	
Cells were trypsinised, centrifuged, and the supernatant removed to yield a cell 
pellet. The pellet was resuspended in 200 µl of PBS, and proteinase K (20 µl) and 
buffer AL (200 µl) added. The mixture was incubated at 56 °C for 10 minutes, 
followed by the addition of 200 µl of 100% ethanol.   
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2.4.1.2 Preparation	of	genomic	DNA	from	tissue		
Genomic DNA (gDNA) was prepared from paired frozen samples of colon tumour 
and normal colonic tissue. A 25 mg sample was minced and placed in a 1.5 ml 
microfuge tube. Subsequently, the QiaAMP Mini Kit was used to prepare gDNA 
following the manufacturer’s instructions. Briefly, 180 µl of lysis buffer (ATL) 
and 20 µl of proteinase K were added, and the sample was placed in an 
Eppendorf Comfort Thermomixer and agitated at 56 °C for a minimum of 2 
hours. 4 µl of RNAse A was added to the resulting mix to obtain RNA-free gDNA. 
200 µl of binding buffer (AL) was added to the sample and incubated at 70 °C for 
10 minutes, followed by brief centrifugation in an Eppendorf 5417R microfuge 
and the addition of 200 µl of 100% ethanol.  
 
Subsequent steps of the protocol were essentially the same for both cells and 
tissue: 
 
The mix was applied to a QiaAMP spin column and centrifuged at 8000 rpm for 1 
minute. The filtrate was discarded, and the column was transferred to a clean 
collection tube. Following two wash steps with 500 µL of buffers AW1 and AW2 
respectively, the column was incubated with elution buffer (AE) for 5 minutes at 
room temperature. The column was subsequently centrifuged at 8000 rpm for 1 
minute to elute gDNA.  
 
The concentration of the gDNA was determined using an Eppendorf 
BioSpectrometer; the sample was diluted in nuclease-free water and the 
absorbance at 260 nm was measured. 
 
2.4.2 Bisulphite	conversion	of	genomic	DNA	
Bisulphite conversion of gDNA was achieved using the EZ DNA Methylation Gold 
Kit (Zymo Research). In summary, the gDNA sample was made up to a volume of 
20 µl with nucleotide-free water. 130 µl of CT conversion reagent was added to 
the gDNA sample and mixed, and the mixture was run in an MJ Research PTL-200 
Peltier thermal cycler using the following programme: 
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Temperature Time 
98 °C  10 minutes 
64 °C 2.5 hours 
4 °C Up to 20 hours 
 
The sample was subsequently loaded into a Zymo spin column with 600 µl of M-
binding buffer, mixed and centrifuged at 13,000 rpm for 30 seconds. After 
discarding the flow-through, 100 µl of M-wash buffer was applied to the column, 
followed by a further centrifuge and 20 minute incubation with 200 µl of M-
desulphonation buffer. Following two additional wash steps with 200 µl of M-
wash buffer, 10 µl of M-elution buffer was applied to the column, which was 
centrifuged at 13,000 rpm for 30 seconds in a fresh collection tube to elute the 
converted gDNA. 
 
2.4.3 PCR	(for	bisulphite	sequencing)	
Oligonucleotides were designed using the Zymo Research primer design tool. The 
primer sequences are detailed below: 
Promoter Primer name Sequence 
Promoter A LIMK2 Forward A tttaaatatttggatttttggtatgttttgaaaggttg 
Promoter A LIMK2 Reverse A aaaaatattacaataaaaaaaccaaatctatcccac 
Promoter B LIMK2 Forward B tttagaggggtygtttgagtttttgagaattagggag 
Promoter B LIMK2 Reverse B ataaaataaaccraaactaacaaataactccccatc 
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A 50µl PCR mix was set up in a 200µl PCR tube as follows: 
 
Reagent Volume (µl) 
 
2x Reaction buffer 
Nuclease-free water 
Forward primer 
(10µM) 
Reverse primer (10µM) 
Template DNA (100ng) 
dNTPs 
Zymo Taq 
 
25 
18.1 
2 
2 
2 
0.5 
0.4 
 
Total 50 
 
The mix was run on a PCR thermal cycler using the following programme: 
 
Temperature Time 
94 °C 3 minutes 
40 cycles of: 
94 °C 
46 °C or 49 °C (depending on promoter) 
72 °C 
 
1 minute 
1 minute 
30 seconds 
72 °C 10 minutes 
4 °C ∞ 
 
Agarose gel electrophoresis was then utilised to confirm amplification of 
appropriately-sized PCR products. 
 
2.4.4 Agarose	gel	electrophoresis	
In order to make a 1% agarose gel, 1 g of agarose was added to 100 ml of 1xTBE 
in a 250 ml conical flask. The mix was microwaved at medium power for 3 
minutes, and then swirled to ensure the agarose was fully dissolved. 1 µl of 2 
µg/ml ethidium bromide was added and the mix was allowed to cool slightly. It 
was then poured into a gel tray with caster and comb, and left to set at room 
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temperature for 45-60 minutes. The gel was subsequently transferred to a Bio 
Rad gel tank, and 1xTBE was added, covering the gel by 1-2 mm. DNA samples 
were prepared with DNA loading buffer and added to the gel, with Hyperladders 
I and IV loaded simultaneously as markers. Gels were run at 100-120 V for 45-60 
minutes. Bands were subsequently imaged on a Syngene Genius Bio Imaging 
Transilluminator with the GeneSnap programme. 
 
2.4.5 PCR	Product	Purification	
PCR products were purified using the Qiagen Qiaquick PCR purification kit, 
following the manufacturer’s instructions. In summary, buffer PB was added to 
the PCR product (5 parts to 1 part), mixed, and applied to a Qiaquick Spin 
Column in a collection tube. The sample was centrifuged in an Eppendorf 5417R 
centrifuge at 13,200 rpm for 1 minute at room temperature. The flow-through 
was discarded and 750 µl of buffer PE was added to the Qiaquick column before 
centrifuging a further two times under the same conditions, with removal of 
flow-through between spins. The Qiaquick column was subsequently transferred 
to a clean collection tube, and 30 µl of Buffer EB was applied to the Qiaquick 
column membrane. Following 1 minute incubation at room temperature, the 
Qiaquick column was centrifuged for 1 minute at 13,200 rpm at room 
temperature.  The resulting eluted DNA was run on an agarose gel to confirm 
purification of PCR product.  
 
In the event of multiple products being visible on agarose gel electrophoresis, 
the Qiagen Gel Extraction Kit was utilised as follows: the appropriately sized 
band was excised from the gel with a scalpel and placed in a 1.5 ml Eppendorf 
tube. Three volumes of Buffer QG were then added to the gel band and the 
sample was incubated in a heat block at 50 °C for 10 minutes, with vortexing 
every 2-3 minutes. Following this, 1 volume of isopropanol was added to the 
sample and the mix was transferred to a Qiaquick Spin Column. This was 
centrifuged for 1 minute at 13,200 rpm, and the flow-through was discarded. 
500 µl of Buffer QG was added to the Qiaquick column, which was centrifuged 
for 1 minute at 13,200 rpm, followed by the addition of 750 µl of Buffer PE and a 
further 1 minute centrifuge. The flow-through was discarded, and the Qiaquick 
column was centrifuged for 1 minute before being transferred to a clean 
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collection tube. The subsequent elution steps using Buffer EB were as per the 
PCR purification protocol.  
  
2.4.6 Cloning,	transforming	and	sequencing	bisulphite-converted	
PCR	products	
The TOPO® TA cloning® kit was used to clone PCR products. Cloning reactions 
were set up in a PCR tube as follows: 
 
Reagent Volume 
Fresh PCR product 4 µl 
Salt solution 1 µl 
TOPO vector 1 µl 
 
The reagents were gently mixed, and incubated in a PCR thermal cycler for 30 
minutes at 23 °C. The reaction was then placed on ice. 2 µl of the TOPO® 
cloning reaction was added to one vial of One Shot® chemically competent 
E.coli on ice and mixed gently. The mixture was incubated on ice for 30 
minutes. Subsequently, the bacteria were heat-shocked by placing the vial in a 
42 °C water bath for 30 seconds, then immediately placed on ice. 250 µl of room 
temperature SOC medium was added, and the mixture was transferred to a 15 
ml polypropylene round-bottomed snap-cap tube. The tube was placed in a 37 
°C shaking incubator for 1 hour.  
 
Meanwhile, X-GAL (40 mg/ml in dimethylformamide) was spread over the 
surface of an ampicillin-containing agar plate and incubated at 37 °C until 
required. Following the 1 hour incubation, the transformation mixture was 
spread over the plate, which was then inverted and placed in a 37 °C incubator 
for a minimum of 16 hours.  
 
Following incubation, blue-white selection was used to pick 10 white colonies 
per plate with an inoculation loop. Each colony was placed in a snap-cap tube 
with L-broth (5 ml) and ampicillin (5 µl) and incubated at 37 °C in a shaking 
incubator for at least 16 hours. The samples were then centrifuged in a Beckman 
Coulter J6-M1 centrifuge at 2000 rpm for 15 minutes at 4 °C; the supernatant 
was discarded and DNA was isolated from the resulting pellets using a Qiagen 
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8000 robot. DNA was sequenced on an Applied Biosystems sequencer. DNA 
sequencing reactions were set up, and the samples loaded and precipitated 
following the Applied Biosystems DNA sequencing protocol. DNA sequencing was 
performed by the Beatson Molecular Technology Services.  
 
2.4.7 Restriction	enzyme	digestion	
Digestion of DNA with restriction endonucleases was performed in REact 3 buffer 
2 µl of 10 x) at 37 °C for 2 hours. 10 units of restriction enzyme (EcoR I) was 
added per 1 µg of DNA, and nuclease-free water was added to a total volume of 
20 µl. The reaction was stopped by adding 5 µl of 10 x DNA loading buffer. 
Digestion of DNA was confirmed by agarose gel electrophoresis as previously 
described. 
 
2.4.8 Analysis	of	sequencing	results	
DNA sequences were analysed on the CLC Genomics Workbench version 5.5.1. 
 
2.4.9 Methylation	specific	PCR	
Methylation-specific primers were designed for individual CpG islands within the 
promoter sequence using the Urogene Methprimer tool (Department of Urology, 
UCSF). One primer pair was specific to unmethylated and one to methylated 
DNA. The primer sequences are detailed below: 
 
Primer name Sequence 
Unmethylated forward tttgtattaaaaatataaaaattagtcga 
Unmethylated reverse gtactaaccaccatacccaacgta 
Methylated forward ttgtattaaaaatataaaaattagttga 
Methylated reverse catactaaccaccatacccaacata 
 
Following bisulphite conversion of gDNA, a PCR reaction was set up in a 200 µl 
PCR tube, and run on a thermal cycler. Agarose gel electrophoresis was 
subsequently used to differentiate unmethylated and methylated bands. 
 
103 
 
2.5 Cellular	protein	extraction	and	analysis	
2.5.1 Total	cell	lysate	preparation	
Cells are lysed to obtain soluble proteins. After placing the culture dish on ice, 
the cell culture medium was aspirated and the cells washed twice with ice-cold 
PBS. An appropriate volume of SDS lysis buffer was added to the culture dish 
(e.g. 30 µl per well of a 6-well plate), and a cell lifter used to scrape the cells 
from the surface of the dish. The resulting lysate was applied to a Qiagen 
Qiashredder column and centrifuged at 13,200 rpm for 1 minute. The 
homogenized lysate was transferred to a 1.5 ml Eppendorf microfuge tube and 
placed on dry ice for 1 minute. After thawing, the sample was centrifuged at 
13,200 rpm for 15 minutes at 4 °C. The supernatant was transferred to a fresh 
tube and the protein concentration was determined.  
 
2.5.2 Measurement	of	protein	concentration	
The Bicinchoninic acid (BCA) assay was used to determine the protein 
concentration of cell lysates. Protein standards were prepared using bovine 
serum albumin (stock concentration 2 mg/ml) in SDS lysis buffer at the following 
concentrations: 0.08, 0.1, 0.2, 0.4, 1 and 2 mg/ml. Samples were added to a 
Greiner Bio One 96 well plate: 10 µl of blank (SDS buffer alone) in triplicate, and 
10 µl of standards and samples. 200 µl of developing solution (bicinchoninic acid 
and copper sulphate; 50:1) was added to each well, and the plate was incubated 
at 37 °C for 45-60 minutes. After equilibrating to room temperature, absorbance 
was measured on a Molecular Devices Microplate reader. A standard curve was 
plotted, and sample concentrations thus determined.  
 
2.5.3 SDS-Polyacrylamide	gel	electrophoresis	
Separation of protein samples by molecular weight was achieved by SDS-
polyacrylamide gel electrophoresis. 8% Tris-glycine gels (recipe below) and 
NuPAGE Bis-Tris 4-12% gradient gels were used. Protein samples were prepared 
in SDS sample buffer and heated at 95 °C for 4 minutes. Samples were 
centrifuged briefly after heating, and loaded onto the gel alongside Precision 
Plus ProteinTM All Blue molecular weight marker or Thermo Scientific 
PageRulerTM Prestained protein ladder. 8% gels were run in tanks containing 1 x 
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SDS running buffer at 90 V for 2 hours 45 minutes; Bis-Tris gels were run in tanks 
containing 1 x NuPAGE MES or MOPS running buffer (depending on the expected 
molecular weight of the protein of interest) at 160 V for approximately 1 hour 30 
minutes. Subsequently, gels were used for western blotting. 
 
Reagent Separating gel Stacking gel 
Distilled water  46.4 ml 20.4 ml 
30% Acrylamide mix 26.6 ml 5.1 ml 
1.5 M Tris pH 8.8 25 ml - 
1.0 M Tris pH 6.8 - 3.75 ml 
10% SDS 1 ml 300 µl 
10% Ammonium 
persulphate 
1 ml  300 µl 
TEMED 60 µl 30 µl 
 
 
2.5.4 Western	blotting	
Proteins were transferred to ProtranTM nitrocellulose membrane in a Bio-Rad Mini 
Trans-Blot Cell® containing 1 x NuPAGE Transfer Buffer with 10-20% methanol. 
All transfers were run at 100 V for 1 hour. The membrane was stained with 
Ponceau red solution to verify equivalent loading, washed with distilled water, 
and blocked in 5% non-fat milk powder in TBS-T (TBS-TM) for 1 hour at room 
temperature. Primary antibodies were diluted to the desired concentration in 
TBS-TM) and membranes were incubated with the solution at 4 °C overnight. 
This was followed by three 5 minute washes in TBS-T, and 1 hour incubation in 
secondary antibody at the required concentration in TBS-TM at room 
temperature. The membrane was washed again: 10 minutes in TBS-T, 2 x 5 
minutes in TBS-T, and 10 minutes in TBS. The membrane was then scanned using 
the LI-COR Odyssey CLx system, and protein bands were visualised and 
quantified using Image Studio version 3.1.  
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2.5.5 Preparation	of	nuclear	and	cytoplasmic	extracts	
Following trypsinisation, cells were harvested with serum-containing DMEM, 
transferred into a 14 ml Falcon tube and centrifuged at 500 g for 5 minutes in an 
Eppendorf 5804R centrifuge. The medium was removed, and the pellet 
resuspended in 1 ml of cold PBS and transferred to a 1.5 ml Eppendorf tube. This 
was centrifuged in an Eppendorf 5415 centrifuge at 500 g for 3 minutes at 4 °C, 
and the supernatant was removed, leaving the pellet as dry as possible. 
Thereafter, the Thermoscientific NE-PER Nuclear and Cytoplasmic Extraction kit 
was used, following the manufacturer’s instructions. In summary, the volume of 
the cell pellet was estimated, and an appropriate volume of CER I (cytoplasmic 
extraction reagent I), with protease inhibitor, was added. This was vortexed for 
15 seconds, and incubated on ice for 10 minutes. Next, an appropriate volume of 
CER II was added, followed by vortexing for 5 seconds, and a 1 minute 
incubation on ice. The tube was again vortexed, and subsequently centrifuged at 
13,200 rpm for 5 minutes at 4 °C. The supernatant (cytoplasmic extract) was 
transferred to a clean, pre-chilled tube and kept on ice. The remaining pellet 
was suspended in an appropriate volume of NER (nuclear extraction reagent) 
with added protease inhibitor and vortexed for 15 seconds every 10 minutes for 
a total of 40 minutes. Following this, the tube was centrifuged at 13,200 rpm at 
4 °C for 10 minutes. The resulting supernatant (nuclear extract) was transferred 
to a clean, pre-chilled tube. Both cytoplasmic and nuclear extracts were 
homogenised using a Qiashredder spin column. Thereafter, the extracts were 
used for gel electrophoresis as previously described.  
 
2.5.6 TGFβ	ELISA	
An R&D Systems Quantikine ELISA kit was used to detect TGFβ in cell culture 
medium. In order to activate latent TGFβ to the immunoreactive form, acid 
reactivation and neutralisation is necessary. This was achieved by adding 200 µl 
of cell culture supernatant to 40 µl of 1 N hydrochloric acid, mixing, and 
incubating at room temperature for 10 minutes. 20 µl of 1.2 N sodium 
hydroxide/0.5 M HEPES was then added to neutralise the sample. The standard 
stock solution was used to produce a two-fold dilution series at the following 
concentrations: 31.2, 62.5, 125, 250, 500, 1000 and 2000 pg/ml. Subsequently, 
50 µl of assay diluent and 50 µl of standard or sample were added to each well 
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of the ELISA plate and incubated for 1 hour at room temperature. Following this, 
the plate was washed and 100 µl of TGFβ 1 conjugate was added to each well. 
This was incubated for 2 hours at room temperature, followed by washing and 
incubation with colour reagents. Stop solution was added after 30 minutes, and 
the optical density of each well was determined with SoftMax Pro 4.8 software 
on a Molecular Devices Microplate Reader set to 450 nm wavelength. 
 
2.5.7 TGFβ	Bioassay	
To determine the responsiveness of NIH3T3 TGFβ reporter cells, cells were 
plated at 1 x 105 per well of a 24-well plate, in DMEM supplemented with FCS. 24 
hours later, cells were washed with PBS, and serum-free medium was added. 
After 6 hours had elapsed, recombinant TGFβ was added at a range of 
concentrations (from 20 pg/ml to 5 ng/ml). Cells were incubated at 37 °C for 16 
hours. Subsequently, Promega luciferase reagents were prepared: a 1X solution 
of reporter lysis buffer was made up, and 10 ml of luciferase buffer was added 
to lypophilized luciferase substrate and mixed. Following this, the cells were 
washed with PBS and 100 µl of 1X reporter lysis buffer was added to each well. 
The plate was placed at -80 °C for 1 hour to ensure adequate cell lysis. After 
thawing, the plate was placed on a rocker at room temperature for 
approximately 5 minutes. The cells were scraped, and the lysates transferred to 
1.5 ml Eppendorf tubes on ice. These were vortexed for 10 seconds, and 
centrifuged at 12,000 g for 2 minutes at 4 °C in an Eppendorf 5415 centrifuge. 
The supernatant was transferred to a fresh tube, and 40 µl of each sample was 
added to a 96-well white plate. The plate was placed on a Turner Biosystems 
Veritas™ Microplate Luminometer, and automated injectors used to add 40 µl of 
luciferase assay reagent per well; the readout was recorded by GloMax® 
software.  
 
2.6 Microscopy	
2.6.1 Histological	tissue	collection,	fixation,	processing	and	staining	
Animals were euthanized by rising concentrations of CO2 and tissues were 
immediately dissected and fixed by immersion in 10% buffer formaldehyde. The 
fixed tissue was subsequently processed by the Beatson Institute Histology 
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Service, which undertook paraffin embedding, sectioning and staining. Samples 
were de-waxed prior to staining by immersing in xylene, and then rehydrated in 
97% ethanol and washed in deionised water. Slides were stained with 
haematoxylin and eosin (H&E). Additionally, samples were probed for the 
presence of TNC as follows: heat-induced antigen retrieval was performed with 
PT Module™ pH 8 EDTA retrieval buffer. After washing with Tris-buffered saline 
with tween (TBST), the samples were blocked with endogenous peroxidase for 5 
minutes, washed again, and blocked with ImmPRESS™ normal goat serum for 30 
minutes. Subsequently, the samples were incubated with mouse anti-TNC 
antibody (1:300; Sigma) for 40 minutes at room temperature. Following this, the 
slides were washed, and ImmPRESS™ anti-rat reagent was applied for 30 
minutes. Thereafter, they were incubated with 3,3’-Diaminobenzidine 
tetrahydrochloride for 10 minutes, washed and counterstained with 
haematoxylin Z for 7 minutes. Finally, the slides were washed and mounted.  
 
2.6.2 Immunofluorescence	
Cells were plated on autoclaved 13 mm coverslips in 24 well plates; following 
treatment, medium was aspirated from the well and cells washed, fixed with 4% 
paraformaldehyde, permeabilised with 0.3% Triton X100 and blocked with 1% 
BSA. Primary antibody was diluted to the required concentration in 1% BSA and 
applied to the coverslip for 1 hour at room temperature. The coverslip was 
subsequently washed before being incubated with secondary antibody for 1 hour. 
Thereafter, the coverslip was washed, inverted on Vectashield™ mounting 
medium on a glass slide, and sealed with nail polish. Cells were imaged on a 
Zeiss 710 upright confocal microscope, using a 40X oil objective and 1,3 
aperture. 
2.6.3 Time	lapse	microscopy	
K14 KD:ER Lifeact GFP and K14 ROCK:ER Lifeact GFP keratinocytes were isolated 
as described previously and plated on collagen-coated 6-well plates for 24 to 48 
hours. They subsequently underwent serum starvation and treatment with 4HT 
(1 µM) or ethanol vehicle. Bright field differential interference contrast (DIC) 
and GFP fluorescent time lapse microscopy images were acquired with a 10X 
objective using a Nikon Eclipse Ti microscope (with Perfect Focus System) with a 
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heated stage and 5% CO2 gas line. The plated cells were placed on the 
microscope immediately following treatment, and time lapse images were taken 
every 10 minutes for 24 hours using a CoolSNAP HQ2 camera with 0.3 aperture. 
The resulting images were analysed using MetaMorph® software.  
2.7 Gene	expression	studies	
2.7.1 Preparation	of	RNA	from	primary	keratinocytes	
In order to prepare RNA from primary keratinocytes, cultured cells were washed 
with PBS and trypsinised with 0.25% trypsin. Medium was added to the 
trypsinised cells, and the mix was centrifuged at 14,000 rpm for 10 minutes at 4 
°C. The supernatant was removed, and RNA was isolated from the resulting cell 
pellet. 
Using the RNeasy Kit (Qiagen), the cells were lysed with lysis buffer, then 
homogenised in a Qiashredder spin column. 70% ethanol was added to the 
resulting flow through, and the mix was passed through the RNeasy spin column 
to bind the RNA. Following a wash step, to reduce the possibility of DNA 
contamination the RNase-free DNase set was used to digest DNA on the spin 
column. The solution was prepared by adding 10µl of RNase-free DNase I to 70 µl 
of RNase-free buffer and mixing. This was then added directly to the column 
membrane and incubated at room temperature for 15 minutes. Subsequently, a 
further two wash steps were followed by elution of the RNA in RNase-free water. 
2.7.2 Determination	of	RNA	concentration	and	quality	
Concentration of RNA samples was determined using the Qubit® Assay, 
comprising a fluorescent dye that binds to RNA and emits a signal that can be 
read in the Qubit® fluorometer.  
 
To determine the integrity of RNA samples, the Agilent Bioanalyzer RNA 6000 kit 
was used. Gel matrix was filtered by applying to a spin column and centrifuging 
for 10 minutes at 4000 rpm in an Eppendorf 5417R microfuge. 1 µl of dye 
concentrate was added to a 65 µl aliquot of filtered gel, vortexed, and 
centrifuged at 13,200 rpm for 10 minutes. The gel-dye mix was applied to the 
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microfluidic chip, and RNA samples were loaded into the appropriate wells. The 
chip was vortexed, and run in an Agilent Bioanalyzer 2100. 
 
2.7.3 Quantitative	Real	Time	PCR	
To carry out quantitative RT PCR, complementary DNA (cDNA) was prepared 
from RNA samples using the Quantitect Reverse Transcription kit. The initial step 
involved a genomic DNA elimination reaction, in which 2 µl of gDNA wipeout 
buffer was added to 1 µg of template RNA, and nuclease-free water added to a 
total volume of 14 µl. The mixture was incubated at 42 °C for 2 minutes in a PCR 
thermal cycler, and added to a reverse transcription mix, consisting of 1 µl of 
reverse transcriptase, 4 µl of RT buffer, and 1 µl of RT primer mix. The resulting 
solution was incubated in a thermal cycler as follows:  
 
Temperature Time 
42 °C 15 minutes 
95 °C 5 minutes 
  
Thereafter, resulting cDNA samples were diluted to 1:5 with nuclease-free 
water; 10 µl of each sample was pooled and standards were prepared at the 
following concentrations: 0.01, 0.04, 0.2, 1. A reaction mixture was then 
prepared as follows (volumes for 1 reaction): 
 
 
Component Volume 
Master mix 
Nuclease-free water 
Primer 
ROX passive reference dye 
10 µl 
6.1 µl 
2 µl 
0.4 µl 
Total 18.5 µl 
 
NB. Master mix contains hot-start polymerase, SYBR green, PCR buffer, 5 mM 
MgCl2, and dNTP mix.  
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The reaction mixture was then dispensed into a MicroAmp® Fast Optical 96 well 
reaction plate, and 1.5 µl of standard or sample was added to each well. The 
plate was covered with optically transparent sealing film, and run on an Applied 
Biosystems 7500 Fast Real-Time PCR System. Data were analysed on Applied 
Biosystems 7500 Software version 2.0.5.  
 
2.7.4 RNA	microarray	
Affymetrix mouse gene 1.0 ST array was performed on RNA samples by the 
Molecular Core Biology Facility at the CRUK Manchester Institute. 
 
2.7.5 RNA	sequencing	
Next-generation RNA sequencing was carried out on the Illumina® NextSeq 500 
platform by the Beatson Institute Molecular Technology Services. Data were 
analysed by the Computational Biology department at the CRUK Beatson 
Institute. 
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3 The role of LIM kinases as potential tumour 
suppressor genes in colorectal cancer 
3.1 LIM	kinases	in	colorectal	cancer	
The LIM kinases (LIMK 1 & 2) play a downstream role in the Rho/ROCK pathway 
in the regulation of actin-myosin cytoskeletal dynamics; they act by 
phosphorylating cofilin on serine 3 and inactivating its F-actin severing function, 
thus regulating actin filament dynamics. It has been proposed that the balance 
of phosphorylated versus non-phosphorylated cofilin, under the influence of 
LIMKs, may participate in determining the metastatic potential of a cancer cell.  
Using Oncomine®, it was identified that LIMK2 expression was down-regulated in 
colorectal cancer (CRC), and a statistically significant reduction in LIMK2 levels 
in adenocarcinoma samples relative to normal colon tissue in CRC microarray 
datasets was observed (Figure 3-1). In addition, a progressive reduction in LIMK2 
levels with increasing tumour stage was noted, and a statistically significant 
positive correlation between low LIMK2 levels and poor patient outcomes has 
been shown 224. It was also found that LIMK2 expression in CRC cell lines is lower 
than levels observed in normal colon cell lines (Figure 3-2). 
 
The “cell of origin” in CRC is understood to be the intestinal crypt stem cell, 
which functions as a self-renewing multipotent cell capable of regenerating the 
intestinal epithelium. LIMK2 was found to impede intestinal stem cell 
proliferation in both Drosophila melanogaster and murine models, implying that 
reduced LIMK2 expression may permit intestinal stem cells to proliferate without 
restraint.  
 
Based on these findings, it was proposed that loss or silencing of LIMK2 may play 
an important role in the initiation and progression of CRC.  
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B      C 
 
Figure 3-1 LIMK2 expression is down-regulated in colorectal cancer versus normal colonic 
tissue 
A) Log2 median-centred LIMK2 mRNA expression in normal versus adenocarcinoma tissue samples 
from Kaiser et al 462 (left side) and The Cancer Genome Atlas Network 463 (right side). B) Log2 
median-centred LIMK2 mRNA expression in microdissected healthy lamina propria or epithelia 
versus corresponding adenoma or carcinoma from Skrzypczak et al 464. C) Log2 median-centred 
LIMK2 mRNA expression in normal versus carcinoma samples from Skrzypczak et al 464 (left side) 
and Hong et al 465 (right side). Statistical significance was determined by one way analysis of 
variance followed by Tukey’s post-hoc tests. 
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Figure 3-2 LIMK2 expression in normal colon versus CRC cell line. 
Western blot of lysates prepared from HCT116 and SW48 (CRC cell lines) and from normal human 
colon confirms higher expression of LIMK2 in healthy colon tissue compared to colon cancer. α-
tubulin served as a loading control. 
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3.2 Epigenetics	
By a process known as DNA methylation, DNA molecules can be altered 
covalently by the attachment of methyl groups to cytosine bases; this 
modification has been shown to be as important as mutation in altering gene 
expression 270. A class of enzymes known as maintenance methylases functions to 
maintain the methylation state of a DNA sequence through multiple rounds of 
DNA replication 466; thus, DNA methylation can be considered a heritable 
property. However, as DNA methylation does not alter the nucleotide sequence 
it is regarded as an epigenetic, as opposed to genetic, mechanism. De novo DNA 
methylation also occurs, primarily during embryogenesis and cell differentiation 
467; it is mediated by DNMT3a and DNMT3b 468.  
 
It is well established that the disruption of normal epigenetic patterns can occur 
in the early phases of tumorigenesis, and continue to accumulate throughout 
tumour progression 469. Aberrant DNA methylation, with the excessive addition of 
methyl groups to the 5’ position of cytosine nucleotides in gene promoter 
regions, leads to silencing of gene transcription. This is of particular relevance in 
the context of tumour suppressor genes 470. Conversely, global hypomethylation 
can result in the expression of previously suppressed genes, and has been 
implicated in genetic instability and cancer progression. 
 
3.3 Hypotheses		
Thus, the hypotheses that LIMK2 may function as a tumour suppressor gene in 
CRC and that its down-regulation may be under the influence of 
hypermethylation of the gene promoter region were proposed.  
3.4 Assessing	methylation	status	
To assess the methylation status of a DNA sequence, a number of options are 
available. These include (1) methylation-specific PCR (MSP) and (2) bisulphite 
sequencing, both of which entail initial conversion of DNA with sodium 
bisulphite, modifying unmethylated cytosines to uracil whilst leaving methylated 
cytosines unaltered. Thereafter, in the case of MSP, primers are designed that 
utilise the sequence differences following bisulphite conversion to amplify either 
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methylated or unmethylated DNA. Whilst this technique provides useful 
information on methylation of “blocks” of CpG dinucleotides, it has limitations 
in that it gives a fairly crude “yes or no” outcome. In contrast, bisulphite 
sequencing relies on the design of primers that do not contain CpGs, so that PCR 
amplification does not depend on methylation status; this provides an unbiased 
approach, with no presupposition of the degree of methylation of the sequence 
of interest. In addition, bisulphite sequencing enables a more accurate and 
detailed assessment of methylation status of individual CpGs within the 
sequence. I elected to adopt both approaches; however I chose to focus my 
efforts on bisulphite sequencing for the aforementioned reasons. 
 
3.5 LIMK2	promoters	are	methylated	in	CRC	cell	lines	
3.5.1 Methylation-specific	PCR	
To establish if methylation status was influencing LIMK2 expression, I cultured 
two human CRC cell lines: HCT 116 and SW48. These had previously been shown 
to have reduced LIMK2 levels compared with normal colon. I designed 
methylation-specific primers: one pair specific for methylated DNA and one pair 
specific for unmethylated DNA. I prepared genomic DNA from the cells; this was 
bisulphite converted, a process in which, on exposure to bisulphite, 
unmethylated C nucleotides undergo conversion to T nucleotides, while 
methylated CpGs are resistant to conversion and are unaltered. I carried out 
methylation-specific PCR on the converted samples, confirming that LIMK2 
promoter B is methylated (Figure 3-3). 
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Figure 3-3 Methylation-specific PCR on CRC cell lines. 
Genomic DNA was prepared from HCT116 and SW48 CRC cell lines. Following bisulphite 
conversion, PCR using primer pairs specific for methylated and unmethylated DNA was carried 
out. Primer pairs A1 and A2 were targeted to LIMK2 promoter A; primer pair B was targeted to 
LIMK2 promoter B. M = methylated, U = unmethylated. A band is visible in the appropriate 
location in the “methylated” primer B reaction, indicating that promoter B is predominantly 
methylated as opposed to unmethylated. 
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3.5.2 Bisulphite	sequencing		
To elucidate the degree of methylation, I went on to design oligonucleotides 
(using the Zymo Research bisulphite primer seeker programme) with the 
capability to amplify both methylated and non-methylated DNA (after identifying 
CG-rich sequences in the region of both LIMK2 promoters). In order to optimise 
the bisulphite sequencing method, multiple primer pairs were designed and 
trialled. In addition, both temperature and magnesium gradients were utilised, 
as PCR on bisulphite-converted gDNA is notoriously difficult to perfect. 
Ultimately, the correct primer pair and optimal conditions with regard to 
temperature and magnesium concentration were established and used in all 
experiments going forward. I then performed PCR on the bisulphite-converted 
genomic DNA from HCT116 and SW48 cell lines, and carried out agarose gel 
electrophoresis on the PCR products. Following purification, the products were 
cloned, transformed and sequenced. On obtaining sequences for 10 clones from 
each cell line, I analysed the DNA sequences using the CLC Genomics Workbench 
(version 5.1.1). This enabled a direct comparison between the unmodified LIMK2 
promoter sequences, and the bisulphite converted promoter sequences. I could 
thus identify individual CpG subunits that had remained resistant to conversion 
and could therefore be deemed methylated. Analysing 10 separate clones 
allowed me to determine a map of the methylation status of the promoter 
regions in the CRC cell lines (Figure 3-4).   
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Figure 3-4 Schematic of methylation status of individual CpG dinucleotides 
Each panel shows the methylation status of individual CpG dinucleotides as determined by 
bisulphite sequencing; each horizontal row represents a single clone. HCT116 promoter A 
demonstrates 94.3% CpG methylation; promoter B demonstrates 88.6% CpG methylation. SW48 
promoter A and promoter B demonstrate 95.7% CpG methylation. 
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3.6 Treatment	with	DNMTi	leads	to	upregulation	of	LIMK2	
expression	in	CRC	cell	lines	
 
It is well established that aberrant gene promoter methylation is a pivotal 
mechanism of tumour suppressor gene inactivation and many genes, including 
p15INK4B and E-cadherin 471,472, are inactivated by promoter hypermethylation. 
It has previously been shown that treatment with DNA methyltransferase (DNMT) 
inhibitors such as 5-AZA-2’-deoxycytidine causes re-expression of genes silenced 
through promoter hypermethylation. Both 5-Azacytidine (5-AZA) and 5-AZA-2’-
deoxycytidine are converted to deoxynucleotide triphosphates and subsequently 
incorporated in place of cytosine as azacytosine into replicating DNA when cells 
are in S-phase 473. DNA demethylation as a consequence of Azacytidine exposure 
is observed following extended drug exposure, typically 48 hours 474, a time 
period that permits a sufficient number of cell division cycles for incorporation 
into the DNA to occur 475. Thus, in the presence of DNMT inhibitors, there is a 
progressive loss of DNA methylation as cells continue to grow and divide. 
 
In order to determine if the reduction in LIMK2 levels observed in CRC cell lines 
is under epigenetic control, I again used HCT116 and SW48 cells. 24 hours after 
plating the cells in 6 well plates at 2 x 105 cells per well, I treated the cell lines 
with DNMT inhibitors, compounds that are capable of inhibiting the transfer of 
methyl groups to DNA by preventing the activity of DNA methyltransferases. I 
used the well-characterised DNMT inhibitor 5-Azacytidine (5-AZA; final 
concentration 10 µM), and the novel DNMT inhibitor RG108 (final concentration 
100 µM), with dimethyl sulfoxide (DMSO) vehicle 1% as a control. Following 48 
hours of treatment with the DNMT inhibitors, I confirmed by western blot that 
there was an increase in the protein level of LIMK2 when compared with the 
vehicle-treated SW48 cell line (Figure 3-5). This effect was not observed in the 
HCT116 cell line. 
 
There is some evidence that genes that undergo demethylation following 
treatment with DNMT inhibitors display enrichment of transcription factor 
binding motifs; this may interfere with maintenance methylation at specific 
regions of the new DNA strand during replication and thus potentially facilitate 
non-random demethylation at specific loci 202,476. It is therefore possible that 
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both direct and indirect effects of DNMT inhibition on LIMK2 are responsible for 
the alterations in expression observed. 
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Figure 3-5 Treatment with DNMTi increases LIMK2 expression in CRC cell lines 
A. Representative western blot showing an increase in LIMK2 levels in SW48 cells following 48 
hours of treatment with the DNMT inhibitors 5-Azacytidine and RG108 versus DMSO vehicle 
control. α-tubulin was used as a loading control to ensure equivalent protein concentrations. All 
antibodies used at a concentration of 1:1000. B. Quantification of fold change in LIMK2 relative 
to α-tubulin in SW48 cells. Arbitrary units, n = 1.  
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3.7 Treatment	with	DNMTi	reduces	methylation	of	the	
LIMK2	promoters	in	CRC	cell	lines	
Having previously confirmed that DNMT inhibitor treatment led to increased 
protein levels of LIMK2, I next wanted to investigate the DNA methylation profile 
of the gene promoters following exposure to DNMT inhibition. In order to do so, I 
again used HCT116 and SW48 cells and treated them with 5-AZA and RG108. 
Vehicle-treated cells were again used as a comparator. Following 48 hours of 
treatment, I carried out bisulphite sequencing as described previously; this 
confirmed that the number of methylated CpG dinucleotides was lower in cells 
treated with 5-AZA than in those treated with vehicle (Figure 3-6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
123 
 
A 
 
 
 
 
 
 
 
 
 
 
124 
 
B 
 
Figure 3-6 CpG methylation in CRC cell lines treated with 5-Azacytidine 
SW48 cells were treated with 5-Azacytidine or DMSO vehicle for 48 hours. Subsequently, genomic 
DNA was prepared and bisulphite converted as described previously and, following amplification, 
PCR products were cloned and sequenced. A) Each panel shows the methylation status of 
individual CpG dinucleotides as determined by bisulphite sequencing; each horizontal row 
represents a single clone. B) The schematic shows the location of the CpG islands in relation to 
the transcriptional start sites for the LIMK2a and LIMK2b promoters. The pie charts show the 
degree of methylation of untreated CpG dinucleotides versus 5-Aza treated dinucleotides. The 
degree of methylation following DNMT inhibitor treatment decreased in both the LIMK2a 
promoter and LIMK2b promoter. With permission from Lourenço et al 224. 
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3.8 The	LIMK2	promoters	are	significantly	more	
methylated	in	human	CRC	tumour	samples	than	in	
normal	colonic	tissue	
Having established that expression of LIMK2 is dependent on the methylation 
status of the promoters in vitro, I next wished to investigate the role of 
methylation in human CRC. To do so, I obtained matched samples of normal 
colon and colonic adenocarcinoma (through collaboration with Professor Graeme 
Murray, Pathology Department, Aberdeen University). I initially wanted to 
investigate a range of stages of disease, to reflect the stepwise progression that 
occurs in the development of CRC. CRC is conventionally staged by the Duke’s 
system (Dukes, C. E. (1932), The classification of cancer of the rectum. J. 
Pathol., 35: 323–332. doi: 10.1002/path.1700350303); however, I felt that 
Duke’s stage C encompasses too many potential variables as the primary tumour 
can be of any degree of invasiveness in the presence of lymph node disease. 
Therefore, I elected to focus my efforts on Duke’s stage A and stage B tumours.  
I acquired paired samples from 6 patients, 3 representing each different stage of 
CRC, with matched normal tissue from the same patients. I prepared genomic 
DNA from the healthy tissue and the tumour samples, and carried out bisulphite 
sequencing using primers for LIMK2a and LIMK2b promoters. After selecting 10 
clones for each sample, I again used the CLC Genomics Workbench to analyse 
the degree of CpG methylation.  
 
I discovered that normal colon samples had significantly lower CpG dinucleotide 
methylation than colon adenocarcinoma samples (Figures 3-7 and 3-8). 
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  % methylation normal % methylation tumour 
Promoter A 57.1 87.1 
Promoter B 68.6 84.3 
 
Figure 3-7 Tumour samples show a greater degree of methylation than matched healthy 
tissue 
Bisulphite sequencing confirms that individual CpG dinucleotides display higher levels of 
methylation in tumour samples compared to healthy colon from the same individual. 
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Figure 3-8 CpG methylation of LIMK2a and LIMK2b promoters in paired normal and tumour 
samples. 
A) Schematic indicates the position of CpG islands relative to the transcriptional start site for 
each promoter. The pie charts indicate the proportion of methylation from multiple independent 
clones for each CpG island in the bisulphite-converted genomic DNA of a representative patient. 
B) Cumulative LIMK2a and LIMK2b promoter methylation from matched healthy and tumour 
tissue obtained from six patients with CRC. Statistical significance determined by one way 
analysis of variance followed by Tukey’s post-hoc tests. 
 
 
 
128 
 
I next wanted to determine if a relationship existed between the stage of the 
tumour and the degree of methylation of CpG islands. I therefore analysed the 
degree of methylation of Duke’s A versus Duke’s B tumours, with the matched 
normal tissue also categorised as per the stage of the patient’s tumour. I found a 
trend towards increasing methylation of the LIMK2a and LIMK2b promoters with 
increasing depth of invasion of the primary tumour (Figure 3-9). 
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Figure 3-9 Methylation status of LIMK2a and LIMK2b promoters by Duke’s stage 
A trend towards increasing CpG methylation is observed in tumour samples obtained from 
patients with Duke’s B tumours versus Duke’s A tumours. Duke’s A promoter A versus Duke’s B 
promoter A: p = 0.0686. Duke’s A promoter B versus Duke’s B promoter B: p = 0.0682 (unpaired t 
test). A larger sample size would be necessary to establish if a significant relationship does exist 
between advancing tumour stage and degree of methylation. 
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3.9 LIMK2	deficiency	in	mouse	models	of	colorectal	cancer	
I subsequently wanted to investigate whether Limk2 deletion in a CRC animal 
model would promote the development and progression of CRC. This work was 
undertaken with Dr Filipe Lourenço. The Limk2 knock-out mouse model was 
developed by obtaining Limk2 gene-trap embryonic stem cells from the European 
Conditional Mouse Mutagenesis Program (EUCOMM); the Beatson transgenic 
facility subsequently performed blastocyst injections using a standard approach. 
The gene-trap targeted the second intron of the Limk2 gene, thus preventing the 
expression of a functional protein. Gene trapping is an approach through which a 
promoterless reporter construct is integrated into a gene expressed in an 
embryonic stem cell. The gene trap cassette is flanked with genomic sequences, 
enabling the insertion to be directed precisely into introns of genes by 
homologous recombination 477. Genotyping of the mice was carried out by 
Transnetyx molecular diagnostics, with the desired phenotype (Limk2-KO) being 
present in 26.8% of animals at birth. Mice homozygous for gene-trapped Limk2 
loci were validated by immunofluorescence, which showed no Limk2 or 
phosphorylated cofilin expression in the intestine (compared with Limk2-WT 
mice) 224. In the first experiment, performed by Dr Lourenço with my assistance, 
8 – 12 week-old Limk2 wild-type (WT) and knock-out mice underwent a single 
intraperitoneal injection of azoxymethane (AOM) solution at a dose of 12.5 
mg/kg. AOM is metabolised by cytochrome P450, ultimately forming 
formaldehyde and a highly reactive alkylating species, resulting in alkylation of 
DNA. Following this, mice received drinking water with dextran sodium sulphate 
(DSS), an agent that is directly toxic to colonic epithelium, mimicking the 
chronic inflammatory state observed in inflammatory bowel disease in man (e.g. 
Crohn’s disease or ulcerative colitis), and compounding the tumorigenic effects 
of AOM. It was found that Limk2-deficient mice experienced a greater degree of 
weight loss, and also were shown to have larger tumour foci with a greater 
propensity to invasiveness than WT mice 224. 
Further to this work, we crossed the Limk2 knock-out model with a genetically 
modified CRC model: Vilin Cre:ER, Apcfl/+, Kras G12D mutant. Cre was induced 
with four daily intraperitoneal injections of tamoxifen, and I monitored the 
animals for evidence of weight loss and signs of gastrointestinal disease. There 
was no significant difference between the two groups in terms of survival or 
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extent of weight loss (Figure 3-10). This could possibly be explained by the high 
malignant potential of the mutant Kras, Apc heterozygous phenotype, which may 
not be modulated by the relatively small effect of loss of Limk2. 
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Figure 3-10 Loss of Limk2 in a GM mouse model of CRC shows no significant difference in 
survival or weight loss 
A)Kaplan Meier curve of survival in two cohorts of Vilin Cre:ER, APCfl/+, KRAS G12D mutant mice, 
one expressing wild type (WT) Limk2, the other with Limk2 knock out. Survival was not 
significantly altered between the groups. B) Baseline and final weights of the mice reveals no 
acceleration in weight loss in the Limk2 KO group versus the Limk2 WT group. 
 
 
 
 
133 
 
3.10 Summary	
In summary, the results presented in this chapter show that: 
• LIMK2 expression is downregulated in CRC when compared with normal 
colon tissue at the mRNA and protein level 
• LIMK2 promoters are methylated in CRC cell lines 
• Treatment with DNMT inhibitors reverses this hypermethylation 
• Primary colonic tumours display a greater degree of LIMK2 methylation 
than matched healthy colon tissue 
• There is a trend towards increased methylation with increasing depth of 
invasion of primary tumour 
• Loss of LIMK2 in an inflammation-related CRC mouse model predisposes to 
larger tumour foci with a greater depth of invasion 
• Loss of LIMK2 in a GM mouse model with mutant KRAS and loss of APC 
does not give the same outcome 
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4 Modulation of the Actin Cytoskeleton Impacts on 
Extracellular Matrix Composition 
Skin is an organ that is subject to external mechanical stress, prompting 
interactions between the cells of the dermis and epidermis, and the 
extracellular matrix. A conditionally active ROCK construct had previously been 
developed in the lab (Figure 4-1) 478. In order to determine the impact of 
alterations in the actin cytoskeleton in the context of skin’s response to differing 
levels of tension, genetically modified mice with a conditionally regulated 
oestrogen receptor (ER) fusion form of the ROCKII kinase domain under 
transcriptional control of the cytokeratin 14 (K14) promoter were previously 
developed in the laboratory 479. This construct consisted of a modified ER, with a 
glycine to arginine point mutation at position 525, resulting in an inability to 
bind 17β-oestradiol, but retained 4-HT-binding capacity; this was inserted in the 
ROCK II gene, in place of the Rho-binding domain, resulting in a ROCK II kinase 
domain that was responsive to 4-HT as opposed to RhoA-GTP 478. Through 
targeting the K14 gene promoter to the hypoxanthine phosphoribosyltransferase 
(Hprt) gene locus, tissue-selective expression of conditionally active 
ROCKII:mER™ within a specific target tissue was possible (Figure 4-2); in this 
instance, as K14 is a cytokeratin that is expressed at high levels in the stratified 
epithelium of the epidermis, permitting skin localisation. A kinase dead control 
construct had also previously been created by point mutation (lysine 121 was 
altered to glycine in the ATP-binding pocket) 478. In vivo studies with these mice 
previously revealed that ROCK activation leads to an elevation in skin stiffness 
and thickness 83; however, the specific mechanisms by which this occurs have 
not yet been determined. I therefore sought to identify alterations in gene 
expression that occur as a consequence of ROCK activation in keratinocytes. The 
results of these investigations are presented in this chapter. 
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Figure 4-1 Schematic of ROCKII and the conditionally regulated ROCK:ER construct 
PH: pleckstrin homology domain; CRD: cysteine-rich domain. Amino acids 5-553 were joined in 
frame to enhanced GFP (EGFP) and ER hormone-binding domain (hbER) to create the ROCK:ER 
fusion protein. A kinase dead version was created by altering lysine 121 to glycine 
(ROCK(K121G)). Adapted from Croft and Olson478 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
136 
 
 
 
 
 
Figure 4-2 The gene targeting approach for developing K14-ROCKII:mER™ mice 
A K14-ROCKII:mER™ expression cassette was targeted to the mutant mouse Hprt locus, with the 
promoter and first exon of human HPRT and the second exon of murine Hprt to reconstitute an 
active chimeric Hprt locus. EG: green fluorescent protein; *: β globin intron; PK14: K14 promoter 
sequence; ER: mER™ sequence; pA: K14 polyadenylation signal. This represents the ROCK2 kinase 
domain alone, not full length ROCK2. Not to scale. Adapted from Samuel et al 479. 
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4.1 Confirmation	of	ROCK	activation	in	primary	
keratinocytes	
In order to investigate the impact of ROCK activation in vitro in keratinocytes, I 
first wished to confirm that ROCK activation was induced by treatment with 4-
hydroxytamoxifen (4-HT). I therefore isolated and cultured keratinocytes from 
the tail skin of ROCK:ER and control kinase dead (KD):ER mice. Following 16 
hours of treatment with 4-HT or ethanol drug vehicle, I stained cells with Texas 
Red-conjugated Phalloidin and utilised confocal microscopy to visualise actin 
fibres. In cells with activated ROCK, these were apparent as stress fibres, while 
stress fibre formation was not evident in either the KD cells treated with 4-HT or 
the ROCK:ER cells treated with vehicle.  
In addition, I prepared protein lysates from keratinocytes and used western blot 
to determine levels of phosphorylated myosin light chain (pMLC) in response to 
ROCK activation. This showed that pMLC was elevated in ROCK-activated cells 
(Figure 4-3). 
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Figure 4-3 Confirmation of ROCK activation with 4-HT treatment 
A) Confocal microscopy of primary keratinocytes shows Texas Red-conjugated phalloidin staining 
of actin fibres (1:500), with more intense phalloidin staining indicating increased cortical actin 
and a number of K14 ROCK:ER cells demonstrating stress fibre formation. DAPI is used to stain 
nuclei. B) Western blot confirms an increase in phosphorylated myosin light chain (pMLC) relative 
to total myosin light chain (MLC) following ROCK activation. The membrane was probed with 
antibodies against both phosphorylated myosin light chain (1:500) and total myosin light chain 
(1:1000). C) Quantification of fold change of pMLC relative to ERK. n = 4. Significance 
determined by unpaired t test. 
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4.2 Increases	in	extracellular	matrix	protein	gene	
expression	following	ROCK	activation	
Having validated ROCK activation in keratinocytes, I next set out to investigate 
the alterations in gene expression observed in these cells when compared with 
control cells. Attempts had previously been made in the laboratory to 
investigate gene expression changes in tissue derived directly from transgenic 
mice treated with 4-HT; however, due to a high degree of inter-animal 
variability, this approach was not felt to be viable. In order to interrogate 
changes in primary cells, I again isolated and cultured primary keratinocytes, 
and treated them with 4-HT or ethanol vehicle. Thereafter, I prepared RNA from 
the cells, and Affymetrix gene expression microarray analysis was performed at 
the Cancer Research UK facility at the Paterson Institute. The results of the 
microarray were analysed by the Computational Biology Service at the Beatson 
Institute, and Ingenuity® Pathway Analysis was undertaken. This identified a 
number of possible networks of molecular relationships that may be contributing 
to the differences observed following ROCK activation, including the “cell 
movement network” (Figure 4-4). Numbering among the components of this 
network were the extracellular matrix glycoproteins tenascin C (Tnc) and 
thrombospondin-1 (Thbs1), and the plasminogen activator, urokinase receptor 
(Plaur) (which is upregulated in cutaneous squamous skin cancer 480, and also 
functions as a high-affinity receptor for the extracellular matrix glycoprotein 
vitronectin (VTN) 481). TNC, THBS-1 and VTN are up-regulated at sites of 
physiological tissue-remodelling, e.g. during wound healing; in addition, these 
ECM proteins have been implicated in the permissive interplay between cancer 
cells and the tumour microenvironment. Of the ECM components I had 
identified, I decided to pursue investigation of TNC. This was in part due to 
evidence linking the expression of TNC to alterations in mechanical properties, 
and also due to the fact that TNC has been shown to be overexpressed in most 
solid tumours. It is believed to participate in a number of pro-tumorigenic 
processes, including: 
• Supporting the capacity of some cancer types to form a metastatic niche 
446 
• Promoting epithelial-mesenchymal transition 433-435 
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• Mediating resistance to apoptosis 446,482  
To validate the gene expression changes observed in the microarray, I proceeded 
to carry out quantitative real-time PCR (q RT-PCR). This confirmed that ROCK 
activation by 4-HT led to an increase in Tnc transcripts (Figure 4-5).  
 
The RNA microarray data is available at the following URL: 
https://docs.google.com/spreadsheets/d/1hko3Tf9E34s6fR6mJhrjA8NpVvPl82mK
SkoUcxDQsFc/edit?usp=sharing. 
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Figure 4-4 Ingenuity ® Pathway Analysis: Cell movement network 
Following RNA isolation from primary keratinocytes +/- ROCK activation, Affymetrix gene 
expression microarray was performed. Pathway analysis shows changes in the cell movement 
network following activation of ROCK in primary keratinocytes. The network analysis identifies 
the upstream regulators that may be responsible for observed gene expression changes. IPA 
predicts which upstream regulators are activated or inhibited to explain the upregulated and 
downregulated genes. Red = upregulated; Green = downregulated. Tenascin C (Tnc), 
Thrombospondin 1 (Thbs1) and plasminogen activator, urokinase receptor (Plaur) are highlighted 
by *. Lines link genes with up or downstream relationships; solid line = direct relationship, 
dotted line = indirect relationship. 
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Figure 4-5 Increase in TNC RNA transcripts following ROCK activation of keratinocytes with 
4-HT.  
Replicates of paired primary keratinocytes isolated from K14 KD:ER and ROCK:ER animals, 
activated for 16 hours with 4-HT in serum-free medium. Fold change of Tnc transcripts is shown 
relative to 18s abundance determined by q RT-PCR. Statistical significance of differences was 
determined by one-way ANOVA. n = 4. 
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4.3 Validation	of	TNC	antibody	
Having decided that TNC was a target I wished to pursue in further experiments, 
I next wanted to conduct studies of TNC on the protein level. In order to do so, I 
set out to validate the TNC antibody by probing tissues in which I expected to 
observe high levels of TNC expression. TNC is highly expressed during 
embryogenesis; therefore, I prepared protein lysates from wild type (WT) mouse 
embryonic fibroblasts (MEFs), and performed a western blot. This confirmed high 
levels of TNC expression. In adults, physiological TNC expression is limited to 
regions of the brain such as the hypothalamus, where it mediates neuron-glial 
interactions. I obtained TNC knock-out (KO) mice and, along with WT mice, 
dissected the brains and stained sections for TNC. This confirmed the presence 
of TNC in the hypothalamus of WT mice, and its absence in the hypothalamus of 
KO mice (Figure 4-6).   
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Figure 4-6 TNC antibody validation: western blot and immunohistochemistry. 
A) Early-passage MEFs were cultured in 6-well plates. Cells were washed and lysed with SDS lysis 
buffer, and protein electrophoresis was performed. Following transfer, the membrane was 
probed for TNC expression (1:500). Two bands were visible, one of 260 kDA, and a fainter band 
(a probable splice variant) of 210 kDA. B) 11-month-old WT and TNC KO animals were euthanized 
humanely. The spinal cords were severed, the skull removed, and the entire brain dissected en 
bloc and placed in formalin. The brain was subsequently embedded in paraffin, sectioned, and 
stained for TNC. TNC expression was apparent in the hypothalamus of the WT animal, but not in 
that of the KO animal. Sections show whole brain, with the hypothalamus at higher magnification 
(20X). 
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4.4 ROCK	activation	leads	to	increased	protein	levels	of	TNC	
I subsequently wished to determine if the increase I had observed in TNC RNA 
transcripts was translated to the protein level following ROCK activation. To do 
this, I utilised primary keratinocytes, isolated as described previously. I found 
that, following treatment with 4-HT, ROCK-activated keratinocytes had higher 
levels of TNC protein on western blot (Figure 4-7). 
Having confirmed that TNC expression was influenced by ROCK activation, I 
wished to investigate the role TNC could be playing in squamous skin cancer. 
Using Oncomine®, I analysed data that revealed TNC was consistently 
overexpressed in squamous skin cancer (Figure 4-8). Furthermore, there was 
literature suggesting that TNC may be associated with a worse clinical prognosis 
in a number of cancer types. Consequently, I decided to further investigate the 
relationship between ROCK activation and TNC expression. 
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Figure 4-7 Tenascin C protein expression is increased in ROCK-activated cells. 
Primary keratinocytes were isolated, cultured, and treated with 4-HT or ethanol vehicle. Lysates 
were prepared, and following protein electrophoresis and transfer, the membrane was probed 
for TNC (1:500) and ERK2 (loading control; 1:1000). A) Representative western blot showing 
increase in Tnc levels following treatment with 4-HT. B) Replicates of above (n = 2). Statistical 
significance determined by ANOVA. 
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Figure 4-8 TNC expression is increased in squamous skin cancer versus normal skin samples 
Log2 median-centred TNC mRNA expression in normal versus squamous skin cancer samples from 
A) Riker et al 483 and B) Nindl et al 484. Statistical significance of differences was determined by 
an unpaired t-test.   
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4.5 ROCK	activation	increases	TNC	expression	in	murine	
skin	in	vivo		
Previous work carried out in the laboratory had revealed that ROCK activation 
led to an increase in skin thickness and stiffness. This work had used 
phosphorylation of MYPT1 in the epidermis to confirm ROCK activation 83,479. I 
considered the possibility that TNC may be one of the components contributing 
to the observed thickening, and so decided to activate ROCK in vivo, using the 
K14 ROCK:ER animal model, and then examine the skin for TNC expression. In 
order to do so, I used two methods: the first of these was to commence K14 
KD:ER and ROCK:ER animals on a tamoxifen diet. This was an attractive 
approach as it is less stressful for animals than topical or invasive (i.e. 
intraperitoneal) methods, can be continued for a relatively lengthy period and in 
theory should cause ubiquitous transgene expression. Age- and weight-matched 
animals were fed tamoxifen diet for a period of 36 days. The animals and the 
food were weighed 3 times per week to ensure that they were maintaining an 
adequate nutritional status; initially, both groups experienced a degree of 
weight loss. This is a common issue when using tamoxifen diet, but tends to be 
overcome after approximately one week, as was the case in this experiment. 
However, following stabilisation of the animals’ weight, no subsequent weight 
gain was observed. At the end of the experimental period, the animals were 
humanely euthanized and the back skin was dissected and placed in formalin. 
Staining for haematoxylin and eosin (H&E), and TNC did not reveal any 
difference between the two groups. I suspected that this may reflect inadequate 
intake or reduced oral absorption due to the absence of weight gain, and 
therefore I considered an alternative approach, namely the topical application 
of 4-HT directly to the ear skin of K14 KD:ER and ROCK:ER mice. Six KD mice and 
five ROCK mice were treated, and 500 µg was applied to each ear daily for 21 
days. Subsequently, the animals were humanely euthanized, and the ears were 
removed and placed in formalin, before being embedded in paraffin, sectioned 
and stained for H&E and TNC. In the ROCK-activated animals, I noted a 
substantial increase in TNC deposition in the junction between the epidermis 
and dermis (Figure 4-9). 
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Figure 4-9 Increased TNC staining is localised to sites of cell-cell adhesion following ROCK-
activation in keratinocytes. 
K14 KD:ER and K14 ROCK:ER animals were treated with topical 4-HT for 36 days. At the 
completion of treatment, animals were humanely euthanized and the ears were processed at the 
Beatson Institute core histology facility. TNC staining was negligible in the KD:ER animals; 
distinct TNC staining was apparent at the sites of cell-cell adhesion in the ROCK:ER animals. 
Representative examples from one KD and one ROCK animal; total numbers, 6 KD:ER and 5 
ROCK:ER animals. 
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4.5.1 ROCK	activation	in	a	tumorigenic	model	increases	TNC	
deposition	
In order to further investigate the interaction between ROCK activation and TNC 
expression in the context of malignancy, a collaboration was established 
between our laboratory and the laboratory of Dr David Greenhalgh in the 
Department of Dermatology, University of Glasgow, with a contribution by Ms 
Siti Masre, who established the crosses between genetically modified animal 
models and performed the application of topical 4-HT at the University of 
Glasgow animal facility. This involved animal models expressing various 
oncogenic driver mutations and loss of tumour suppressor genes, in isolation and 
in combination, including epidermis-specific expression of c-fos, H-RAS 
mutation, and PTEN deletion (PTENnull). These tumour models were crossed with 
the K14 ROCK:ER model, and ROCK was activated by application of topical 4-HT. 
A comparison was made between the RAS/c-fos/PTENnull animals with and 
without ROCK:ER expression. Most animals, regardless of ROCK activation, 
developed papillomas following treatment with 4-HT for 8-10 weeks. However, 
following 13 weeks of 4-HT application, the animals expressing ROCK:ER 
exhibited malignant conversion and were observed to develop foci of squamous 
skin cancer. On obtaining sections from the malignant tumours, I carried out TNC 
staining and found a significant upregulation of TNC expression in the mutant 
RAS plus ROCK specimens (Figure 4-10). Rho has been shown to act downstream 
of RAS in transformed fibroblasts, relaying proliferative signals 485. In murine 
models expressing oncogenic RAS and conditionally active ROCK, papillomas 
expressed low levels of TNC. Following malignant conversion to squamous cell 
cancers, which occurred only in ROCK-activated animals, TNC expression 
increased. The implication may be that, through the increased proliferation and 
cytoskeletal tension seen through RAS/ROCK co-operation, deposition of 
tumorigenic ECM components occurs. 
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Figure 4-10 Increased TNC staining in a tumorigenic animal model with concurrent ROCK-
activation. 
Animals expressing mutant RAS in the epidermis were crossed with K14 ROCK:ER animals. ROCK 
activation was achieved by topical application of 4-HT for 13 weeks, and specimens of skin 
bearing papillomas with foci of malignant conversion were subsequently blocked, sectioned and 
stained for TNC. A significant increase in TNC deposition at the sites of cell-cell adhesion was 
observed in these animals compared with animals in which mutant RAS alone was present. The 
top panels show sections from animals expressing RAS treated with topical 4-HT. The lower 
panels show sections from animals expressing RAS and the ROCK:ER transgene treated with 4-HT. 
Scale bars represent 100 µm. Red arrows indicate the epidermal-dermal junction. 
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4.6 Investigating	TGFβ	as	a	contributing	factor	to	ROCK-
induced	epidermal	stiffening	and	thickening	
As had previously been noted, ROCK activation was seen to increase stiffness and 
thickness of the epidermis through collagen and extracellular matrix deposition. 
This bears similarities to the process of fibrosis (an excess of connective tissue), 
which is observed: 
• during wound healing (scar formation) 304 
• in rheumatological conditions such as systemic sclerosis (a multi-system 
autoimmune disorder characterised by the pathological accumulation of 
collagen)486  
• within the tumour microenvironment in some cancer types (through the 
activation of cancer-associated fibroblasts) 312.  
Keratinocytes and fibroblasts are known to interact in a number of ways, and it 
has been shown that fibroblasts can become activated to myofibroblasts through 
signalling pathways initiated by keratinocytes. In particular, increased 
mechanical tension and transforming growth factor beta (TGFβ) activity are 
known to cause differentiation to a myofibroblast phenotype. These cells then 
have the capacity to synthesise collagen and other ECM components, leading to 
deposition of fibrotic tissue.  
4.6.1 Investigating	endogenous	TGFβ	levels	
As I had observed that TNC expression appeared to be predominantly within the 
junction between the epidermis and dermis, I hypothesised that the 
keratinocytes within the epidermis may be prompting the dermal fibroblasts to 
produce TNC, along with other ECM components. I decided to investigate if ROCK 
activation, in addition to altering the mechanical tension of cells, may be 
contributing to TGFβ signalling. In order to do so, I performed quantitative RT-
PCR on cDNA prepared from ROCK activated keratinocytes with primers for Tgfb. 
This showed an increase in Tgfb transcripts following ROCK activation (Figure 4-
11).  
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Figure 4-11 Increase in TGFβ transcripts following ROCK activation 
RT-PCR (from 3 paired experiments) shows a statistically significant increase in TGFβ transcripts 
following ROCK activation in primary keratinocytes. 
 
 
 
 
 
 
 
 
154 
 
Subsequently, I isolated and cultured 3 pairs of primary keratinocytes from K14 
KD:ER and ROCK:ER mice (the same type of cells and using the same technique 
as previously described). Following ROCK activation with 4-HT for 16 hours, I 
harvested the medium from the cells and, after using hydrochloric acid to 
activate latent TGFβ, went on to perform an enzyme-linked immunosorbent 
assay (ELISA). This did not show an increase in TGFβ1 levels in the ROCK-
activated supernatant. However, I considered that this may be a consequence of 
culturing keratinocytes in isolation; I therefore attempted to develop a robust 
co-culture system to determine the impact of ROCK activation in keratinocytes 
on fibroblasts. 
I initially adopted a “hanging drop” technique, in which primary keratinocytes 
were dyed and mixed with NIH3T3 fibroblasts and grown in a drop suspended 
from the lid of a cell culture dish. Unfortunately, it was not possible to maintain 
the viability of the primary cells in this context. 
I went on to work with an NIH3T3 fibroblast cell line that had been stably 
transfected with a TGFβ reporter plasmid. This was a kind gift of Dr Gareth 
Inman, University of Dundee, Division of Cancer Research. Upon exposure to 
TGFβ, luciferase expression was induced and could be quantified on a 
luminometer. I first wanted to determine the sensitivity of the cell line; 
therefore, using recombinant human TGFβ (Peprotech), I established that the 
bioassay had a range of responsiveness from 50 pg/ml to 500 pg/ml (Figure 4-
12). Thereafter, I cultured primary keratinocytes and reporter fibroblasts, 
activated ROCK in the keratinocytes, and carried out a luciferase reporter assay. 
No difference was apparent between co-cultured cells with or without ROCK 
activation, possibly as it was not feasible to activate latent TGFβ in a living cell 
system (Figure 4-13). 
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Figure 4-12 The TGFβ bioassay has a range of responsiveness from 50 pg/ml to 500 pg/ml. 
NIH3T3 fibroblasts had been selected to stably express a TGFβ reporter. Serum-free medium 
with increasing concentrations of recombinant TGFβ was added to the cells in a 24-well plate, 
and the cells were cultured at 37 °C overnight. Thereafter, a luciferase reporter assay was 
performed, and the read-out determined on a luminometer. At a concentration of 20 pg/ml, 
TGFβ activity was not detectable. At concentrations above 500 pg/ml, there was no dose-
response relationship. The sensitivity range was therefore determined to be 50 pg/ml to 500 
pg/ml. 
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Figure 4-13 No increase in TGFβ is detected following ROCK activation of primary 
keratinocytes using a fibroblast reporter system 
Reporter NIH3T3 cells were established in culture. The following day primary ROCK:ER or KD 
keratinocytes were added to the fibroblast culture, and subsequently treated with 4-HT or 
vehicle. Thereafter a reporter luciferase assay was performed on the medium. Luminometer 
values are plotted, corrected for protein concentration. No statistically significant difference 
was apparent between each condition. n = 2. 
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4.6.2 Using	exogenous	TGFβ	to	investigate	effects	on	the	actin	
cytoskeleton	and	the	extracellular	matrix	
As there appeared to be inherent difficulties in determining the part played by 
endogenous TGFβ in the observed changes in epidermal composition, I elected to 
delineate the effect of adding exogenous recombinant TGFβ (rTGFβ) to cells. I 
serum starved parental NIH3T3 fibroblasts and added rTGFβ at a range of 
concentrations (500 pg/ml to 10 ng/ml) for 16 hours. I subsequently prepared 
protein lysates, and following protein electrophoresis I probed the membrane 
with antibody against pMLC. This confirmed that at a dose of 10 ng/ml there was 
an increase in pMLC, indicating that TGFβ also impacts turnover of the actin 
cytoskeleton (Figure 4-12). 
I went on to determine if there was an additive effect of activating ROCK and 
treating cells with rTGFβ. To do this, I used NIH3T3 fibroblasts expressing KD:ER 
or ROCK:ER transgenes, and added 4-HT alone, rTGFβ alone, and both 
treatments together. Cell lysates were again prepared, and I carried out a 
western blot, probing for TNC and pMLC. This confirmed that the greatest 
increase in both pMLC and TNC was seen in those cells treated with rTGFβ 
concurrent with ROCK activation (Figure 4-13). This suggested that both cellular 
mechanical tension and TGFβ are participants in determining ECM component 
production, with a cumulative effect when both factors are present.   
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Figure 4-14 Phosphorylation of myosin light chain is increased following treatment with 
rTGFβ 
A) Representative western blot of NIH3T3 fibroblasts treated with rTGFβ showing a dose-
dependent increase in pMLC. Parental NIH3T3 fibroblasts were plated at 1x105 cells per well of a 
24-well plate. 24 hours later, serum-free medium was added with increasing concentrations of 
rTGFβ (200 pg/ml, 1 ng/ml, 2 ng/ml, 5 ng/ml, 10 ng/ml). Cells were cultured at 37 °C for 24 
hours, and protein lysates were made. The membrane was probed with pMLC antibody (1:500); 
ERK2 served as a loading control(1:1000). B) Quantification of western blots, showing the fold 
change in pMLC relative to ERK2 levels; n = 2. One-way ANOVA p = 0.0017. 
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Figure 4-15 ROCK activation and TGFβ combine to increase pMLC and TNC expression 
A) Representative western blot of NIH3T3 fibroblasts +/- ROCK activation and +/- TGFβ. NIH3T3 
cells stably expressing the ROCK:ER or KD:ER transgene were plated at 3x105 cells per well of a 
6-well plate. 12 hours later, cells were washed with PBS, and serum-free medium plus 4-HT (1 
µM)/ethanol vehicle +/- TGFβ (10 ng/ml) was added. Cells were incubated at 37 °C for 16 hours 
before lysates were prepared. The membrane was probed with antibodies against TNC (1:500) 
and pMLC (1:500), and ERK2 (1:1000) served as a loading control. The highest levels of TNC and 
pMLC were observed in ROCK-activated cells treated with TGFβ. B) Quantification of western 
blots, showing the fold change in TNC relative to ERK2 levels; n = 3. NS 
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4.7 Regulation	of	TNC	expression	
I undertook further review of the literature, which revealed that TNC is 
regulated by megakaryoblastic leukaemia 1 (MKL1; also known as myocardin-
related transcription factor A (MRTFA)), a member of the myocardin-related 
transcription factor family. MKL1 interacts with serum response factor (SRF) to 
activate transcription of genes with serum response element (SRE)-containing 
promoters. In turn, MKL1 is regulated through its interaction with actin, 
remaining localised within the cytoplasm in association with G-actin when 
unstimulated, and translocating to the nucleus when the balance shifts towards 
F-actin production.  
As a consequence, I sought to determine if ROCK transgene activation would 
cause MKL1 to accumulate within the nucleus and thus, by implication, induce 
TNC expression. To do so, I initially plated NIH3T3 ROCK:ER fibroblasts and 
activated ROCK with 4-HT for 16 hours; subsequently, I prepared nuclear and 
cytoplasmic extracts, using the Thermoscientific NE-PER Nuclear and 
Cytoplasmic Extraction kit. I went on to perform a western blot, probing for 
MKL1 in the nucleus (using Lamin A/C antibody to ensure that the extracts were 
entirely nuclear in origin) and in the cytoplasm (with GAPDH antibody to 
determine that extracts were cytoplasmic). I did not detect a discernible 
difference in MKL1 levels following ROCK activation; I hypothesised that this may 
have been as consequence of culturing the cells on a stiff (i.e. non-
physiologically representative) surface. To further evaluate this, I plated NIH3T3 
ROCK:ER fibroblasts on glass coverslips and activated ROCK with 4-HT for 16 
hours before fixing and permeabilising cells, then probing with anti-MRTFA 
antibody (1:50 for 1 hour at room temperature; Santa Cruz). The cells were 
subsequently visualised on a Zeiss 710 upright confocal microscope. I felt that 
those ROCK-activated fibroblasts that exhibited marked stress fibre formation 
possibly demonstrated greater levels of perinuclear MRTFA staining, while 
vehicle treated cells showed predominantly cytoplasmic staining (Figure 4-14). 
The data are not sufficiently convincing to draw any conclusions, but this could 
be an area worthy of further investigation. 
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Figure 4-16 Perinuclear localisation of MKL1 following ROCK activation. 
Representative immunofluorescence confocal images of serum-starved ROCK:ER NIH3T3 
fibroblasts treated with 4-HT or ethanol vehicle and stained for F-actin (left panels) and MKL1 
(centre panels). Cellular nuclei, stained with DAPI, are shown in blue in the merged images (right 
panels). Scale bars represent 20 µm. After plating on glass coverslips, cells were serum-starved 
and treated with 4-HT or ethanol vehicle for 16 hours, then fixed and stained as described 
previously. Confocal images were obtained using a Zeiss 710 upright confocal microscope. ROCK-
activated cells with prominent stress fibre formation show possible localisation of MKL1 around 
the nucleus. 
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Next, to look specifically at the effect of ROCK activation on SRE, I obtained a 
plasmid construct: SRE fused to a secreted alkaline phosphatase (SEAP) reporter. 
This was a kind gift of Professor Ruth Chiquet-Ehrismann, Friedrich Miescher 
Institute for Biomedical Research, Basel. I transfected the plasmid into NIH3T3 
cells with the KD:ER and ROCK:ER transgenes using Lipofectamine 2000, and 
following 16 hours of serum-starvation and treatment with 4-HT or ethanol 
vehicle, I determined the level of SEAP in the culture supernatant. In parallel, I 
transfected identical cells with secreted Metridia luciferase construct, to ensure 
transfection efficiency. I found there was a non-significant > 2-fold increase in 
SEAP activity in ROCK-activated cells compared with vehicle-treated or KD cells; 
Metridia luciferase activity remained relatively constant across all conditions 
(Figure 4-15). These results confirmed that SRE and MKL1 localisation are 
influenced by ROCK activation; this is borne out by the knowledge that Rho 
family members upregulate SRE gene expression 487. 
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Figure 4-17 ROCK activation causes an increase in SRE-SEAP activity 
NIH3T3 fibroblasts stably expressing the KD:ER or ROCK:ER transgene were transiently 
transfected with A) Metridia secreted luciferase plasmid or B) SRE-SEAP plasmid, then cultured 
in serum-free medium with 4-HT or ethanol vehicle for 16 hours. Luciferase reporter assay 
showed no difference following ROCK activation; SRE-SEAP levels were increased following ROCK 
activation. Results shown are for 4 independent experiments; the increase in SRE-SEAP following 
ROCK activation did not reach statistical significance (determined by unpaired t-test. p=0.071). 
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4.8 Altering	the	stiffness	of	the	cell	culture	substrate	
impacts	cell	behaviour	
Having observed that TGFβ was capable of enhancing the effect of ROCK 
activation in terms of ECM component production, I next wished to investigate 
the impact of altering the tension of the surface that cells are cultured upon. 
In order to perform these experiments, I obtained Excellness® biomimetic tissue 
culture plates of differing levels of stiffness, to replicate a physiological cellular 
environment. I chose to use 2 kPa plates, with a surface approximately 
analogous to fat or brain tissue, denoted “soft”, and 30 kPa plates, representing 
intestinal tissue, denoted “medium”. In addition, I used conventional plastic 
tissue culture dishes which, with a stiffness of >10,000 kPa are most similar to 
mammalian bone, and are denoted “hard”.  
4.8.1 Levels	of	myosin	light	chain	phosphorylation	are	increased	in	
cells	cultured	on	stiffer	surfaces	
First, I wanted to investigate whether simply culturing cells on a stiffer surface 
would be sufficient to promote an increase in phosphorylation of myosin light 
chain. To do this, I plated parental NIH3T3 fibroblasts at 1 x 105 cells in 3 cm 
dishes of differing stiffness for 24 hours. Subsequently, I used SDS lysis buffer to 
prepare protein lysates. Due to the nature of the soft polymer surface, it was 
not possible to use traditional cell scrapers; therefore, a pipette tip was used to 
lyse cells and transfer them to a column to undergo homogenisation. Thereafter, 
the protein concentration was determined, and the samples were run on a 
gradient gel. Following transfer, the membrane was probed with antibody 
against pMLC. This revealed that a consistently higher level of pMLC was seen in 
cells plated on a stiff surface when compared with those cultured on a softer 
substrate (Figure 4-16 A, B). 
4.8.2 ROCK	activation	and	stiff	culture	substrate	have	a	cumulative	
effect	
Next, I wanted to determine the effect of combining ROCK activation with 
culturing cells on a stiffer surface. This was an effort to replicate the 
cytoskeletal alterations a cell experiences when maintaining force equilibrium in 
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response to increasing external tension. I plated NIH3T3 cells with the ROCK:ER 
transgene stably expressed on both Excellness® plates (2 kPa and 30 kPa) and 
conventional tissue culture plates (>10,000 kPa). 24 hours after seeding, the 
cells were treated with serum-free medium containing 4-HT or ethanol vehicle 
for 16 hours. Subsequently, I prepared protein lysates and performed a western 
blot. This confirmed that, in cells plated on a stiff surface, ROCK activation had 
an additive effect, with the greatest level of pMLC observed in these conditions 
(Figure 4-16 C).  
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Figure 4-18 Cells grown on stiff culture substrates have increased levels of pMLC. 
A)  Representative western blot of parental NIH3T3 fibroblasts cultured on hard (conventional 
tissue culture plastic; >10,000 kPa), medium (30 kPa), and soft (2 kPa), substrates for 24 hours. 
Protein lysates were prepared and western blot carried out, showing that levels of pMLC were 
significantly higher in those cells cultured on the stiff substrate than those cultured on softer 
substrates. B) Graph of replicates showing quantification of fold change relative to loading 
control (ERK2); n=3. C) The experiment was repeated with NIH3T3 ROCK:ER fibroblasts; 4-HT or 
ethanol vehicle was added to serum-free medium on cells for 16 hours prior to harvesting protein 
lysates. The increase in pMLC was greatest in those cells in which ROCK activation occurred in 
the context of culture on a stiff surface. Endogenous ROCK acted as a loading control (1:1000). 
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4.8.3 The	impact	of	differing	levels	of	stiffness	on	TNC	expression	
The relationship between differing levels of stiffness, ROCK activation and TNC 
expression was less clear-cut, with a degree of variability between experiments. 
Taking this into account, I queried whether using rTGFβ to treat cells on 
different substrates would enable subtle alterations in TNC expression to be 
more accurately determined. To do this, I plated parental NIH3T3 fibroblasts on 
different substrates (soft, medium and hard) and after 24 hours added serum-
free medium +/- rTGFβ. TNC levels were higher (as determined by western blot) 
in cells treated with rTGFβ on all surfaces, but the greatest increase was 
observed in treated cells on a stiff surface (Figure 4-17). Thus, I concluded that 
a relationship exists between intra- and extracellular tension, TGFβ, and 
synthesis of ECM components.  
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Figure 4-19 TNC expression is highest in cells plated on a stiff substrate and treated with 
rTGFβ 
A) Representative western blot showing increased levels of TNC in cells plated on a stiff 
substrate and treated with TGFβ. NIH3T3 fibroblasts were plated on soft, medium and hard 
substrates (as previous) and treated with rTGFβ for 16 hours. Subsequently, protein lysates were 
prepared and a western blot carried out to determine TNC levels. ERK2 was probed as a loading 
control. B) Quantification of fold change in TNC determined from 3 replicates of the experiment. 
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4.9 The	transition	from	fibroblast	to	myofibroblast	is	
triggered	by	alterations	in	the	actin	cytoskeleton			
Next, I wanted to investigate the mechanism by which cells were producing ECM 
components. Evidence suggests that the activation of fibroblasts to 
myofibroblasts leads to the adoption of a pro-fibrotic phenotype; cells 
consequently exhibit enhanced secretory and contractile properties. α smooth 
muscle actin (α SMA) is the classic marker of myofibroblast activity, and can be 
used to illustrate the transition from quiescent fibroblast to activated cell. I 
therefore considered if the factors I had been investigating (1. cytoskeletal 
remodelling through intrinsic ROCK activation; 2. TGFβ stimulation of cells; and 
3. altering the stiffness of cell culture substrates) could, in isolation and/or 
combination be prompting the development of myofibroblasts and consequent 
production of TNC. I therefore used antibody raised against α SMA to investigate 
this. I found that ROCK activation in/TGFβ treatment of cells plated on a soft or 
medium surface was sufficient to drive an increase in α SMA expression. 
However, cells plated on a stiff substrate displayed baseline higher levels of α 
SMA, with no discernible increase following ROCK activation (Figure 4-18) or 
TGFβ  exposure (Figure 4-19). This reinforces the integral role the cellular 
environment plays, illustrating that elements that affect the actin cytoskeleton 
have a different impact depending on the context in which the cell exists. 
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Figure 4-20 α SMA expression varies with substrate stiffness and ROCK activation 
A) Representative western blot showing increased α SMA in ROCK-activated cells on a soft or 
medium stiffness substrate, and in all cells (+/- ROCK activation) plated on a stiff substrate. 
NIH3T3 fibroblasts expressing the KD:ER or ROCK:ER transgene were plated on soft, medium, and 
hard surfaces at a concentration of 1x105 cells per plate, and treated with 4-HT(1 µM) or ethanol 
vehicle in serum-free medium for 16 hours. Protein lysates were prepared and, following gel 
electrophoresis and transfer, the membrane was probed with antibody against α SMA (1:200). 
Lamin B antibody was used as a loading control (1:500). B) Fold change in α SMA levels (relative 
to Lamin B; fold change in arbitrary units).  
 
 
171 
 
A 
 
 
B 
 
Figure 4-21 α SMA expression varies with substrate stiffness and TGFβ treatment 
A) Representative western blot showing increased α SMA in TGFβ-treated cells on a medium 
stiffness substrate, and in cells plated on a stiff substrate regardless of TGFβ exposure. Parental 
NIH3T3 fibroblasts were plated at 1x105 cells per plate for 24 hours, before washing and adding 
serum-free medium +/- rTGFβ (10 ng/ml). Western blot was performed on protein lysates, and 
the membrane was subsequently probed with α SMA antibody (1:200). Lamin B was probed as a 
loading control (1:500). B) Quantification of the fold change in α SMA in TGFβ treated cells (n = 
2). 
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4.10 Summary	
In summary, the results presented in this chapter show that: 
• ROCK activation in primary keratinocytes leads to increased ECM 
component expression 
• TNC is one of these components 
• ROCK activation in vivo also leads to increased TNC deposition in the 
epidermis and dermis of GM mice 
• This effect is enhanced in a tumorigenic animal model with mutant RAS 
and ROCK activation 
• A synergistic effect is observed between increased substrate stiffness, 
ROCK activation and exogenous TGFβ, suggesting a potential positive 
feedback cycle that may drive the transition of fibroblast to CAFs 
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5 RNA sequencing of ROCK-activated versus 
control epidermal keratinocytes 
I undertook RNA sequencing in order to verify and expand on the results 
garnered by carrying out the ROCK-activated keratinocyte microarray 
experiments. 
5.1 RNA	quality	control	assessment	
As previously described, I isolated primary keratinocytes from epidermis taken 
from the tails of K14 ROCK:ER mice; once established in culture, the cells were 
treated with 4-HT or ethanol vehicle for 16 hours. Thereafter, RNA was isolated 
from the cells and a quality control check was performed using the Agilent 
Bioanalyzer 2100. This assigns an RNA integrity number (RIN) to each sample, 
with 10 corresponding to a pure, non-degraded sample and 1 corresponding to a 
completely degraded sample. It is recommended that samples with an RIN of less 
than 7 are not utilised in experiments. This confirmed that the RNA was of 
sufficient quality to proceed to sequencing (Figure 5-1).  
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Figure 5-1 Agilent Bioanalyzer 2100 RNA read-out 
Results from analysis of RNA isolated from primary keratinocytes confirmed that samples were 
sufficiently intact to proceed to further interrogation (RIN values ranging from 7.90 to 9.10). 
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5.2 RNA	sequencing	
Having confirmed that the RNA was of adequate integrity, RNA sequencing was 
performed on the Illumina® NextSeq 500 platform. This revealed alterations in 
gene expression in those cells treated with 4-HT when compared with cells 
treated with vehicle (Figure 5-2). 
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Figure 5-2 RNA sequencing heat map  
Data analysis of RNA sequencing output confirms that genes are differentially expressed in 
keratinocytes with ROCK activation compared to those in which ROCK is not activated. The left 
hand columns (RV1, RV2 and RV3) represent three replicate experiments of cells treated with 
ethanol vehicle, while the right hand columns (RT1, RT2 and RT3) represent three replicate 
experiments of cells treated with 4-HT. Heat map generated by Gabriela Kalna, Computational 
Biology Department, CRUK Beatson Institute. 
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A number of common pathways and networks were found to demonstrate 
different expression levels. Those genes with biological functions related to 
cancer showed the most frequent alterations (Table 5-1), while genes belonging 
to the “connective tissue” and “cell-to-cell signalling/cellular growth and 
proliferation” networks also displayed aberrant expression (Table 5-2).  
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Table 5-1 RNA sequencing data analysis (biological functions) 
Interrogation of RNA sequencing data shows that genes with specific biological functions more 
frequently display altered expression levels. 
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Table 5-2 RNA sequencing data analysis (networks) 
Genes that participate in networks related to connective tissue disorders, developmental 
disorders, and cell-to-cell signalling demonstrated a greater degree of discordance between 
those cells with and without ROCK activation. 
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6 Lifeact GFP enables live cell imaging of dynamic 
alterations in the actin cytoskeleton  
 
“Lifeact” is a 17-amino-acid peptide fused to GFP that is able to bind to F-actin, 
yet does not corrupt normal cellular behaviour. It displays selective, low-affinity 
binding to actin structures, permitting direct visualisation of the actin 
cytoskeleton 488. Transgenic mice expressing Lifeact have been generated to 
permit the study of actin structures in primary cells and animal models 489. 
 
Transgenic mice that express Lifeact fused to GFP had been generated by the 
Beatson Institute transgenic facility. This had been achieved through use of 
pROSA26, a generic targeting vector, which was used in association with pBigT to 
target the ROSA locus. The Lifeact GFP was sub-cloned into the pBigT vector; 
subsequently, a larger fragment from pBigT was placed into the pROSA26 vector. 
The final step involved the extraction of the targeting sequence and insertion 
into the mouse genome. Using a Deleter Cre mouse, I established matings that 
produced progeny displaying ubiquitous Lifeact GFP expression. Initially I 
ensured that mice were expressing Lifeact GFP with the IVIS® Spectrum in vivo 
imaging system (Figure 6-1); thereafter I used GFP goggles to confirm 
expression, with GFP being detected primarily in the murine tail and feet. 
 
I subsequently bred the Lifeact GFP animals with K14 ROCK:ER and K14 KD:ER 
mice, ultimately to derive homozygous ROCK/KD animals with global Lifeact GFP 
expression. Thereafter, I isolated epidermal tail keratinocytes as previously 
described, and established the cells in culture. Following treatment with 4-HT, I 
captured live time-lapse imaging of the cells using a Nikon Eclipse Ti microscope 
(Figure 6-2). This proved to be a useful method to visualise dynamic alterations 
in the cytoskeleton in live cells, and is a technique that can hopefully be utilised 
further in the future. The hypothesis being tested was that deriving animals with 
conditional ROCK expression and Lifeact GFP expression would enable the direct 
visualisation of altered live cell behaviour in real time. I anticipated that, 
following ROCK activation, the keratinocytes would display greater levels of 
motility and enhanced proliferation; I did not have sufficient time to test this 
adequately. 
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Figure 6-1 IVIS® Spectrum in vivo imaging system confirms Lifact GFP expression 
The IVIS® imaging system permits live imaging of animals to ensure GFP expression. On the left 
is a Lifeact GFP mouse, with GFP evident in the feet and nose. On the right is a control mouse 
with no GFP expression evident. 
 
 
 
 
 
 
 
 
 
 
182 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-2 Lifeact GFP primary keratinocytes 
Representative images of primary keratinocytes isolated from the epidermis of Lifeact 
GFP/ROCK:ER animals. The panel on the left shows cells visualised by fluorescent microscopy; 
the panel on the right shows the same cells under bright field microscopy. Images taken at 10X 
magnification. 
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7 Discussion 
7.1 LIMK	expression	in	colorectal	cancer	
7.1.1 Loss	of	LIMK	in	colorectal	cancer	versus	other	tumour	types	
The prevailing school of thought has long been that constituents of the Rho-
ROCK pathway tend to be upregulated in cancer, due to their role in promoting 
cell motility. LIM kinase expression has been noted to be elevated in several 
cancer types, and shown to participate in tumour cell proliferation and invasion. 
Breast cancer cell lines expressing LIM kinase 1 demonstrate a proliferative, 
invasive phenotype with enhanced angiogenesis in vitro 107, while increased 
expression of LIMK1 in breast tumour xenografts promotes tumour growth 490. A 
tumour-promoting role for the LIM kinases has also been identified in prostate 
cancer 108,491. Furthermore, knockdown or inhibition of LIMK has been shown to 
reduce pancreatic cancer progression 110,492. 
The assumption had been that, in the majority of cancer types, LIMK expression 
would directly correlate with the degree of invasiveness and aggression. 
However, when the role of actin cytoskeleton pathway members is examined 
out-with the conceptual framework of cell motility, it becomes clear that they 
participate in a range of other processes; indeed, the relative balance of the 
components may be the determinant of the metastatic potential of a cancer 
cell. 
In response to cellular stress, such as ionising radiation or doxorubicin (a DNA-
damaging chemotherapeutic agent that exerts a cytotoxic effect through 
intercalating DNA and binding to topoisomerase I and II) 493, the Rho-ROCK-LIMK 
pathway is activated 111. LIMK2 has previously been identified as a p53-
responsive gene, and further studies have confirmed that LIMK2 is a direct p53 
target 111,112. In turn, loss of LIMK2 through knockdown or inhibition results in 
G2/M arrest when cells receive a genotoxic insult. Ultimately, it was shown that 
loss of LIMK2 increases the sensitivity of cells to apoptosis through DNA-damage 
pathways. These findings are compatible with the knowledge that LIMK2 
regulates microtubule and spindle dynamics during mitosis 494. The implication is 
that, in the context of colorectal cancer, where intestinal stem cells serve as 
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the cell of origin, silencing of LIMK through hypermethylation relieves 
constraints on gastrointestinal stem cell proliferation, thus facilitating 
tumorigenesis and tumour propagation. 
There is evidence that downregulation of LIMK1 via diallyl disulphide compounds 
inhibits the migration and invasion of human CRC cell lines 495, thus highlighting 
the apparent disparate roles of LIMK1 and LIMK2 in the context of cancer. This 
should be borne in mind when considering the nuances of alterations in actin 
cytoskeleton pathway members and dynamics. 
7.1.2 Prognostic	and	predictive	factors	in	CRC	
At present, a number of factors have been identified as prognostic and 
predictive markers of outcome in early stage CRC. These include pathological 
findings such as TNM staging, tumour perforation, degree of tumour 
differentiation and presence of lymphatic or vascular invasion 496, and evidence 
of pre-operative systemic inflammation (based on elevated serum C-reactive 
protein and/or hypoalbuminaemia) 497.  
In advanced disease (inoperable locally advanced or metastatic), the presence of 
KRAS or BRAF mutations is deemed to be a negative prognostic indicator and is 
also predictive of a lack of response to EGFR inhibitor therapy such as cetuximab 
163,498. 
The ability to more accurately stratify patients by their risk of 
relapse/recurrence is a goal that has long been sought. It is becoming 
increasingly evident that CRC is a group of distinct entities, with some patients 
destined to have poor outcomes despite optimal adjuvant therapy, and some in 
whom the disease would be cured by surgery alone with no need to suffer the 
toxicities associated with systemic chemotherapy. Loss of LIMK2 is associated 
with poorer clinical outcomes; this could translate as a prospective prognostic 
biomarker, potentially being utilised as a method to determine which patients 
would derive the greatest benefit from adjuvant systemic treatment following 
surgical resection.  
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Furthermore, as loss of LIMK2 appears to play a pro-apoptotic role following 
treatment with DNA-damaging agents such as doxorubicin 111, this may influence 
the choice of cytotoxic agent used in the context of colorectal tumours with 
reduced LIMK2 expression. In addition, LIMK2 inhibition also appears to sensitise 
cells to a number of other compounds. These include Aurora A inhibitors, which 
synergise with shRNA-mediated silencing of LIMK2 to promote cell death 499, and 
RAS inhibitors, which co-operate with LIMK inhibition to reduce cell proliferation 
500. This could have future implications for the development of targeted, 
personalised cancer treatments for individual patients. 
7.1.3 Mouse	models	of	colorectal	cancer	
As stated in the CRC epigenetics section, an effect was noted in the AOM-DSS 
CRC model when LIMK2 was absent. The model I utilised (KRAS G12D mutant, 
APC mutant heterozygous) has a high propensity to malignant conversion, and 
therefore the effect of Limk2 knock out was insufficient to produce a detectable 
difference. Apc mutant heterozygous mice, without KRAS mutation, are a good 
model for studying early events in CRC 501, and would possibly be appropriate for 
further investigation of the effect of Limk2 loss.  
7.1.4 Epigenetic	manipulation	in	colorectal	cancer	
It has been shown that DNA hypomethylation inhibits intestinal tumorigenesis 502, 
consistent with my finding that hypermethylation, with consequent LIMK2 
repression, accelerates colonic tumour progression. Treatment with DNMT 
inhibitors has been evaluated to a degree in CRC 503, where it was shown that 
DNMT inhibition potentiated the effects of standard cytotoxics on human CRC 
cell lines. The strategy of combining epigenetic therapies (including DNMT 
inhibitors and deacetylase inhibitors) with targeted therapies and 
chemotherapeutic agents in the treatment of solid tumours is one that is being 
continually evaluated in early phase clinical trials 504. The knowledge that LIMK2 
is hypermethylated could prove valuable in developing a predictive biomarker in 
CRC patients treated with epigenetic therapies. 
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7.2 Tumour	microenvironment	
I found that activating ROCK, and thus promoting actin stress fibre formation, 
led to the synthesis and deposition of ECM components, including TNC. As the 
density of the ECM increases, so does the mechanical tension within the stromal 
compartment and, as I showed in fibroblasts cultured on stiffer substrates, this 
alters the cellular phenotype to a more contractile myofibroblast, capable of 
depositing further ECM glycoproteins. This work was performed in a non-
malignant context, but there is evidently considerable overlap between the 
alterations observed in benign fibrotic conditions and malignant desmoplastic 
tumour stroma. Certainly, ROCK inhibition has been evaluated and found to be 
effective in the reduction of hepatic fibrosis 505 and pulmonary fibrosis 506. In the 
context of pancreatic ductal adenocarcinoma, a tumour type classically 
associated with desmoplasia and thus poor cytotoxic penetrance, ROCK 
inhibition has been utilised and found to reduce tumour collagen content 
(Whatcott Cancer Res 2012 (AACR abstract)). While other constituents of the 
stroma were not examined in this study, the question is raised: would ROCK 
inhibition reduce the TNC content of desmoplastic stroma? As previously 
outlined, a clear relationship exists between TNC and cancer progression; it 
would therefore be interesting to investigate the impact of ROCK inhibition on 
the TNC content of the tumour stroma and consequent tumour susceptibility to 
chemotherapeutic agents. It must be borne in mind that this work would need to 
be replicated in the cancer context to determine if the effects seen in fibrotic-
like tissue are reproduced. 
TNC knock out mice have been examined in cancer models, including the 
polyomavirus middle T breast cancer model 507. It was found that the TNC null 
tumours formed smaller “nests”, and the architecture of the stromal 
compartment was altered, with a significantly higher degree of immune cell 
(macrophage and monocyte) infiltration. This observation is of particular 
significance, given recent developments in the arena of cancer immunotherapy. 
It has been shown that stimulating the immune system, either through inhibition 
of the programmed death 1 (PD1) pathway or blockade of cytotoxic T-
lymphocyte protein 4 (CTLA4), produces impressive responses in multiple tumour 
types, including melanoma, renal cancer and non-small cell lung cancer 508. 
There appears to be a correlation between patients with pre-existing cellular 
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immune responses and degree and duration of tumour shrinkage 509. The 
knowledge that ROCK inhibition may reduce stromal TNC and permit a greater 
number of immune cells to enter the tumour microenvironment could be utilised 
to enhance the effectiveness of immunotherapies in those patients who have 
mounted an inadequate innate immune response. As previously outlined, TNC 
also appears to function in both cancer and wound healing through the induction 
of pro-inflammatory cytokines and immune cell modulation. It may be that the 
balance of differing immune cells present in the tumour stroma is under the 
influence of TNC, and can impact on host-environment responses. As headway 
continues to be made with implementing immunotherapy in clinical practice, 
more information will be gathered regarding this possibility. 
Recent work has found that K14 ROCK:ER mice display accelerated wound-
healing with an associated increase in collage, periostin and TNC deposition 
when compared with K14 KD:ER mice 510, Interestingly, the authors sought the 
presence of TNC in unwounded skin of WT animals and animals deficient in 14-3-
3ζ (a member of a family of phosphor-serine binding proteins; these mice also 
display rapid wound-healing). While they found that TNC was not detectable in 
unwounded skin, this was not examined in the ROCK-activated animals. I did not 
carry out any epidermal wounding studies, but it seems feasible that wound-
healing in the context of ROCK-activation would indeed lead to higher levels of 
TNC deposition. 
7.2.1 Gene	expression:	microarray	versus	RNA	sequencing	
There is a vast diversity of RNA expression from the genome; the transcriptome 
is dynamic, altering as a result of alternative splicing, post-transcriptional 
modifications, gene fusion, mutations, and changes in gene expression 511.  
 
Gene expression microarrays utilise probes that target a specific sequence 
within an mRNA transcript of interest, producing a record of genes that are 
actively expressed at a unique time-point. Microarrays have the capacity to 
concurrently investigate over 10,000 transcripts, permitting identification of 
genes with differential expression levels in healthy versus diseased tissues, 
evolutionary changes in gene regulation within disparate species, 
pharmacogenomic profiling and interrogation of developmental processes 512. 
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Gene expression microarrays have tended to be a widely utilised approach due 
to their affordability and accessibility since their introduction in the 1990s. 
 
However, there are limitations inherent to the use of gene expression microarray 
technology, as the ability to detect previously unidentified genes or transcripts 
is absent; consequently, alterations in their expression cannot be captured. 
Furthermore, transcripts present in low abundance may not be accurately 
detected due to background hybridisation. 
 
In the first instance, I elected to perform a gene expression microarray using the 
Affymetrix Mouse Gene 1.0 ST array platform, as this technology has been 
extensively used; thus, the results have been repeatedly validated, and the tools 
available to analyse the output are more mature. This yielded interesting 
results, and triggered further interrogation of TNC as a gene of interest. While 
TNC is seen to be present in the invading front and microenvironment of several 
tumour types, further research continues to elucidate the function that TNC may 
serve in this context; for example, TNC has been observed to induce resistance 
to apoptosis in pancreatic cancer cells via ERK/NFκB pathway activation 482.  
 
Technological advances have resulted in RNA sequencing becoming a more 
widely used technique to determine differential gene expression patterns. As the 
facility was available at the Beatson Institute Molecular Technology Service, I 
was keen to determine what new data could be garnered on the differences seen 
in ROCK-activated keratinocytes. In particular, the opportunity to detect new 
and unidentified genes, and transcripts with a low copy number was attractive. 
 
7.2.2 RNA	sequencing	of	ROCK-activated	versus	control	epidermal	
keratinocytes	
RNA sequencing was carried out on primary epidermal keratinocytes with and 
without ROCK activation. The finding that biological functions related to cancer 
show the most frequently altered gene expression patterns following ROCK 
activation is unsurprising given the high rate of somatic mutations in ROCK in 
numerous cancer types. RNA sequencing revealed differences in 65 genes with 
known functions; of those, 59 (90.8%) displayed “cancer” biological functions.  
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Upon further investigation, utilising Ingenuity® Pathway Analysis software, a 
number of networks were identified that showed differences in gene expression 
between the ROCK-activated and control cells. These included the “connective 
tissue disorders” network, confirming the previously noted relationship between 
ROCK activation, cytoskeletal contraction, and tissue fibrosis.  
As previously noted, ROCK signalling induces integrin signalling and consequent 
epidermal hyperproliferation 83; consistent with this, 18% of the noted genes 
were members of the “cell-to-cell signalling, cellular growth and proliferation” 
network. 
A number of putative “hits” were identified through RNA sequencing that were 
of particular interest from the perspective of determining the pathways and 
mechanisms at play to facilitate the epidermal thickening identified in ROCK-
activated animals. I have outlined the most intriguing of these below. 
7.2.2.1 Growth	differentiation	factor	15	
Growth differentiation factor 15 (GDF15), also known as macrophage inhibitory 
cytokine-1 (MIC1), belongs to the bone morphogenic protein group, which is in 
turn a member of the TGFβ family 513. In conditions of health, the majority of 
tissues display low levels of GDF15 expression (macrophages and the placenta 
being notable exceptions 514). In contrast, in chronic inflammatory states or 
following injury, GDF15 undergoes striking upregulation 515. Furthermore, GDF15 
is overexpressed in a number of solid tumours, including colon, prostate, breast, 
thyroid and pancreatic cancers 516, and a relationship has been observed 
between the presence of GDF15 in the primary tumour and GDF15 serum levels. 
High serum GDF15 levels are positively correlated with adverse clinical outcomes 
in both prostate and colon cancers 517,518.  
In the context of prostatic malignancy, GDF15 is highly upregulated in the 
tumour stroma; fibroblasts expressing GDF15 appear to display a high degree of 
commonality with myofibroblasts, with α smooth muscle actin expression and 
increased deposition of extracellular matrix components noted in both. In 
addition, stromally-derived GDF15 appears to facilitate prostate cancer cell 
proliferation, invasion and migration 519.  
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In addition to the role of GDF15 in the tumour microenvironment, there is also 
evidence that GDF15 may contribute to fibrosis in benign pathologies. In 
particular, patients with the diffuse cutaneous variant of systemic sclerosis have 
increased GDF15 levels in the serum when compared with both healthy controls 
and patients with limited cutaneous systemic sclerosis 520. The level of GDF15 
correlates with disease activity 521, indicating a possible role for GDF15 in the 
pathogenesis of chronic fibrotic conditions.  
I found that GDF15 transcripts were 1.75-fold more abundant in ROCK-activated 
compared with control keratinocytes (p=0.00244). My finding that GDF15 
transcripts are more abundant in ROCK-activated keratinocytes could thus 
explain the thickening and stiffening noted in the epidermis in vivo, as GDF15 
expression effectively generates a myofibroblast phenotype and appears to have 
a pro-fibrotic effect on the skin. 
7.2.2.2 Thymic	stromal	lymphopoietin	
Thymic stromal lymphopoietin (TSLP) is a cytokine that belongs to the IL-7 
family; it is largely expressed by the epithelial cells found on barrier surfaces 
(e.g. the skin and gut), where it is thought to function to maintain homeostasis 
through regulating immune cell activation 522.  
An animal model with a Tslp transgene expressed specifically in epidermal 
keratinocytes was shown to spontaneously develop cutaneous lesions resembling 
atopic dermatitis 523, an inflammatory skin condition characterised by epidermal 
hypertrophy, hyperkeratosis, and dermal inflammatory cell infiltrates 524. 
Subsequent studies have revealed that patients with diffuse cutaneous systemic 
sclerosis, a fibrotic skin condition, express high levels of TSLP within the skin. 
Further interrogation of the mechanisms at play suggests that TSLP may trigger 
pro-fibrotic and pro-inflammatory signalling; of note, there appears to be a 
degree of overlap between the effects of TSLP signalling and the alterations 
brought about by TGFβ signalling 525. 
In the context of malignancy, TSLP has been found to facilitate T helper immune 
responses that, in turn, stimulate a dialogue between cancer-associated 
fibroblasts, tumour cells and immune cells that promotes tumour progression 526. 
191 
 
Production of TSLP by CAFs in the tumour stroma surrounding pancreatic cancers 
appears to induce T helper-mediated inflammation, with a correlation being 
noted between TSLP production, T helper cell infiltrates and poor survival 
outcomes 527. 
TSLP has also been shown to facilitate neo-angiogenesis in cervical cancer 
models; the addition of recombinant TSLP to cell culture media enhances HUVEC 
proliferation. Furthermore, TSLP derived from cervical cancer cell lines had a 
similar impact, while blocking TSLP with neutralising antibody reduced the 
production of markers of angiogenesis such as IL-6, IL-6 and VEGF 528. 
Some evidence exists that TSLP may also participate in promoting tumour 
metastasis; it appears that TSLP mediates T helper responses to facilitate the 
escape of cells from the primary tumour. TSLP also apparently recruits 
regulatory T cells, which are necessary for the establishment of lung metastases 
in breast cancer 529. 
These data indicate that TSLP promotes non-malignant tissue fibrosis; in 
addition, there is an apparent role for TSLP in cancer progression, through 
facilitation of an immune cell dialogue between the tumour and the 
microenvironment, via a pro-vascularisation function, and potentially by 
promoting tumour cell metastasis. I found that Tslp transcripts were 2.38-fold 
more abundant in ROCK-activated versus control keratinocytes (p=0.033). My 
finding that Tslp is upregulated in keratinocytes following ROCK-activation 
suggests that increased tissue tension may feed into these facets of cellular 
behaviour. 
7.3 Final	conclusion	
I approached the investigation of the actin cytoskeleton in cancer in two distinct 
manners. In the first instance, using methylation studies including bisulphite 
sequencing, I identified epigenetic regulation as an important determinant of 
LIMK2 expression in colorectal cancer, with consequent impact on clinical 
behaviour of the disease, and thus translational implications. The ability to more 
accurately determine subgroups of patients with a poor prognosis is a 
longstanding goal, as this would enable the intensification of treatment in those 
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patients in whom this was deemed necessary, while sparing those patients with a 
relatively favourable outlook the toxicity associated with many anti-cancer 
treatments. Testing colorectal tumours for the presence or absence of LIMK2 
may be a step towards identifying prognostic biomarkers, and could be further 
evaluated in the clinical setting. 
Following on from this, I chose to interrogate how the changes that occur in the 
cytoskeleton of cells within the tumour stromal compartment are brought about, 
and how these alterations in turn impact upon the microenvironment. The data I 
have presented in this thesis indicate that stromal cells become increasingly 
contractile as the surroundings become stiffer. This promotes the transformation 
of stromal fibroblasts to cancer-associated fibroblasts, leading to the synthesis 
and deposition of extracellular matrix components (including Tenascin C), 
compounding the raised level of mechanical tension. Thus, a positive feedback 
cycle is established within the stroma, with evidence implicating this as an 
adverse prognostic indicator in a number of tumour types.  
This work was a continuation of a project previously carried out in the group 
that had used the epidermis as its model system. In a clinical context, this most 
closely resembles cutaneous squamous cell cancer; indeed there is evidence that 
increased stiffness of cSCC is associated with poor patient outcomes. As this is 
one of the most common types of malignancy encountered in clinical practice, 
the possibility that inhibition of ROCK could play a role in reducing stromal 
stiffness and thus potentially render inoperable tumours amenable to surgery is 
an intriguing one. 
 
 
 
 
 
193 
 
 
  
194 
 
References 
 
1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 
Mar 4 2011;144(5):646-674. 
2. Holmes KC, Popp D, Gebhard W, Kabsch W. Atomic model of the actin 
filament. Nature. Sep 6 1990;347(6288):44-49. 
3. Wegner A. Head to tail polymerization of actin. J Mol Biol. Nov 
1976;108(1):139-150. 
4. Pollard TD, Borisy GG. Cellular motility driven by assembly and 
disassembly of actin filaments. Cell. Feb 21 2003;112(4):453-465. 
5. Isenberg G, Aebi U, Pollard TD. An actin-binding protein from 
Acanthamoeba regulates actin filament polymerization and interactions. 
Nature. Dec 4 1980;288(5790):455-459. 
6. Burridge K, Fath K, Kelly T, Nuckolls G, Turner C. Focal adhesions: 
transmembrane junctions between the extracellular matrix and the 
cytoskeleton. Annu Rev Cell Biol. 1988;4:487-525. 
7. Hall A. The cytoskeleton and cancer. Cancer Metastasis Rev. Jun 
2009;28(1-2):5-14. 
8. Valencia A, Chardin P, Wittinghofer A, Sander C. The ras protein family: 
evolutionary tree and role of conserved amino acids. Biochemistry. May 
14 1991;30(19):4637-4648. 
9. Freeman JL, Abo A, Lambeth JD. Rac "insert region" is a novel effector 
region that is implicated in the activation of NADPH oxidase, but not 
PAK65. J Biol Chem. Aug 16 1996;271(33):19794-19801. 
10. Wheeler AP, Ridley AJ. Why three Rho proteins? RhoA, RhoB, RhoC, and 
cell motility. Exp Cell Res. Nov 15 2004;301(1):43-49. 
11. Kitzing TM, Wang Y, Pertz O, Copeland JW, Grosse R. Formin-like 2 drives 
amoeboid invasive cell motility downstream of RhoC. Oncogene. Apr 22 
2010;29(16):2441-2448. 
195 
 
12. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. 
Genes Dev. Sep 15 1997;11(18):2295-2322. 
13. Lamarche N, Hall A. GAPs for rho-related GTPases. Trends Genet. Dec 
1994;10(12):436-440. 
14. Olofsson B. Rho guanine dissociation inhibitors: pivotal molecules in 
cellular signalling. Cell Signal. Aug 1999;11(8):545-554. 
15. Hoffman GR, Nassar N, Cerione RA. Structure of the Rho family GTP-
binding protein Cdc42 in complex with the multifunctional regulator 
RhoGDI. Cell. Feb 4 2000;100(3):345-356. 
16. Robbe K, Otto-Bruc A, Chardin P, Antonny B. Dissociation of GDP 
dissociation inhibitor and membrane translocation are required for 
efficient activation of Rac by the Dbl homology-pleckstrin homology 
region of Tiam. J Biol Chem. Feb 14 2003;278(7):4756-4762. 
17. Liu M, Bi F, Zhou X, Zheng Y. Rho GTPase regulation by miRNAs and 
covalent modifications. Trends Cell Biol. Jul 2012;22(7):365-373. 
18. Navarro-Lerida I, Sanchez-Perales S, Calvo M, et al. A palmitoylation 
switch mechanism regulates Rac1 function and membrane organization. 
Embo J. Feb 1 2012;31(3):534-551. 
19. Loirand G, Guilluy C, Pacaud P. Regulation of Rho proteins by 
phosphorylation in the cardiovascular system. Trends Cardiovasc Med. Aug 
2006;16(6):199-204. 
20. Yarbrough ML, Li Y, Kinch LN, Grishin NV, Ball HL, Orth K. AMPylation of 
Rho GTPases by Vibrio VopS disrupts effector binding and downstream 
signaling. Science. Jan 9 2009;323(5911):269-272. 
21. Schmidt G, Sehr P, Wilm M, Selzer J, Mann M, Aktories K. Gln 63 of Rho is 
deamidated by Escherichia coli cytotoxic necrotizing factor-1. Nature. Jun 
12 1997;387(6634):725-729. 
196 
 
22. Doye A, Mettouchi A, Bossis G, et al. CNF1 exploits the ubiquitin-
proteasome machinery to restrict Rho GTPase activation for bacterial host 
cell invasion. Cell. Nov 15 2002;111(4):553-564. 
23. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-
binding protein rac regulates growth factor-induced membrane ruffling. 
Cell. Aug 7 1992;70(3):401-410. 
24. Nobes CD, Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of 
multimolecular focal complexes associated with actin stress fibers, 
lamellipodia, and filopodia. Cell. Apr 7 1995;81(1):53-62. 
25. Knaus UG, Wang Y, Reilly AM, Warnock D, Jackson JH. Structural 
requirements for PAK activation by Rac GTPases. J Biol Chem. Aug 21 
1998;273(34):21512-21518. 
26. Morreale A, Venkatesan M, Mott HR, et al. Structure of Cdc42 bound to 
the GTPase binding domain of PAK. Nat Struct Biol. May 2000;7(5):384-
388. 
27. Edwards DC, Sanders LC, Bokoch GM, Gill GN. Activation of LIM-kinase by 
Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. 
Nat Cell Biol. Sep 1999;1(5):253-259. 
28. Sanders LC, Matsumura F, Bokoch GM, de Lanerolle P. Inhibition of myosin 
light chain kinase by p21-activated kinase. Science. Mar 26 
1999;283(5410):2083-2085. 
29. Rohatgi R, Ho HY, Kirschner MW. Mechanism of N-WASP activation by 
CDC42 and phosphatidylinositol 4, 5-bisphosphate. J Cell Biol. Sep 18 
2000;150(6):1299-1310. 
30. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat 
Rev Mol Cell Biol. Jun 2003;4(6):446-456. 
31. Leung T, Chen XQ, Manser E, Lim L. The p160 RhoA-binding kinase ROK 
alpha is a member of a kinase family and is involved in the reorganization 
of the cytoskeleton. Mol Cell Biol. Oct 1996;16(10):5313-5327. 
197 
 
32. Wen W, Liu W, Yan J, Zhang M. Structure basis and unconventional lipid 
membrane binding properties of the PH-C1 tandem of rho kinases. J Biol 
Chem. Sep 19 2008;283(38):26263-26273. 
33. Amano M, Chihara K, Nakamura N, Kaneko T, Matsuura Y, Kaibuchi K. The 
COOH terminus of Rho-kinase negatively regulates rho-kinase activity. J 
Biol Chem. Nov 5 1999;274(45):32418-32424. 
34. Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S. ROCK-I 
and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein 
serine/threonine kinase in mice. FEBS Lett. Aug 26 1996;392(2):189-193. 
35. Amano M, Ito M, Kimura K, et al. Phosphorylation and activation of myosin 
by Rho-associated kinase (Rho-kinase). J Biol Chem. Aug 23 
1996;271(34):20246-20249. 
36. Rath N, Olson MF. Rho-associated kinases in tumorigenesis: re-considering 
ROCK inhibition for cancer therapy. EMBO Rep. Oct 2012;13(10):900-908. 
37. Matsuoka T, Yashiro M. Rho/ROCK signaling in motility and metastasis of 
gastric cancer. World journal of gastroenterology. Oct 14 
2014;20(38):13756-13766. 
38. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho 
and Rho-associated kinase (Rho-kinase). Science. Jul 12 
1996;273(5272):245-248. 
39. Velasco G, Armstrong C, Morrice N, Frame S, Cohen P. Phosphorylation of 
the regulatory subunit of smooth muscle protein phosphatase 1M at 
Thr850 induces its dissociation from myosin. FEBS Lett. Sep 11 
2002;527(1-3):101-104. 
40. Scott RW, Olson MF. LIM kinases: function, regulation and association with 
human disease. J Mol Med (Berl). Jun 2007;85(6):555-568. 
41. Arber S, Barbayannis FA, Hanser H, et al. Regulation of actin dynamics 
through phosphorylation of cofilin by LIM-kinase. Nature. Jun 25 
1998;393(6687):805-809. 
198 
 
42. Fujisawa K, Fujita A, Ishizaki T, Saito Y, Narumiya S. Identification of the 
Rho-binding domain of p160ROCK, a Rho-associated coiled-coil containing 
protein kinase. J Biol Chem. Sep 20 1996;271(38):23022-23028. 
43. Takahashi N, Tuiki H, Saya H, Kaibuchi K. Localization of the gene coding 
for ROCK II/Rho kinase on human chromosome 2p24. Genomics. Jan 15 
1999;55(2):235-237. 
44. Shimizu Y, Thumkeo D, Keel J, et al. ROCK-I regulates closure of the 
eyelids and ventral body wall by inducing assembly of actomyosin bundles. 
J Cell Biol. Mar 14 2005;168(6):941-953. 
45. Thumkeo D, Keel J, Ishizaki T, et al. Targeted disruption of the mouse 
rho-associated kinase 2 gene results in intrauterine growth retardation 
and fetal death. Mol Cell Biol. Jul 2003;23(14):5043-5055. 
46. Amano M, Chihara K, Kimura K, et al. Formation of actin stress fibers and 
focal adhesions enhanced by Rho-kinase. Science. Feb 28 
1997;275(5304):1308-1311. 
47. Burridge K, Chrzanowska-Wodnicka M. Focal adhesions, contractility, and 
signaling. Annu Rev Cell Dev Biol. 1996;12:463-518. 
48. Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem 
cell lineage specification. Cell. Aug 25 2006;126(4):677-689. 
49. Trybus KM. Assembly of cytoplasmic and smooth muscle myosins. Curr 
Opin Cell Biol. Feb 1991;3(1):105-111. 
50. Gordon AM, Homsher E, Regnier M. Regulation of contraction in striated 
muscle. Physiol Rev. Apr 2000;80(2):853-924. 
51. Heissler SM, Sellers JR. Various themes of myosin regulation. J Mol Biol. 
Jan 28 2016. 
52. Kamm KE, Stull JT. The function of myosin and myosin light chain kinase 
phosphorylation in smooth muscle. Annu Rev Pharmacol Toxicol. 
1985;25:593-620. 
199 
 
53. Ye LH, Kishi H, Nakamura A, et al. Myosin light-chain kinase of smooth 
muscle stimulates myosin ATPase activity without phosphorylating myosin 
light chain. Proc Natl Acad Sci U S A. Jun 8 1999;96(12):6666-6671. 
54. Gao Y, Ye LH, Kishi H, et al. Myosin light chain kinase as a multifunctional 
regulatory protein of smooth muscle contraction. IUBMB Life. Jun 
2001;51(6):337-344. 
55. Qi D, Mitchell RW, Burdyga T, Ford LE, Kuo KH, Seow CY. Myosin light 
chain phosphorylation facilitates in vivo myosin filament reassembly after 
mechanical perturbation. Am J Physiol Cell Physiol. Jun 
2002;282(6):C1298-1305. 
56. O'Connell CB, Tyska MJ, Mooseker MS. Myosin at work: motor adaptations 
for a variety of cellular functions. Biochim Biophys Acta. May 
2007;1773(5):615-630. 
57. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rho-kinase and 
protein phosphatase to smooth muscle and non-muscle myosin II. J 
Physiol. Jan 15 2000;522 Pt 2:177-185. 
58. Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF. Membrane 
blebbing during apoptosis results from caspase-mediated activation of 
ROCK I. Nat Cell Biol. Apr 2001;3(4):339-345. 
59. Gilmore AP. Anoikis. Cell Death Differ. Nov 2005;12 Suppl 2:1473-1477. 
60. Boudreau N, Sympson CJ, Werb Z, Bissell MJ. Suppression of ICE and 
apoptosis in mammary epithelial cells by extracellular matrix. Science. 
Feb 10 1995;267(5199):891-893. 
61. Walsh SV, Hopkins AM, Chen J, Narumiya S, Parkos CA, Nusrat A. Rho 
kinase regulates tight junction function and is necessary for tight junction 
assembly in polarized intestinal epithelia. Gastroenterology. Sep 
2001;121(3):566-579. 
62. McKenzie JA, Ridley AJ. Roles of Rho/ROCK and MLCK in TNF-alpha-
induced changes in endothelial morphology and permeability. J Cell 
Physiol. Oct 2007;213(1):221-228. 
200 
 
63. Sahai E, Marshall CJ. ROCK and Dia have opposing effects on adherens 
junctions downstream of Rho. Nat Cell Biol. Jun 2002;4(6):408-415. 
64. Bhowmick NA, Ghiassi M, Bakin A, et al. Transforming growth factor-beta1 
mediates epithelial to mesenchymal transdifferentiation through a RhoA-
dependent mechanism. Mol Biol Cell. Jan 2001;12(1):27-36. 
65. Pawlak G, Helfman DM. Post-transcriptional down-regulation of 
ROCKI/Rho-kinase through an MEK-dependent pathway leads to 
cytoskeleton disruption in Ras-transformed fibroblasts. Mol Biol Cell. Jan 
2002;13(1):336-347. 
66. Sahai E, Ishizaki T, Narumiya S, Treisman R. Transformation mediated by 
RhoA requires activity of ROCK kinases. Curr Biol. Feb 11 1999;9(3):136-
145. 
67. Chevrier V, Piel M, Collomb N, et al. The Rho-associated protein kinase 
p160ROCK is required for centrosome positioning. J Cell Biol. May 27 
2002;157(5):807-817. 
68. Croft DR, Olson MF. The Rho GTPase effector ROCK regulates cyclin A, 
cyclin D1, and p27Kip1 levels by distinct mechanisms. Mol Cell Biol. Jun 
2006;26(12):4612-4627. 
69. Ohgushi M, Sasai Y. Lonely death dance of human pluripotent stem cells: 
ROCKing between metastable cell states. Trends Cell Biol. May 
2011;21(5):274-282. 
70. Watanabe K, Ueno M, Kamiya D, et al. A ROCK inhibitor permits survival 
of dissociated human embryonic stem cells. Nat Biotechnol. Jun 
2007;25(6):681-686. 
71. Krawetz RJ, Li X, Rancourt DE. Human embryonic stem cells: caught 
between a ROCK inhibitor and a hard place. Bioessays. Mar 
2009;31(3):336-343. 
72. Rungsiwiwut R, Manolertthewan C, Numchaisrika P, et al. The ROCK 
inhibitor Y-26732 enhances the survival and proliferation of human 
201 
 
embryonic stem cell-derived neural progenitor cells upon dissociation. 
Cells Tissues Organs. 2013;198(2):127-138. 
73. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in 
human cancer genomes. Nature. Mar 8 2007;446(7132):153-158. 
74. Lochhead PA, Wickman G, Mezna M, Olson MF. Activating ROCK1 somatic 
mutations in human cancer. Oncogene. Apr 29 2010;29(17):2591-2598. 
75. Lane J, Martin TA, Watkins G, Mansel RE, Jiang WG. The expression and 
prognostic value of ROCK I and ROCK II and their role in human breast 
cancer. Int J Oncol. Sep 2008;33(3):585-593. 
76. Liu X, Choy E, Hornicek FJ, et al. ROCK1 as a potential therapeutic target 
in osteosarcoma. J Orthop Res. Aug 2011;29(8):1259-1266. 
77. Wong CC, Wong CM, Tung EK, Man K, Ng IO. Rho-kinase 2 is frequently 
overexpressed in hepatocellular carcinoma and involved in tumor 
invasion. Hepatology. May 2009;49(5):1583-1594. 
78. Kamai T, Tsujii T, Arai K, et al. Significant association of Rho/ROCK 
pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 
Jul 2003;9(7):2632-2641. 
79. Provenzano PP, Inman DR, Eliceiri KW, et al. Collagen density promotes 
mammary tumor initiation and progression. BMC Med. 2008;6:11. 
80. Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic 
ductal adenocarcinoma. Mol Cancer Ther. Apr 2007;6(4):1186-1197. 
81. Conklin MW, Eickhoff JC, Riching KM, et al. Aligned collagen is a 
prognostic signature for survival in human breast carcinoma. Am J Pathol. 
Mar 2011;178(3):1221-1232. 
82. Whatcott CJ, Diep CH, Jiang P, et al. Desmoplasia in Primary Tumors and 
Metastatic Lesions of Pancreatic Cancer. Clin Cancer Res. Aug 1 
2015;21(15):3561-3568. 
83. Samuel MS, Lopez JI, McGhee EJ, et al. Actomyosin-mediated cellular 
tension drives increased tissue stiffness and beta-catenin activation to 
202 
 
induce epidermal hyperplasia and tumor growth. Cancer Cell. Jun 14 
2011;19(6):776-791. 
84. Ibbetson SJ, Pyne NT, Pollard AN, Olson MF, Samuel MS. 
Mechanotransduction pathways promoting tumor progression are activated 
in invasive human squamous cell carcinoma. Am J Pathol. Sep 
2013;183(3):930-937. 
85. Raviraj V, Fok S, Zhao J, et al. Regulation of ROCK1 via Notch1 during 
breast cancer cell migration into dense matrices. BMC Cell Biol. 
2012;13:12. 
86. Gaggioli C, Hooper S, Hidalgo-Carcedo C, et al. Fibroblast-led collective 
invasion of carcinoma cells with differing roles for RhoGTPases in leading 
and following cells. Nat Cell Biol. Dec 2007;9(12):1392-1400. 
87. Sanz-Moreno V, Gaggioli C, Yeo M, et al. ROCK and JAK1 signaling 
cooperate to control actomyosin contractility in tumor cells and stroma. 
Cancer Cell. Aug 16 2011;20(2):229-245. 
88. Neri S, Ishii G, Hashimoto H, et al. Podoplanin-expressing cancer-
associated fibroblasts lead and enhance the local invasion of cancer cells 
in lung adenocarcinoma. Int J Cancer. Aug 15 2015;137(4):784-796. 
89. Nagumo H, Sasaki Y, Ono Y, Okamoto H, Seto M, Takuwa Y. Rho kinase 
inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in 
smooth muscle cells. Am J Physiol Cell Physiol. Jan 2000;278(1):C57-65. 
90. Ishizaki T, Uehata M, Tamechika I, et al. Pharmacological properties of Y-
27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. May 
2000;57(5):976-983. 
91. Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor 
(S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as 
a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther. 
Feb-Mar 2002;93(2-3):225-232. 
203 
 
92. Breitenlechner C, Gassel M, Hidaka H, et al. Protein kinase A in complex 
with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis 
of selectivity. Structure. Dec 2003;11(12):1595-1607. 
93. Wermke M, Camgoz A, Paszkowski-Rogacz M, et al. RNAi profiling of 
primary human AML cells identifies ROCK1 as a therapeutic target and 
nominates fasudil as an antileukemic drug. Blood. Jun 11 
2015;125(24):3760-3768. 
94. Fagan-Solis KD, Schneider SS, Pentecost BT, et al. The RhoA pathway 
mediates MMP-2 and MMP-9-independent invasive behavior in a triple-
negative breast cancer cell line. J Cell Biochem. Jun 2013;114(6):1385-
1394. 
95. Abe H, Kamai T, Hayashi K, et al. The Rho-kinase inhibitor HA-1077 
suppresses proliferation/migration and induces apoptosis of urothelial 
cancer cells. BMC Cancer. 2014;14:412. 
96. Yang X, Di J, Zhang Y, et al. The Rho-kinase inhibitor inhibits proliferation 
and metastasis of small cell lung cancer. Biomed Pharmacother. Apr 
2012;66(3):221-227. 
97. Deng L, Li G, Li R, Liu Q, He Q, Zhang J. Rho-kinase inhibitor, fasudil, 
suppresses glioblastoma cell line progression in vitro and in vivo. Cancer 
Biol Ther. Jun 1 2010;9(11):875-884. 
98. Chen W, Mao K, Hua-Huy T, Bei Y, Liu Z, Dinh-Xuan AT. Fasudil inhibits 
prostate cancer-induced angiogenesis in vitro. Oncol Rep. Dec 
2014;32(6):2795-2802. 
99. Zhang JG, Li XY, Wang YZ, et al. ROCK is involved in vasculogenic mimicry 
formation in hepatocellular carcinoma cell line. PLoS One. 
2014;9(9):e107661. 
100. Routhier A, Astuccio M, Lahey D, et al. Pharmacological inhibition of Rho-
kinase signaling with Y-27632 blocks melanoma tumor growth. Oncol Rep. 
Mar 2010;23(3):861-867. 
204 
 
101. Ikebe C, Ohashi K, Fujimori T, et al. Mouse LIM-kinase 2 gene: cDNA 
cloning, genomic organization, and tissue-specific expression of two 
alternatively initiated transcripts. Genomics. Dec 15 1997;46(3):504-508. 
102. Foletta VC, Moussi N, Sarmiere PD, Bamburg JR, Bernard O. LIM kinase 1, 
a key regulator of actin dynamics, is widely expressed in embryonic and 
adult tissues. Exp Cell Res. Apr 1 2004;294(2):392-405. 
103. Acevedo K, Moussi N, Li R, Soo P, Bernard O. LIM kinase 2 is widely 
expressed in all tissues. J Histochem Cytochem. May 2006;54(5):487-501. 
104. Bernstein BW, Bamburg JR. ADF/cofilin: a functional node in cell biology. 
Trends Cell Biol. Apr 2010;20(4):187-195. 
105. Ghosh M, Song X, Mouneimne G, Sidani M, Lawrence DS, Condeelis JS. 
Cofilin promotes actin polymerization and defines the direction of cell 
motility. Science. Apr 30 2004;304(5671):743-746. 
106. Gorovoy M, Niu J, Bernard O, et al. LIM kinase 1 coordinates microtubule 
stability and actin polymerization in human endothelial cells. J Biol 
Chem. Jul 15 2005;280(28):26533-26542. 
107. Bagheri-Yarmand R, Mazumdar A, Sahin AA, Kumar R. LIM kinase 1 
increases tumor metastasis of human breast cancer cells via regulation of 
the urokinase-type plasminogen activator system. Int J Cancer. Jun 1 
2006;118(11):2703-2710. 
108. Davila M, Frost AR, Grizzle WE, Chakrabarti R. LIM kinase 1 is essential for 
the invasive growth of prostate epithelial cells: implications in prostate 
cancer. J Biol Chem. Sep 19 2003;278(38):36868-36875. 
109. Yoshioka K, Foletta V, Bernard O, Itoh K. A role for LIM kinase in cancer 
invasion. Proc Natl Acad Sci U S A. Jun 10 2003;100(12):7247-7252. 
110. Vlecken DH, Bagowski CP. LIMK1 and LIMK2 are important for metastatic 
behavior and tumor cell-induced angiogenesis of pancreatic cancer cells. 
Zebrafish. Dec 2009;6(4):433-439. 
205 
 
111. Croft DR, Crighton D, Samuel MS, et al. p53-mediated transcriptional 
regulation and activation of the actin cytoskeleton regulatory RhoC to 
LIMK2 signaling pathway promotes cell survival. Cell Res. Apr 
2011;21(4):666-682. 
112. Hsu FF, Lin TY, Chen JY, Shieh SY. p53-Mediated transactivation of LIMK2b 
links actin dynamics to cell cycle checkpoint control. Oncogene. May 13 
2010;29(19):2864-2876. 
113. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during 
colorectal-tumor development. N Engl J Med. Sep 1 1988;319(9):525-532. 
114. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal 
cancers. Nature. Apr 10 1997;386(6625):623-627. 
115. Cottrell S, Bicknell D, Kaklamanis L, Bodmer WF. Molecular analysis of 
APC mutations in familial adenomatous polyposis and sporadic colon 
carcinomas. Lancet. Sep 12 1992;340(8820):626-630. 
116. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, 
Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair 
status. Nature. Aug 29 2002;418(6901):934. 
117. Thiagalingam S, Lengauer C, Leach FS, et al. Evaluation of candidate 
tumour suppressor genes on chromosome 18 in colorectal cancers. Nat 
Genet. Jul 1996;13(3):343-346. 
118. Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 
gene mutations in colorectal carcinomas. Science. Apr 14 
1989;244(4901):217-221. 
119. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and 
caretakers. Nature. Apr 24 1997;386(6627):761, 763. 
120. Herman JG, Umar A, Polyak K, et al. Incidence and functional 
consequences of hMLH1 promoter hypermethylation in colorectal 
carcinoma. Proc Natl Acad Sci U S A. Jun 9 1998;95(12):6870-6875. 
206 
 
121. Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the 
Wnt pathway. Oncogene. Dec 4 2006;25(57):7531-7537. 
122. van der Klift H, Wijnen J, Wagner A, et al. Molecular characterization of 
the spectrum of genomic deletions in the mismatch repair genes MSH2, 
MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal 
cancer (HNPCC). Genes Chromosomes Cancer. Oct 2005;44(2):123-138. 
123. Parsons R, Myeroff LL, Liu B, et al. Microsatellite instability and mutations 
of the transforming growth factor beta type II receptor gene in colorectal 
cancer. Cancer Res. Dec 1 1995;55(23):5548-5550. 
124. Souza RF, Appel R, Yin J, et al. Microsatellite instability in the insulin-like 
growth factor II receptor gene in gastrointestinal tumours. Nat Genet. Nov 
1996;14(3):255-257. 
125. Rampino N, Yamamoto H, Ionov Y, et al. Somatic frameshift mutations in 
the BAX gene in colon cancers of the microsatellite mutator phenotype. 
Science. Feb 14 1997;275(5302):967-969. 
126. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG 
island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S 
A. Jul 20 1999;96(15):8681-8686. 
127. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. 
Genetic prognostic and predictive markers in colorectal cancer. Nat Rev 
Cancer. Jul 2009;9(7):489-499. 
128. Ponz de Leon M, Benatti P, Borghi F, et al. Aetiology of colorectal cancer 
and relevance of monogenic inheritance. Gut. Jan 2004;53(1):115-122. 
129. Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ. Hereditary 
factors in cancer. Study of two large midwestern kindreds. Arch Intern 
Med. Feb 1966;117(2):206-212. 
130. Pedroni M, Sala E, Scarselli A, et al. Microsatellite instability and 
mismatch-repair protein expression in hereditary and sporadic colorectal 
carcinogenesis. Cancer Res. Feb 1 2001;61(3):896-899. 
207 
 
131. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of 
DNA-mismatch-repair genes. Int J Cancer. Apr 12 1999;81(2):214-218. 
132. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for 
hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) 
proposed by the International Collaborative group on HNPCC. 
Gastroenterology. Jun 1999;116(6):1453-1456. 
133. Gardner EJ. A genetic and clinical study of intestinal polyposis, a 
predisposing factor for carcinoma of the colon and rectum. Am J Hum 
Genet. Jun 1951;3(2):167-176. 
134. Groden J, Thliveris A, Samowitz W, et al. Identification and 
characterization of the familial adenomatous polyposis coli gene. Cell. 
Aug 9 1991;66(3):589-600. 
135. Bulow S. Familial polyposis coli. Dan Med Bull. Mar 1987;34(1):1-15. 
136. Hernegger GS, Moore HG, Guillem JG. Attenuated familial adenomatous 
polyposis: an evolving and poorly understood entity. Dis Colon Rectum. 
Jan 2002;45(1):127-134; discussion 134-126. 
137. Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH 
associated with somatic G:C-->T:A mutations in colorectal tumors. Nat 
Genet. Feb 2002;30(2):227-232. 
138. Crohn BB, Ginzburg L, Oppenheimer GD. Landmark article Oct 15, 1932. 
Regional ileitis. A pathological and clinical entity. By Burril B. Crohn, Leon 
Ginzburg, and Gordon D. Oppenheimer. Jama. Jan 6 1984;251(1):73-79. 
139. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and 
immunobiology. Lancet. May 12 2007;369(9573):1627-1640. 
140. Franchimont D, Vermeire S, El Housni H, et al. Deficient host-bacteria 
interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 
Asp299gly polymorphism is associated with Crohn's disease and ulcerative 
colitis. Gut. Jul 2004;53(7):987-992. 
208 
 
141. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in 
ulcerative colitis: a meta-analysis. Gut. Apr 2001;48(4):526-535. 
142. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk 
factor for progression to colorectal neoplasia in ulcerative colitis: a 
cohort study. Gastroenterology. Oct 2007;133(4):1099-1105; quiz 1340-
1091. 
143. Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J 
Gastroenterol. Jan 21 2008;14(3):378-389. 
144. Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and 
inflammatory bowel disease: epidemiology, risk factors, mechanisms of 
carcinogenesis and prevention strategies. Anticancer Res. Jul 
2009;29(7):2727-2737. 
145. Fukata M, Chen A, Vamadevan AS, et al. Toll-like receptor-4 promotes the 
development of colitis-associated colorectal tumors. Gastroenterology. 
Dec 2007;133(6):1869-1881. 
146. Roessner A, Kuester D, Malfertheiner P, Schneider-Stock R. Oxidative 
stress in ulcerative colitis-associated carcinogenesis. Pathol Res Pract. 
2008;204(7):511-524. 
147. Fantini MC, Pallone F. Cytokines: from gut inflammation to colorectal 
cancer. Curr Drug Targets. May 2008;9(5):375-380. 
148. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human 
cancers. Nature. Dec 17 1998;396(6712):643-649. 
149. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the 
proximal colon. Science. May 7 1993;260(5109):816-819. 
150. Merok MA, Ahlquist T, Royrvik EC, et al. Microsatellite instability has a 
positive prognostic impact on stage II colorectal cancer after complete 
resection: results from a large, consecutive Norwegian series. Ann Oncol. 
May 2013;24(5):1274-1282. 
209 
 
151. Soreide K, Janssen EA, Soiland H, Korner H, Baak JP. Microsatellite 
instability in colorectal cancer. Br J Surg. Apr 2006;93(4):395-406. 
152. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite 
instability and colorectal cancer prognosis. J Clin Oncol. Jan 20 
2005;23(3):609-618. 
153. Guastadisegni C, Colafranceschi M, Ottini L, Dogliotti E. Microsatellite 
instability as a marker of prognosis and response to therapy: a meta-
analysis of colorectal cancer survival data. Eur J Cancer. Oct 
2010;46(15):2788-2798. 
154. Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P. Regulation of 
intracellular beta-catenin levels by the adenomatous polyposis coli (APC) 
tumor-suppressor protein. Proc Natl Acad Sci U S A. Mar 28 
1995;92(7):3046-3050. 
155. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf 
signaling in colon cancer by mutations in beta-catenin or APC. Science. 
Mar 21 1997;275(5307):1787-1790. 
156. Sansom OJ, Reed KR, Hayes AJ, et al. Loss of Apc in vivo immediately 
perturbs Wnt signaling, differentiation, and migration. Genes Dev. Jun 15 
2004;18(12):1385-1390. 
157. Stamos JL, Weis WI. The beta-catenin destruction complex. Cold Spring 
Harb Perspect Biol. Jan 2013;5(1):a007898. 
158. Xing Y, Clements WK, Kimelman D, Xu W. Crystal structure of a beta-
catenin/axin complex suggests a mechanism for the beta-catenin 
destruction complex. Genes Dev. Nov 15 2003;17(22):2753-2764. 
159. Roberts DM, Pronobis MI, Poulton JS, et al. Deconstructing the sscatenin 
destruction complex: mechanistic roles for the tumor suppressor APC in 
regulating Wnt signaling. Mol Biol Cell. Jun 1 2011;22(11):1845-1863. 
160. Koinuma K, Yamashita Y, Liu W, et al. Epigenetic silencing of AXIN2 in 
colorectal carcinoma with microsatellite instability. Oncogene. Jan 5 
2006;25(1):139-146. 
210 
 
161. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat 
Rev Cancer. Jan 2003;3(1):11-22. 
162. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator 
phenotype underlies sporadic microsatellite instability and is tightly 
associated with BRAF mutation in colorectal cancer. Nat Genet. Jul 
2006;38(7):787-793. 
163. Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in 
advanced colorectal cancer are associated with poor prognosis but do not 
preclude benefit from oxaliplatin or irinotecan: results from the MRC 
FOCUS trial. J Clin Oncol. Dec 10 2009;27(35):5931-5937. 
164. Sarli L, Bottarelli L, Bader G, et al. Association between recurrence of 
sporadic colorectal cancer, high level of microsatellite instability, and 
loss of heterozygosity at chromosome 18q. Dis Colon Rectum. Sep 
2004;47(9):1467-1482. 
165. Schmitt CA, Thaler KR, Wittig BM, Kaulen H, Meyer zum Buschenfelde KH, 
Dippold WG. Detection of the DCC gene product in normal and malignant 
colorectal tissues and its relation to a codon 201 mutation. Br J Cancer. 
Feb 1998;77(4):588-594. 
166. Rodrigues S, De Wever O, Bruyneel E, Rooney RJ, Gespach C. Opposing 
roles of netrin-1 and the dependence receptor DCC in cancer cell 
invasion, tumor growth and metastasis. Oncogene. Aug 16 
2007;26(38):5615-5625. 
167. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell 
membrane to nucleus through SMAD proteins. Nature. Dec 4 
1997;390(6659):465-471. 
168. Alazzouzi H, Alhopuro P, Salovaara R, et al. SMAD4 as a prognostic marker 
in colorectal cancer. Clin Cancer Res. Apr 1 2005;11(7):2606-2611. 
169. Papageorgis P, Cheng K, Ozturk S, et al. Smad4 inactivation promotes 
malignancy and drug resistance of colon cancer. Cancer Res. Feb 1 
2011;71(3):998-1008. 
211 
 
170. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. 
Cell. Jun 1 1990;61(5):759-767. 
171. Westra JL, Boven LG, van der Vlies P, et al. A substantial proportion of 
microsatellite-unstable colon tumors carry TP53 mutations while not 
showing chromosomal instability. Genes Chromosomes Cancer. Jun 
2005;43(2):194-201. 
172. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal 
cancer: a systematic review. Br J Cancer. Feb 14 2005;92(3):434-444. 
173. Hoosein NM, McKnight MK, Levine AE, et al. Differential sensitivity of 
subclasses of human colon carcinoma cell lines to the growth inhibitory 
effects of transforming growth factor-beta 1. Exp Cell Res. Apr 
1989;181(2):442-453. 
174. Riggins GJ, Kinzler KW, Vogelstein B, Thiagalingam S. Frequency of Smad 
gene mutations in human cancers. Cancer Res. Jul 1 1997;57(13):2578-
2580. 
175. Akhurst RJ, Derynck R. TGF-beta signaling in cancer--a double-edged 
sword. Trends Cell Biol. Nov 2001;11(11):S44-51. 
176. Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, Cohen A. High levels 
of transforming growth factor beta 1 correlate with disease progression in 
human colon cancer. Cancer Epidemiol Biomarkers Prev. Jul-Aug 
1995;4(5):549-554. 
177. Calon A, Espinet E, Palomo-Ponce S, et al. Dependency of colorectal 
cancer on a TGF-beta-driven program in stromal cells for metastasis 
initiation. Cancer Cell. Nov 13 2012;22(5):571-584. 
178. Herman JG, Baylin SB. Gene silencing in cancer in association with 
promoter hypermethylation. N Engl J Med. Nov 20 2003;349(21):2042-
2054. 
179. Ahuja N, Mohan AL, Li Q, et al. Association between CpG island 
methylation and microsatellite instability in colorectal cancer. Cancer 
Res. Aug 15 1997;57(16):3370-3374. 
212 
 
180. Burri N, Shaw P, Bouzourene H, et al. Methylation silencing and mutations 
of the p14ARF and p16INK4a genes in colon cancer. Lab Invest. Feb 
2001;81(2):217-229. 
181. Hernandez-Blazquez FJ, Habib M, Dumollard JM, et al. Evaluation of 
global DNA hypomethylation in human colon cancer tissues by 
immunohistochemistry and image analysis. Gut. Nov 2000;47(5):689-693. 
182. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. Sep 21 
2006;355(12):1253-1261. 
183. Barker N, van Es JH, Kuipers J, et al. Identification of stem cells in small 
intestine and colon by marker gene Lgr5. Nature. Oct 25 
2007;449(7165):1003-1007. 
184. Barker N, Ridgway RA, van Es JH, et al. Crypt stem cells as the cells-of-
origin of intestinal cancer. Nature. Jan 29 2009;457(7229):608-611. 
185. Vermeulen L, De Sousa EMF, van der Heijden M, et al. Wnt activity defines 
colon cancer stem cells and is regulated by the microenvironment. Nat 
Cell Biol. May 2010;12(5):468-476. 
186. van der Flier LG, van Gijn ME, Hatzis P, et al. Transcription factor 
achaete scute-like 2 controls intestinal stem cell fate. Cell. Mar 6 
2009;136(5):903-912. 
187. Jubb AM, Hoeflich KP, Haverty PM, Wang J, Koeppen H. Ascl2 and 11p15.5 
amplification in colorectal cancer. Gut. Nov 2011;60(11):1606-1607; 
author reply 1607. 
188. Zhu R, Yang Y, Tian Y, et al. Ascl2 knockdown results in tumor growth 
arrest by miRNA-302b-related inhibition of colon cancer progenitor cells. 
PLoS One. 2012;7(2):e32170. 
189. Jung P, Sato T, Merlos-Suarez A, et al. Isolation and in vitro expansion of 
human colonic stem cells. Nat Med. Oct 2011;17(10):1225-1227. 
213 
 
190. Merlos-Suarez A, Barriga FM, Jung P, et al. The intestinal stem cell 
signature identifies colorectal cancer stem cells and predicts disease 
relapse. Cell Stem Cell. May 6 2011;8(5):511-524. 
191. Fre S, Huyghe M, Mourikis P, Robine S, Louvard D, Artavanis-Tsakonas S. 
Notch signals control the fate of immature progenitor cells in the 
intestine. Nature. Jun 16 2005;435(7044):964-968. 
192. Anderson EC, Wong MH. Caught in the Akt: regulation of Wnt signaling in 
the intestine. Gastroenterology. Sep 2010;139(3):718-722. 
193. Zhang Y, Li B, Ji ZZ, Zheng PS. Notch1 regulates the growth of human 
colon cancers. Cancer. Nov 15 2010;116(22):5207-5218. 
194. Kosinski C, Li VS, Chan AS, et al. Gene expression patterns of human colon 
tops and basal crypts and BMP antagonists as intestinal stem cell niche 
factors. Proc Natl Acad Sci U S A. Sep 25 2007;104(39):15418-15423. 
195. Lombardo Y, Scopelliti A, Cammareri P, et al. Bone morphogenetic 
protein 4 induces differentiation of colorectal cancer stem cells and 
increases their response to chemotherapy in mice. Gastroenterology. Jan 
2011;140(1):297-309. 
196. He XC, Zhang J, Tong WG, et al. BMP signaling inhibits intestinal stem cell 
self-renewal through suppression of Wnt-beta-catenin signaling. Nat 
Genet. Oct 2004;36(10):1117-1121. 
197. Powell DW, Adegboyega PA, Di Mari JF, Mifflin RC. Epithelial cells and 
their neighbors I. Role of intestinal myofibroblasts in development, repair, 
and cancer. Am J Physiol Gastrointest Liver Physiol. Jul 2005;289(1):G2-
7. 
198. Pinchuk IV, Beswick EJ, Saada JI, et al. Human colonic myofibroblasts 
promote expansion of CD4+ CD25high Foxp3+ regulatory T cells. 
Gastroenterology. Jun 2011;140(7):2019-2030. 
199. Yeung TM, Gandhi SC, Bodmer WF. Hypoxia and lineage specification of 
cell line-derived colorectal cancer stem cells. Proc Natl Acad Sci U S A. 
Mar 15 2011;108(11):4382-4387. 
214 
 
200. Mathieu J, Zhang Z, Zhou W, et al. HIF induces human embryonic stem 
cell markers in cancer cells. Cancer Res. Jul 1 2011;71(13):4640-4652. 
201. de Sousa EMF, Colak S, Buikhuisen J, et al. Methylation of cancer-stem-
cell-associated Wnt target genes predicts poor prognosis in colorectal 
cancer patients. Cell Stem Cell. Nov 4 2011;9(5):476-485. 
202. Gebhard C, Benner C, Ehrich M, et al. General transcription factor binding 
at CpG islands in normal cells correlates with resistance to de novo DNA 
methylation in cancer cells. Cancer Res. Feb 15 2010;70(4):1398-1407. 
203. Behrens J, Vakaet L, Friis R, et al. Loss of epithelial differentiation and 
gain of invasiveness correlates with tyrosine phosphorylation of the E-
cadherin/beta-catenin complex in cells transformed with a temperature-
sensitive v-SRC gene. J Cell Biol. Feb 1993;120(3):757-766. 
204. Bendardaf R, Elzagheid A, Lamlum H, Ristamaki R, Collan Y, Pyrhonen S. 
E-cadherin, CD44s and CD44v6 correlate with tumour differentiation in 
colorectal cancer. Oncol Rep. May 2005;13(5):831-835. 
205. Elzagheid A, Algars A, Bendardaf R, et al. E-cadherin expression pattern in 
primary colorectal carcinomas and their metastases reflects disease 
outcome. World J Gastroenterol. Jul 21 2006;12(27):4304-4309. 
206. Zumbrunn J, Kinoshita K, Hyman AA, Nathke IS. Binding of the 
adenomatous polyposis coli protein to microtubules increases microtubule 
stability and is regulated by GSK3 beta phosphorylation. Curr Biol. Jan 9 
2001;11(1):44-49. 
207. Rosin-Arbesfeld R, Ihrke G, Bienz M. Actin-dependent membrane 
association of the APC tumour suppressor in polarized mammalian 
epithelial cells. Embo J. Nov 1 2001;20(21):5929-5939. 
208. Watanabe T, Wang S, Noritake J, et al. Interaction with IQGAP1 links APC 
to Rac1, Cdc42, and actin filaments during cell polarization and 
migration. Dev Cell. Dec 2004;7(6):871-883. 
215 
 
209. Kawasaki Y, Senda T, Ishidate T, et al. Asef, a link between the tumor 
suppressor APC and G-protein signaling. Science. Aug 18 
2000;289(5482):1194-1197. 
210. Kawasaki Y, Sato R, Akiyama T. Mutated APC and Asef are involved in the 
migration of colorectal tumour cells. Nat Cell Biol. Mar 2003;5(3):211-
215. 
211. van der Flier A, Sonnenberg A. Function and interactions of integrins. Cell 
Tissue Res. Sep 2001;305(3):285-298. 
212. Ziegler WH, Gingras AR, Critchley DR, Emsley J. Integrin connections to 
the cytoskeleton through talin and vinculin. Biochem Soc Trans. Apr 
2008;36(Pt 2):235-239. 
213. Otey CA, Pavalko FM, Burridge K. An interaction between alpha-actinin 
and the beta 1 integrin subunit in vitro. J Cell Biol. Aug 1990;111(2):721-
729. 
214. Cabodi S, Di Stefano P, Leal Mdel P, et al. Integrins and signal 
transduction. Adv Exp Med Biol. 2010;674:43-54. 
215. Nemeth JA, Nakada MT, Trikha M, et al. Alpha-v integrins as therapeutic 
targets in oncology. Cancer Invest. Oct 2007;25(7):632-646. 
216. Denadai MV, Viana LS, Affonso RJ, Jr., et al. Expression of integrin genes 
and proteins in progression and dissemination of colorectal 
adenocarcinoma. BMC Clin Pathol. 2013;13:16. 
217. Enns A, Korb T, Schluter K, et al. Alphavbeta5-integrins mediate early 
steps of metastasis formation. Eur J Cancer. May 2005;41(7):1065-1072. 
218. Ha SY, Shin J, Kim JH, et al. Overexpression of integrin alphav correlates 
with poor prognosis in colorectal cancer. J Clin Pathol. Jul 
2014;67(7):576-581. 
219. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer. Feb 
2002;2(2):133-142. 
216 
 
220. Ohata H, Ishiguro T, Aihara Y, et al. Induction of the stem-like cell 
regulator CD44 by Rho kinase inhibition contributes to the maintenance of 
colon cancer-initiating cells. Cancer Res. Oct 1 2012;72(19):5101-5110. 
221. Rodrigues P, Macaya I, Bazzocco S, et al. RHOA inactivation enhances Wnt 
signalling and promotes colorectal cancer. Nat Commun. 2014;5:5458. 
222. Braga VM, Machesky LM, Hall A, Hotchin NA. The small GTPases Rho and 
Rac are required for the establishment of cadherin-dependent cell-cell 
contacts. J Cell Biol. Jun 16 1997;137(6):1421-1431. 
223. Scott RW, Hooper S, Crighton D, et al. LIM kinases are required for 
invasive path generation by tumor and tumor-associated stromal cells. J 
Cell Biol. Oct 4 2010;191(1):169-185. 
224. Lourenco FC, Munro J, Brown J, et al. Reduced LIMK2 expression in 
colorectal cancer reflects its role in limiting stem cell proliferation. Gut. 
Mar 2014;63(3):480-493. 
225. Ratushny V, Gober MD, Hick R, Ridky TW, Seykora JT. From keratinocyte 
to cancer: the pathogenesis and modeling of cutaneous squamous cell 
carcinoma. J Clin Invest. Feb 2012;122(2):464-472. 
226. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of 
skin cancer. Nature. Dec 22-29 1994;372(6508):773-776. 
227. Ortonne JP. From actinic keratosis to squamous cell carcinoma. Br J 
Dermatol. Apr 2002;146 Suppl 61:20-23. 
228. Campbell C, Quinn AG, Ro YS, Angus B, Rees JL. p53 mutations are 
common and early events that precede tumor invasion in squamous cell 
neoplasia of the skin. J Invest Dermatol. Jun 1993;100(6):746-748. 
229. Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: 
UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci 
U S A. Nov 15 1991;88(22):10124-10128. 
217 
 
230. Kubo Y, Urano Y, Yoshimoto K, et al. p53 gene mutations in human skin 
cancers and precancerous lesions: comparison with immunohistochemical 
analysis. J Invest Dermatol. Apr 1994;102(4):440-444. 
231. Pierceall WE, Goldberg LH, Tainsky MA, Mukhopadhyay T, Ananthaswamy 
HN. Ras gene mutation and amplification in human nonmelanoma skin 
cancers. Mol Carcinog. 1991;4(3):196-202. 
232. Spencer JM, Kahn SM, Jiang W, DeLeo VA, Weinstein IB. Activated ras 
genes occur in human actinic keratoses, premalignant precursors to 
squamous cell carcinomas. Arch Dermatol. Jul 1995;131(7):796-800. 
233. Khavari PA. Modelling cancer in human skin tissue. Nat Rev Cancer. Apr 
2006;6(4):270-280. 
234. Ridky TW, Chow JM, Wong DJ, Khavari PA. Invasive three-dimensional 
organotypic neoplasia from multiple normal human epithelia. Nat Med. 
Dec 2010;16(12):1450-1455. 
235. Dajee M, Lazarov M, Zhang JY, et al. NF-kappaB blockade and oncogenic 
Ras trigger invasive human epidermal neoplasia. Nature. Feb 6 
2003;421(6923):639-643. 
236. Lazarov M, Kubo Y, Cai T, et al. CDK4 coexpression with Ras generates 
malignant human epidermal tumorigenesis. Nat Med. Oct 
2002;8(10):1105-1114. 
237. Dotto GP. Notch tumor suppressor function. Oncogene. Sep 1 
2008;27(38):5115-5123. 
238. Okuyama R, Nguyen BC, Talora C, et al. High commitment of embryonic 
keratinocytes to terminal differentiation through a Notch1-caspase 3 
regulatory mechanism. Dev Cell. Apr 2004;6(4):551-562. 
239. Lefort K, Mandinova A, Ostano P, et al. Notch1 is a p53 target gene 
involved in human keratinocyte tumor suppression through negative 
regulation of ROCK1/2 and MRCKalpha kinases. Genes Dev. Mar 1 
2007;21(5):562-577. 
218 
 
240. Nicolas M, Wolfer A, Raj K, et al. Notch1 functions as a tumor suppressor 
in mouse skin. Nat Genet. Mar 2003;33(3):416-421. 
241. South AP, Purdie KJ, Watt SA, et al. NOTCH1 mutations occur early during 
cutaneous squamous cell carcinogenesis. J Invest Dermatol. Oct 
2014;134(10):2630-2638. 
242. Kowal-Vern A, Criswell BK. Burn scar neoplasms: a literature review and 
statistical analysis. Burns. Jun 2005;31(4):403-413. 
243. O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as 
the cause of malignancy. Br J Cancer. Aug 17 2001;85(4):473-483. 
244. Coussens LM, Werb Z. Inflammation and cancer. Nature. Dec 19-26 
2002;420(6917):860-867. 
245. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-Associated 
Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-
Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell. 
Feb 17 2010;17(2):135-147. 
246. Griffin JR, Wriston CC, Peters MS, Lehman JS. Decreased expression of 
intercellular adhesion molecules in acantholytic squamous cell carcinoma 
compared with invasive well-differentiated squamous cell carcinoma of 
the skin. Am J Clin Pathol. Apr 2013;139(4):442-447. 
247. Perez OD, Kinoshita S, Hitoshi Y, et al. Activation of the PKB/AKT pathway 
by ICAM-2. Immunity. Jan 2002;16(1):51-65. 
248. Sabeh F, Li XY, Saunders TL, Rowe RG, Weiss SJ. Secreted versus 
membrane-anchored collagenases: relative roles in fibroblast-dependent 
collagenolysis and invasion. J Biol Chem. Aug 21 2009;284(34):23001-
23011. 
249. Sasaki T, Fassler R, Hohenester E. Laminin: the crux of basement 
membrane assembly. J Cell Biol. Mar 29 2004;164(7):959-963. 
250. Ryan MC, Christiano AM, Engvall E, et al. The functions of laminins: 
lessons from in vivo studies. Matrix Biol. Dec 1996;15(6):369-381. 
219 
 
251. Yamamoto H, Itoh F, Iku S, Hosokawa M, Imai K. Expression of the 
gamma(2) chain of laminin-5 at the invasive front is associated with 
recurrence and poor prognosis in human esophageal squamous cell 
carcinoma. Clin Cancer Res. Apr 2001;7(4):896-900. 
252. Katayama M, Sekiguchi K. Laminin-5 in epithelial tumour invasion. J Mol 
Histol. Mar 2004;35(3):277-286. 
253. Waterman EA, Sakai N, Nguyen NT, et al. A laminin-collagen complex 
drives human epidermal carcinogenesis through phosphoinositol-3-kinase 
activation. Cancer Res. May 1 2007;67(9):4264-4270. 
254. Franz M, Hansen T, Richter P, et al. Complex formation of the laminin-5 
gamma2 chain and large unspliced tenascin-C in oral squamous cell 
carcinoma in vitro and in situ: implications for sequential modulation of 
extracellular matrix in the invasive tumor front. Histochem Cell Biol. Jul 
2006;126(1):125-131. 
255. Hennings H, Glick AB, Lowry DT, Krsmanovic LS, Sly LM, Yuspa SH. FVB/N 
mice: an inbred strain sensitive to the chemical induction of squamous 
cell carcinomas in the skin. Carcinogenesis. Nov 1993;14(11):2353-2358. 
256. Lelli KM, Slattery M, Mann RS. Disentangling the many layers of eukaryotic 
transcriptional regulation. Annu Rev Genet. 2012;46:43-68. 
257. Ong CT, Corces VG. Enhancer function: new insights into the regulation of 
tissue-specific gene expression. Nat Rev Genet. Apr 2011;12(4):283-293. 
258. Spitz F, Furlong EE. Transcription factors: from enhancer binding to 
developmental control. Nat Rev Genet. Sep 2012;13(9):613-626. 
259. Lee TI, Young RA. Transcriptional regulation and its misregulation in 
disease. Cell. Mar 14 2013;152(6):1237-1251. 
260. Littlewood TD, Kreuzaler P, Evan GI. All things to all people. Cell. Sep 28 
2012;151(1):11-13. 
220 
 
261. Kotake Y, Nakagawa T, Kitagawa K, et al. Long non-coding RNA ANRIL is 
required for the PRC2 recruitment to and silencing of p15(INK4B) tumor 
suppressor gene. Oncogene. Apr 21 2011;30(16):1956-1962. 
262. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human 
cancers. Nature. Jun 9 2005;435(7043):834-838. 
263. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are 
frequently located at fragile sites and genomic regions involved in 
cancers. Proc Natl Acad Sci U S A. Mar 2 2004;101(9):2999-3004. 
264. Weber B, Stresemann C, Brueckner B, Lyko F. Methylation of human 
microRNA genes in normal and neoplastic cells. Cell Cycle. May 2 
2007;6(9):1001-1005. 
265. Chang TC, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 
broadly influences gene expression and promotes apoptosis. Mol Cell. Jun 
8 2007;26(5):745-752. 
266. Sass S, Dietmann S, Burk UC, et al. MicroRNAs coordinately regulate 
protein complexes. BMC Syst Biol. 2011;5:136. 
267. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic 
pathway: destruction for the sake of construction. Physiol Rev. Apr 
2002;82(2):373-428. 
268. Pray TR, Parlati F, Huang J, et al. Cell cycle regulatory E3 ubiquitin 
ligases as anticancer targets. Drug Resist Updat. Dec 2002;5(6):249-258. 
269. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. Jan 7 
2000;100(1):57-70. 
270. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. Jan 
1 2002;16(1):6-21. 
271. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. Feb 
1999;21(2):163-167. 
272. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. 
Nat Rev Genet. Jun 2002;3(6):415-428. 
221 
 
273. Herman JG. Hypermethylation of tumor suppressor genes in cancer. Semin 
Cancer Biol. Oct 1999;9(5):359-367. 
274. Rideout WM, 3rd, Coetzee GA, Olumi AF, Jones PA. 5-Methylcytosine as an 
endogenous mutagen in the human LDL receptor and p53 genes. Science. 
Sep 14 1990;249(4974):1288-1290. 
275. Gibney ER, Nolan CM. Epigenetics and gene expression. Heredity (Edinb). 
Jul 2010;105(1):4-13. 
276. Antequera F, Bird A. CpG islands. Exs. 1993;64:169-185. 
277. Bird AP, Wolffe AP. Methylation-induced repression--belts, braces, and 
chromatin. Cell. Nov 24 1999;99(5):451-454. 
278. Bestor TH. The host defence function of genomic methylation patterns. 
Novartis Found Symp. 1998;214:187-195; discussion 195-189, 228-132. 
279. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer. 
Nov 2001;1(2):157-162. 
280. Esteller M, Fraga MF, Guo M, et al. DNA methylation patterns in 
hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet. 
Dec 15 2001;10(26):3001-3007. 
281. Kuismanen SA, Holmberg MT, Salovaara R, de la Chapelle A, Peltomaki P. 
Genetic and epigenetic modification of MLH1 accounts for a major share 
of microsatellite-unstable colorectal cancers. Am J Pathol. May 
2000;156(5):1773-1779. 
282. Lee WH, Morton RA, Epstein JI, et al. Cytidine methylation of regulatory 
sequences near the pi-class glutathione S-transferase gene accompanies 
human prostatic carcinogenesis. Proc Natl Acad Sci U S A. Nov 22 
1994;91(24):11733-11737. 
283. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. 
Nat Rev Drug Discov. Jan 2006;5(1):37-50. 
222 
 
284. Muller CI, Ruter B, Koeffler HP, Lubbert M. DNA hypermethylation of 
myeloid cells, a novel therapeutic target in MDS and AML. Curr Pharm 
Biotechnol. Oct 2006;7(5):315-321. 
285. Walsh CP, Chaillet JR, Bestor TH. Transcription of IAP endogenous 
retroviruses is constrained by cytosine methylation. Nat Genet. Oct 
1998;20(2):116-117. 
286. Narayan A, Ji W, Zhang XY, et al. Hypomethylation of pericentromeric 
DNA in breast adenocarcinomas. Int J Cancer. Sep 11 1998;77(6):833-838. 
287. Qu G, Dubeau L, Narayan A, Yu MC, Ehrlich M. Satellite DNA 
hypomethylation vs. overall genomic hypomethylation in ovarian 
epithelial tumors of different malignant potential. Mutat Res. Jan 25 
1999;423(1-2):91-101. 
288. Widschwendter M, Jiang G, Woods C, et al. DNA hypomethylation and 
ovarian cancer biology. Cancer Res. Jul 1 2004;64(13):4472-4480. 
289. Furuichi Y, Wataya Y, Hayatsu H, Ukita T. Chemical modification of tRNA-
Tyr-yeast with bisulfite. A new method to modify isopentenyladenosine 
residue. Biochem Biophys Res Commun. Dec 9 1970;41(5):1185-1191. 
290. Shapiro R, DiFate V, Welcher M. Deamination of cytosine derivatives by 
bisulfite. Mechanism of the reaction. J Am Chem Soc. Feb 6 
1974;96(3):906-912. 
291. Raizis AM, Schmitt F, Jost JP. A bisulfite method of 5-methylcytosine 
mapping that minimizes template degradation. Anal Biochem. Mar 20 
1995;226(1):161-166. 
292. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-
specific PCR: a novel PCR assay for methylation status of CpG islands. 
Proc Natl Acad Sci U S A. Sep 3 1996;93(18):9821-9826. 
293. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol 
that yields a positive display of 5-methylcytosine residues in individual 
DNA strands. Proc Natl Acad Sci U S A. Mar 1 1992;89(5):1827-1831. 
223 
 
294. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to 
bedside to biomarkers. J Clin Oncol. Jun 10 2013;31(17):2205-2218. 
295. Beil M, Micoulet A, von Wichert G, et al. Sphingosylphosphorylcholine 
regulates keratin network architecture and visco-elastic properties of 
human cancer cells. Nat Cell Biol. Sep 2003;5(9):803-811. 
296. Paszek MJ, Weaver VM. The tension mounts: mechanics meets 
morphogenesis and malignancy. J Mammary Gland Biol Neoplasia. Oct 
2004;9(4):325-342. 
297. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. 
Pathology: cancer cells compress intratumour vessels. Nature. Feb 19 
2004;427(6976):695. 
298. Akiri G, Sabo E, Dafni H, et al. Lysyl oxidase-related protein-1 promotes 
tumor fibrosis and tumor progression in vivo. Cancer Res. Apr 1 
2003;63(7):1657-1666. 
299. Egeblad M, Rasch MG, Weaver VM. Dynamic interplay between the 
collagen scaffold and tumor evolution. Curr Opin Cell Biol. Oct 
2010;22(5):697-706. 
300. Parsons JT, Horwitz AR, Schwartz MA. Cell adhesion: integrating 
cytoskeletal dynamics and cellular tension. Nat Rev Mol Cell Biol. Sep 
2010;11(9):633-643. 
301. Wozniak MA, Desai R, Solski PA, Der CJ, Keely PJ. ROCK-generated 
contractility regulates breast epithelial cell differentiation in response to 
the physical properties of a three-dimensional collagen matrix. J Cell 
Biol. Nov 10 2003;163(3):583-595. 
302. Chiquet M, Gelman L, Lutz R, Maier S. From mechanotransduction to 
extracellular matrix gene expression in fibroblasts. Biochim Biophys Acta. 
May 2009;1793(5):911-920. 
303. Wynn TA. Common and unique mechanisms regulate fibrosis in various 
fibroproliferative diseases. J Clin Invest. Mar 2007;117(3):524-529. 
224 
 
304. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. 
The myofibroblast: one function, multiple origins. Am J Pathol. Jun 
2007;170(6):1807-1816. 
305. Wells RG, Discher DE. Matrix elasticity, cytoskeletal tension, and TGF-
beta: the insoluble and soluble meet. Sci Signal. 2008;1(10):pe13. 
306. Junker JP, Kratz C, Tollback A, Kratz G. Mechanical tension stimulates the 
transdifferentiation of fibroblasts into myofibroblasts in human burn 
scars. Burns. Nov 2008;34(7):942-946. 
307. Aarabi S, Bhatt KA, Shi Y, et al. Mechanical load initiates hypertrophic 
scar formation through decreased cellular apoptosis. Faseb J. Oct 
2007;21(12):3250-3261. 
308. Wipff PJ, Rifkin DB, Meister JJ, Hinz B. Myofibroblast contraction 
activates latent TGF-beta1 from the extracellular matrix. J Cell Biol. Dec 
17 2007;179(6):1311-1323. 
309. Wight TN, Potter-Perigo S. The extracellular matrix: an active or passive 
player in fibrosis? Am J Physiol Gastrointest Liver Physiol. Dec 
2011;301(6):G950-955. 
310. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from 
genes to environment. Nat Rev Cancer. Sep 2006;6(9):674-687. 
311. Archontogeorgis K, Steiropoulos P, Tzouvelekis A, Nena E, Bouros D. Lung 
cancer and interstitial lung diseases: a systematic review. Pulm Med. 
2012;2012:315918. 
312. Radisky DC, Kenny PA, Bissell MJ. Fibrosis and cancer: do myofibroblasts 
come also from epithelial cells via EMT? J Cell Biochem. Jul 1 
2007;101(4):830-839. 
313. Daniels CE, Jett JR. Does interstitial lung disease predispose to lung 
cancer? Curr Opin Pulm Med. Sep 2005;11(5):431-437. 
225 
 
314. Neaud V, Faouzi S, Guirouilh J, et al. Human hepatic myofibroblasts 
increase invasiveness of hepatocellular carcinoma cells: evidence for a 
role of hepatocyte growth factor. Hepatology. Dec 1997;26(6):1458-1466. 
315. Quante M, Tu SP, Tomita H, et al. Bone marrow-derived myofibroblasts 
contribute to the mesenchymal stem cell niche and promote tumor 
growth. Cancer Cell. Feb 15 2011;19(2):257-272. 
316. Nielsen BS, Sehested M, Timshel S, Pyke C, Dano K. Messenger RNA for 
urokinase plasminogen activator is expressed in myofibroblasts adjacent 
to cancer cells in human breast cancer. Lab Invest. Jan 1996;74(1):168-
177. 
317. Bisson C, Blacher S, Polette M, et al. Restricted expression of membrane 
type 1-matrix metalloproteinase by myofibroblasts adjacent to human 
breast cancer cells. Int J Cancer. May 20 2003;105(1):7-13. 
318. Offersen BV, Nielsen BS, Hoyer-Hansen G, et al. The myofibroblast is the 
predominant plasminogen activator inhibitor-1-expressing cell type in 
human breast carcinomas. Am J Pathol. Nov 2003;163(5):1887-1899. 
319. Ohtani H, Motohashi H, Sato H, Seiki M, Nagura H. Dual over-expression 
pattern of membrane-type metalloproteinase-1 in cancer and stromal 
cells in human gastrointestinal carcinoma revealed by in situ hybridization 
and immunoelectron microscopy. Int J Cancer. Nov 27 1996;68(5):565-
570. 
320. Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the 
coin. Am J Cancer Res. 2011;1(4):482-497. 
321. Gallagher PG, Bao Y, Prorock A, et al. Gene expression profiling reveals 
cross-talk between melanoma and fibroblasts: implications for host-tumor 
interactions in metastasis. Cancer Res. May 15 2005;65(10):4134-4146. 
322. Bergfeld SA, DeClerck YA. Bone marrow-derived mesenchymal stem cells 
and the tumor microenvironment. Cancer Metastasis Rev. Jun 
2010;29(2):249-261. 
226 
 
323. Schor SL, Haggie JA, Durning P, et al. Occurrence of a fetal fibroblast 
phenotype in familial breast cancer. Int J Cancer. Jun 15 1986;37(6):831-
836. 
324. Kuperwasser C, Chavarria T, Wu M, et al. Reconstruction of functionally 
normal and malignant human breast tissues in mice. Proc Natl Acad Sci U 
S A. Apr 6 2004;101(14):4966-4971. 
325. Bhowmick NA, Chytil A, Plieth D, et al. TGF-beta signaling in fibroblasts 
modulates the oncogenic potential of adjacent epithelia. Science. Feb 6 
2004;303(5659):848-851. 
326. Wang W, Li Q, Yamada T, et al. Crosstalk to stromal fibroblasts induces 
resistance of lung cancer to epidermal growth factor receptor tyrosine 
kinase inhibitors. Clin Cancer Res. Nov 1 2009;15(21):6630-6638. 
327. Gerber PA, Hippe A, Buhren BA, Muller A, Homey B. Chemokines in tumor-
associated angiogenesis. Biol Chem. Dec 2009;390(12):1213-1223. 
328. Hynes RO. The extracellular matrix: not just pretty fibrils. Science. Nov 
27 2009;326(5957):1216-1219. 
329. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers 
and potential therapeutic targets in human cancer. J Clin Oncol. Nov 1 
2009;27(31):5287-5297. 
330. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J 
Clin Invest. Jun 2009;119(6):1420-1428. 
331. Matsumoto K, Nakamura T. Hepatocyte growth factor and the Met system 
as a mediator of tumor-stromal interactions. Int J Cancer. Aug 1 
2006;119(3):477-483. 
332. Paszek MJ, Zahir N, Johnson KR, et al. Tensional homeostasis and the 
malignant phenotype. Cancer Cell. Sep 2005;8(3):241-254. 
333. Levental KR, Yu H, Kass L, et al. Matrix crosslinking forces tumor 
progression by enhancing integrin signaling. Cell. Nov 25 2009;139(5):891-
906. 
227 
 
334. Zaman MH, Trapani LM, Sieminski AL, et al. Migration of tumor cells in 3D 
matrices is governed by matrix stiffness along with cell-matrix adhesion 
and proteolysis. Proc Natl Acad Sci U S A. Jul 18 2006;103(29):10889-
10894. 
335. Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci. Oct 15 
2002;115(Pt 20):3861-3863. 
336. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic 
bone marrow progenitors initiate the pre-metastatic niche. Nature. Dec 8 
2005;438(7069):820-827. 
337. Kobayashi N, Miyoshi S, Mikami T, et al. Hyaluronan deficiency in tumor 
stroma impairs macrophage trafficking and tumor neovascularization. 
Cancer Res. Sep 15 2010;70(18):7073-7083. 
338. De Wever O, Nguyen QD, Van Hoorde L, et al. Tenascin-C and SF/HGF 
produced by myofibroblasts in vitro provide convergent pro-invasive 
signals to human colon cancer cells through RhoA and Rac. Faseb J. Jun 
2004;18(9):1016-1018. 
339. Solis MA, Chen YH, Wong TY, Bittencourt VZ, Lin YC, Huang LL. 
Hyaluronan regulates cell behavior: a potential niche matrix for stem 
cells. Biochem Res Int. 2012;2012:346972. 
340. Kauppila S, Stenback F, Risteli J, Jukkola A, Risteli L. Aberrant type I and 
type III collagen gene expression in human breast cancer in vivo. J Pathol. 
Nov 1998;186(3):262-268. 
341. Hasebe T, Sasaki S, Imoto S, Mukai K, Yokose T, Ochiai A. Prognostic 
significance of fibrotic focus in invasive ductal carcinoma of the breast: a 
prospective observational study. Mod Pathol. May 2002;15(5):502-516. 
342. Hwang RF, Moore T, Arumugam T, et al. Cancer-associated stromal 
fibroblasts promote pancreatic tumor progression. Cancer Res. Feb 1 
2008;68(3):918-926. 
228 
 
343. Malik R, Lelkes PI, Cukierman E. Biomechanical and biochemical 
remodeling of stromal extracellular matrix in cancer. Trends Biotechnol. 
Apr 2015;33(4):230-236. 
344. Butcher DT, Alliston T, Weaver VM. A tense situation: forcing tumour 
progression. Nat Rev Cancer. Feb 2009;9(2):108-122. 
345. Croft DR, Sahai E, Mavria G, et al. Conditional ROCK activation in vivo 
induces tumor cell dissemination and angiogenesis. Cancer Res. Dec 15 
2004;64(24):8994-9001. 
346. Provenzano PP, Keely PJ. Mechanical signaling through the cytoskeleton 
regulates cell proliferation by coordinated focal adhesion and Rho GTPase 
signaling. J Cell Sci. Apr 15 2011;124(Pt 8):1195-1205. 
347. Suresh S. Biomechanics and biophysics of cancer cells. Acta Biomater. Jul 
2007;3(4):413-438. 
348. Ridley AJ, Schwartz MA, Burridge K, et al. Cell migration: integrating 
signals from front to back. Science. Dec 5 2003;302(5651):1704-1709. 
349. Ingber DE. Tensegrity-based mechanosensing from macro to micro. Prog 
Biophys Mol Biol. Jun-Jul 2008;97(2-3):163-179. 
350. Nelson CM, Vanduijn MM, Inman JL, Fletcher DA, Bissell MJ. Tissue 
geometry determines sites of mammary branching morphogenesis in 
organotypic cultures. Science. Oct 13 2006;314(5797):298-300. 
351. Chiquet-Ehrismann R, Kalla P, Pearson CA, Beck K, Chiquet M. Tenascin 
interferes with fibronectin action. Cell. May 6 1988;53(3):383-390. 
352. Gherzi R, Carnemolla B, Siri A, Ponassi M, Balza E, Zardi L. Human 
tenascin gene. Structure of the 5'-region, identification, and 
characterization of the transcription regulatory sequences. J Biol Chem. 
Feb 17 1995;270(7):3429-3434. 
353. Pas J, Wyszko E, Rolle K, et al. Analysis of structure and function of 
tenascin-C. Int J Biochem Cell Biol. 2006;38(9):1594-1602. 
229 
 
354. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, 
function, and regulation during embryonic development and tissue 
remodeling. Dev Dyn. Jun 2000;218(2):235-259. 
355. Prieto AL, Edelman GM, Crossin KL. Multiple integrins mediate cell 
attachment to cytotactin/tenascin. Proc Natl Acad Sci U S A. Nov 1 
1993;90(21):10154-10158. 
356. Chung CY, Murphy-Ullrich JE, Erickson HP. Mitogenesis, cell migration, 
and loss of focal adhesions induced by tenascin-C interacting with its cell 
surface receptor, annexin II. Mol Biol Cell. Jun 1996;7(6):883-892. 
357. Saito Y, Imazeki H, Miura S, et al. A peptide derived from tenascin-C 
induces beta1 integrin activation through syndecan-4. J Biol Chem. Nov 30 
2007;282(48):34929-34937. 
358. Chiquet-Ehrismann R, Matsuoka Y, Hofer U, Spring J, Bernasconi C, 
Chiquet M. Tenascin variants: differential binding to fibronectin and 
distinct distribution in cell cultures and tissues. Cell Regul. Nov 
1991;2(11):927-938. 
359. Swindle CS, Tran KT, Johnson TD, et al. Epidermal growth factor (EGF)-
like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol. 
Jul 23 2001;154(2):459-468. 
360. Chiquet-Ehrismann R. Tenascins. Int J Biochem Cell Biol. Jun 
2004;36(6):986-990. 
361. Webb CM, Zaman G, Mosley JR, Tucker RP, Lanyon LE, Mackie EJ. 
Expression of tenascin-C in bones responding to mechanical load. J Bone 
Miner Res. Jan 1997;12(1):52-58. 
362. Mackie EJ, Halfter W, Liverani D. Induction of tenascin in healing wounds. 
J Cell Biol. Dec 1988;107(6 Pt 2):2757-2767. 
363. Midwood KS, Orend G. The role of tenascin-C in tissue injury and 
tumorigenesis. J Cell Commun Signal. Dec 2009;3(3-4):287-310. 
230 
 
364. Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. 
Cancer Lett. Dec 8 2006;244(2):143-163. 
365. Schalkwijk J, Van Vlijmen I, Oosterling B, et al. Tenascin expression in 
hyperproliferative skin diseases. Br J Dermatol. Jan 1991;124(1):13-20. 
366. Midwood KS, Williams LV, Schwarzbauer JE. Tissue repair and the 
dynamics of the extracellular matrix. Int J Biochem Cell Biol. Jun 
2004;36(6):1031-1037. 
367. Lowy CM, Oskarsson T. Tenascin C in metastasis: A view from the invasive 
front. Cell Adh Migr. 2015;9(1-2):112-124. 
368. Midwood K, Sacre S, Piccinini AM, et al. Tenascin-C is an endogenous 
activator of Toll-like receptor 4 that is essential for maintaining 
inflammation in arthritic joint disease. Nat Med. Jul 2009;15(7):774-780. 
369. Seyger MM, van Pelt JP, van den Born J, Latijnhouwers MA, de Jong EM. 
Epicutaneous application of leukotriene B4 induces patterns of tenascin 
and a heparan sulfate proteoglycan epitope that are typical for psoriatic 
lesions. Arch Dermatol Res. May 1997;289(6):331-336. 
370. Hauzenberger D, Olivier P, Gundersen D, Ruegg C. Tenascin-C inhibits 
beta1 integrin-dependent T lymphocyte adhesion to fibronectin through 
the binding of its fnIII 1-5 repeats to fibronectin. Eur J Immunol. May 
1999;29(5):1435-1447. 
371. Clark RA, Erickson HP, Springer TA. Tenascin supports lymphocyte rolling. 
J Cell Biol. May 5 1997;137(3):755-765. 
372. Puente Navazo MD, Valmori D, Ruegg C. The alternatively spliced domain 
TnFnIII A1A2 of the extracellular matrix protein tenascin-C suppresses 
activation-induced T lymphocyte proliferation and cytokine production. J 
Immunol. Dec 1 2001;167(11):6431-6440. 
373. Betz P, Nerlich A, Tubel J, Penning R, Eisenmenger W. Localization of 
tenascin in human skin wounds--an immunohistochemical study. Int J 
Legal Med. 1993;105(6):325-328. 
231 
 
374. Kaarteenaho-Wiik R, Lakari E, Soini Y, Pollanen R, Kinnula VL, Paakko P. 
Tenascin expression and distribution in pleural inflammatory and fibrotic 
diseases. J Histochem Cytochem. Sep 2000;48(9):1257-1268. 
375. Imanaka-Yoshida K, Hiroe M, Yasutomi Y, et al. Tenascin-C is a useful 
marker for disease activity in myocarditis. J Pathol. Jul 2002;197(3):388-
394. 
376. Latijnhouwers M, Bergers M, Ponec M, Dijkman H, Andriessen M, 
Schalkwijk J. Human epidermal keratinocytes are a source of tenascin-C 
during wound healing. J Invest Dermatol. May 1997;108(5):776-783. 
377. Gerritsen MJ, Elbers ME, de Jong EM, van de Kerkhof PC. Recruitment of 
cycling epidermal cells and expression of filaggrin, involucrin and tenascin 
in the margin of the active psoriatic plaque, in the uninvolved skin of 
psoriatic patients and in the normal healthy skin. J Dermatol Sci. Mar 
1997;14(3):179-188. 
378. Schenk S, Bruckner-Tuderman L, Chiquet-Ehrismann R. Dermo-epidermal 
separation is associated with induced tenascin expression in human skin. 
Br J Dermatol. Jul 1995;133(1):13-22. 
379. Ishii K, Imanaka-Yoshida K, Yoshida T, Sugimura Y. Role of stromal 
tenascin-C in mouse prostatic development and epithelial cell 
differentiation. Dev Biol. Dec 15 2008;324(2):310-319. 
380. McClain SA, Simon M, Jones E, et al. Mesenchymal cell activation is the 
rate-limiting step of granulation tissue induction. Am J Pathol. Oct 
1996;149(4):1257-1270. 
381. Trebaul A, Chan EK, Midwood KS. Regulation of fibroblast migration by 
tenascin-C. Biochem Soc Trans. Aug 2007;35(Pt 4):695-697. 
382. Clark RA. Biology of dermal wound repair. Dermatol Clin. Oct 
1993;11(4):647-666. 
383. El-Karef A, Yoshida T, Gabazza EC, et al. Deficiency of tenascin-C 
attenuates liver fibrosis in immune-mediated chronic hepatitis in mice. J 
Pathol. Jan 2007;211(1):86-94. 
232 
 
384. Nakao N, Hiraiwa N, Yoshiki A, Ike F, Kusakabe M. Tenascin-C promotes 
healing of Habu-snake venom-induced glomerulonephritis: studies in 
knockout congenic mice and in culture. Am J Pathol. May 
1998;152(5):1237-1245. 
385. Tanaka R, Seki Y, Saito Y, et al. Tenascin-C-derived peptide TNIIIA2 highly 
enhances cell survival and platelet-derived growth factor (PDGF)-
dependent cell proliferation through potentiated and sustained activation 
of integrin alpha5beta1. J Biol Chem. Jun 20 2014;289(25):17699-17708. 
386. End P, Panayotou G, Entwistle A, Waterfield MD, Chiquet M. Tenascin: a 
modulator of cell growth. Eur J Biochem. Nov 1 1992;209(3):1041-1051. 
387. Chiquet M, Fambrough DM. Chick myotendinous antigen. II. A novel 
extracellular glycoprotein complex consisting of large disulfide-linked 
subunits. J Cell Biol. Jun 1984;98(6):1937-1946. 
388. Ramos DM, Chen B, Regezi J, Zardi L, Pytela R. Tenascin-C matrix 
assembly in oral squamous cell carcinoma. Int J Cancer. Mar 2 
1998;75(5):680-687. 
389. Faissner A, Kruse J, Kuhn K, Schachner M. Binding of the J1 adhesion 
molecules to extracellular matrix constituents. J Neurochem. Mar 
1990;54(3):1004-1015. 
390. Kii I, Nishiyama T, Li M, et al. Incorporation of tenascin-C into the 
extracellular matrix by periostin underlies an extracellular meshwork 
architecture. J Biol Chem. Jan 15 2010;285(3):2028-2039. 
391. Day JM, Olin AI, Murdoch AD, et al. Alternative splicing in the aggrecan G3 
domain influences binding interactions with tenascin-C and other 
extracellular matrix proteins. J Biol Chem. Mar 26 2004;279(13):12511-
12518. 
392. Latijnhouwers MA, Bergers M, Van Bergen BH, Spruijt KI, Andriessen MP, 
Schalkwijk J. Tenascin expression during wound healing in human skin. J 
Pathol. Jan 1996;178(1):30-35. 
233 
 
393. Ingber DE. Mechanical signaling and the cellular response to extracellular 
matrix in angiogenesis and cardiovascular physiology. Circ Res. Nov 15 
2002;91(10):877-887. 
394. Canfield AE, Schor AM. Evidence that tenascin and thrombospondin-1 
modulate sprouting of endothelial cells. J Cell Sci. Feb 1995;108 ( Pt 
2):797-809. 
395. Nomi M, Miyake H, Sugita Y, Fujisawa M, Soker S. Role of growth factors 
and endothelial cells in therapeutic angiogenesis and tissue engineering. 
Curr Stem Cell Res Ther. Sep 2006;1(3):333-343. 
396. Sumioka T, Fujita N, Kitano A, Okada Y, Saika S. Impaired angiogenic 
response in the cornea of mice lacking tenascin C. Invest Ophthalmol Vis 
Sci. Apr 2011;52(5):2462-2467. 
397. Ballard VL, Sharma A, Duignan I, et al. Vascular tenascin-C regulates 
cardiac endothelial phenotype and neovascularization. Faseb J. Apr 
2006;20(6):717-719. 
398. Hinz B. The myofibroblast: paradigm for a mechanically active cell. J 
Biomech. Jan 5 2010;43(1):146-155. 
399. Desmouliere A, Redard M, Darby I, Gabbiani G. Apoptosis mediates the 
decrease in cellularity during the transition between granulation tissue 
and scar. Am J Pathol. Jan 1995;146(1):56-66. 
400. Fassler R, Sasaki T, Timpl R, Chu ML, Werner S. Differential regulation of 
fibulin, tenascin-C, and nidogen expression during wound healing of 
normal and glucocorticoid-treated mice. Exp Cell Res. Jan 10 
1996;222(1):111-116. 
401. Abergel RP, Pizzurro D, Meeker CA, et al. Biochemical composition of the 
connective tissue in keloids and analysis of collagen metabolism in keloid 
fibroblast cultures. J Invest Dermatol. May 1985;84(5):384-390. 
402. Zouboulis CC, Blume U, Buttner P, Orfanos CE. Outcomes of cryosurgery in 
keloids and hypertrophic scars. A prospective consecutive trial of case 
series. Arch Dermatol. Sep 1993;129(9):1146-1151. 
234 
 
403. Dalkowski A, Schuppan D, Orfanos CE, Zouboulis CC. Increased expression 
of tenascin C by keloids in vivo and in vitro. Br J Dermatol. Jul 
1999;141(1):50-56. 
404. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor 
stroma generation and wound healing. N Engl J Med. Dec 25 
1986;315(26):1650-1659. 
405. Ronnov-Jessen L, Petersen OW, Bissell MJ. Cellular changes involved in 
conversion of normal to malignant breast: importance of the stromal 
reaction. Physiol Rev. Jan 1996;76(1):69-125. 
406. Chiquet-Ehrismann R, Mackie EJ, Pearson CA, Sakakura T. Tenascin: an 
extracellular matrix protein involved in tissue interactions during fetal 
development and oncogenesis. Cell. Oct 10 1986;47(1):131-139. 
407. Latijnhouwers MA, Pfundt R, de Jongh GJ, Schalkwijk J. Tenascin-C 
expression in human epidermal keratinocytes is regulated by 
inflammatory cytokines and a stress response pathway. Matrix Biol. Aug 
1998;17(4):305-316. 
408. Mackie EJ, Abraham LA, Taylor SL, Tucker RP, Murphy LI. Regulation of 
tenascin-C expression in bone cells by transforming growth factor-beta. 
Bone. Apr 1998;22(4):301-307. 
409. Mettouchi A, Cabon F, Montreau N, et al. The c-Jun-induced 
transformation process involves complex regulation of tenascin-C 
expression. Mol Cell Biol. Jun 1997;17(6):3202-3209. 
410. Yamamoto K, Dang QN, Kennedy SP, Osathanondh R, Kelly RA, Lee RT. 
Induction of tenascin-C in cardiac myocytes by mechanical deformation. 
Role of reactive oxygen species. J Biol Chem. Jul 30 1999;274(31):21840-
21846. 
411. Gebb SA, Jones PL. Hypoxia and lung branching morphogenesis. Adv Exp 
Med Biol. 2003;543:117-125. 
235 
 
412. Tucker RP, Chiquet-Ehrismann R. The regulation of tenascin expression by 
tissue microenvironments. Biochim Biophys Acta. May 2009;1793(5):888-
892. 
413. Sarasa-Renedo A, Chiquet M. Mechanical signals regulating extracellular 
matrix gene expression in fibroblasts. Scand J Med Sci Sports. Aug 
2005;15(4):223-230. 
414. Siri A, Knauper V, Veirana N, Caocci F, Murphy G, Zardi L. Different 
susceptibility of small and large human tenascin-C isoforms to degradation 
by matrix metalloproteinases. J Biol Chem. Apr 14 1995;270(15):8650-
8654. 
415. Imai K, Kusakabe M, Sakakura T, Nakanishi I, Okada Y. Susceptibility of 
tenascin to degradation by matrix metalloproteinases and serine 
proteinases. FEBS Lett. Sep 26 1994;352(2):216-218. 
416. Kusagawa H, Onoda K, Namikawa S, et al. Expression and degeneration of 
tenascin-C in human lung cancers. Br J Cancer. 1998;77(1):98-102. 
417. Cai M, Onoda K, Takao M, et al. Degradation of tenascin-C and activity of 
matrix metalloproteinase-2 are associated with tumor recurrence in early 
stage non-small cell lung cancer. Clin Cancer Res. Apr 2002;8(4):1152-
1156. 
418. Huang W, Chiquet-Ehrismann R, Moyano JV, Garcia-Pardo A, Orend G. 
Interference of tenascin-C with syndecan-4 binding to fibronectin blocks 
cell adhesion and stimulates tumor cell proliferation. Cancer Res. Dec 1 
2001;61(23):8586-8594. 
419. Taraseviciute A, Vincent BT, Schedin P, Jones PL. Quantitative analysis of 
three-dimensional human mammary epithelial tissue architecture reveals 
a role for tenascin-C in regulating c-met function. Am J Pathol. Feb 
2010;176(2):827-838. 
420. Fukunaga-Kalabis M, Martinez G, Nguyen TK, et al. Tenascin-C promotes 
melanoma progression by maintaining the ABCB5-positive side population. 
Oncogene. Nov 18 2010;29(46):6115-6124. 
236 
 
421. Vollmer G. Biologic and oncologic implications of tenascin-C/hexabrachion 
proteins. Crit Rev Oncol Hematol. Apr 1997;25(3):187-210. 
422. von Holst A. Tenascin C in stem cell niches: redundant, permissive or 
instructive? Cells Tissues Organs. 2008;188(1-2):170-177. 
423. Garcion E, Faissner A, ffrench-Constant C. Knockout mice reveal a 
contribution of the extracellular matrix molecule tenascin-C to neural 
precursor proliferation and migration. Development. Jul 
2001;128(13):2485-2496. 
424. Nie S, Gurrea M, Zhu J, et al. Tenascin-C: a novel candidate marker for 
cancer stem cells in glioblastoma identified by tissue microarrays. J 
Proteome Res. Feb 6 2015;14(2):814-822. 
425. Klein G, Beck S, Muller CA. Tenascin is a cytoadhesive extracellular matrix 
component of the human hematopoietic microenvironment. J Cell Biol. 
Nov 1993;123(4):1027-1035. 
426. Ohta M, Sakai T, Saga Y, Aizawa S, Saito M. Suppression of hematopoietic 
activity in tenascin-C-deficient mice. Blood. Jun 1 1998;91(11):4074-4083. 
427. Ruiz C, Huang W, Hegi ME, et al. Growth promoting signaling by tenascin-
C [corrected]. Cancer Res. Oct 15 2004;64(20):7377-7385. 
428. Orend G, Chiquet-Ehrismann R. Adhesion modulation by antiadhesive 
molecules of the extracellular matrix. Exp Cell Res. Nov 25 
2000;261(1):104-110. 
429. Woods A, Longley RL, Tumova S, Couchman JR. Syndecan-4 binding to the 
high affinity heparin-binding domain of fibronectin drives focal adhesion 
formation in fibroblasts. Arch Biochem Biophys. Feb 1 2000;374(1):66-72. 
430. Orend G, Huang W, Olayioye MA, Hynes NE, Chiquet-Ehrismann R. 
Tenascin-C blocks cell-cycle progression of anchorage-dependent 
fibroblasts on fibronectin through inhibition of syndecan-4. Oncogene. Jun 
19 2003;22(25):3917-3926. 
237 
 
431. Midwood KS, Schwarzbauer JE. Tenascin-C modulates matrix contraction 
via focal adhesion kinase- and Rho-mediated signaling pathways. Mol Biol 
Cell. Oct 2002;13(10):3601-3613. 
432. Ohh M, Yauch RL, Lonergan KM, et al. The von Hippel-Lindau tumor 
suppressor protein is required for proper assembly of an extracellular 
fibronectin matrix. Mol Cell. Jun 1998;1(7):959-968. 
433. Maschler S, Grunert S, Danielopol A, Beug H, Wirl G. Enhanced tenascin-C 
expression and matrix deposition during Ras/TGF-beta-induced 
progression of mammary tumor cells. Oncogene. Apr 29 2004;23(20):3622-
3633. 
434. Takahashi Y, Sawada G, Kurashige J, et al. Tumor-derived tenascin-C 
promotes the epithelial-mesenchymal transition in colorectal cancer cells. 
Anticancer Res. May 2013;33(5):1927-1934. 
435. Nagaharu K, Zhang X, Yoshida T, et al. Tenascin C induces epithelial-
mesenchymal transition-like change accompanied by SRC activation and 
focal adhesion kinase phosphorylation in human breast cancer cells. Am J 
Pathol. Feb 2011;178(2):754-763. 
436. Deryugina EI, Bourdon MA. Tenascin mediates human glioma cell migration 
and modulates cell migration on fibronectin. J Cell Sci. Mar 1996;109 ( Pt 
3):643-652. 
437. Nishio T, Kawaguchi S, Yamamoto M, Iseda T, Kawasaki T, Hase T. 
Tenascin-C regulates proliferation and migration of cultured astrocytes in 
a scratch wound assay. Neuroscience. 2005;132(1):87-102. 
438. Wilson KE, Bartlett JM, Miller EP, et al. Regulation and function of the 
extracellular matrix protein tenascin-C in ovarian cancer cell lines. Br J 
Cancer. May 1999;80(5-6):685-692. 
439. Yoshida T, Yoshimura E, Numata H, Sakakura Y, Sakakura T. Involvement 
of tenascin-C in proliferation and migration of laryngeal carcinoma cells. 
Virchows Arch. Nov 1999;435(5):496-500. 
238 
 
440. Herold-Mende C, Mueller MM, Bonsanto MM, Schmitt HP, Kunze S, Steiner 
HH. Clinical impact and functional aspects of tenascin-C expression during 
glioma progression. Int J Cancer. Mar 20 2002;98(3):362-369. 
441. Katenkamp K, Berndt A, Hindermann W, et al. mRNA expression and 
protein distribution of the unspliced tenascin-C isoform in prostatic 
adenocarcinoma. J Pathol. Jul 2004;203(3):771-779. 
442. Kaarteenaho-Wiik R, Soini Y, Pollanen R, Paakko P, Kinnula VL. Over-
expression of tenascin-C in malignant pleural mesothelioma. 
Histopathology. Mar 2003;42(3):280-291. 
443. Ilmonen S, Jahkola T, Turunen JP, Muhonen T, Asko-Seljavaara S. 
Tenascin-C in primary malignant melanoma of the skin. Histopathology. 
Oct 2004;45(4):405-411. 
444. Aishima S, Taguchi K, Terashi T, Matsuura S, Shimada M, Tsuneyoshi M. 
Tenascin expression at the invasive front is associated with poor prognosis 
in intrahepatic cholangiocarcinoma. Mod Pathol. Oct 2003;16(10):1019-
1027. 
445. Hancox RA, Allen MD, Holliday DL, et al. Tumour-associated tenascin-C 
isoforms promote breast cancer cell invasion and growth by matrix 
metalloproteinase-dependent and independent mechanisms. Breast 
Cancer Res. 2009;11(2):R24. 
446. Oskarsson T, Acharyya S, Zhang XH, et al. Breast cancer cells produce 
tenascin C as a metastatic niche component to colonize the lungs. Nat 
Med. Jul 2011;17(7):867-874. 
447. O'Connell JT, Sugimoto H, Cooke VG, et al. VEGF-A and Tenascin-C 
produced by S100A4+ stromal cells are important for metastatic 
colonization. Proc Natl Acad Sci U S A. Sep 20 2011;108(38):16002-16007. 
448. Oskarsson T, Massague J. Extracellular matrix players in metastatic 
niches. Embo J. Jan 18 2012;31(2):254-256. 
449. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer 
metastasis to lung. Nature. Jul 28 2005;436(7050):518-524. 
239 
 
450. Gurbuz I, Ferralli J, Roloff T, Chiquet-Ehrismann R, Asparuhova MB. SAP 
domain-dependent Mkl1 signaling stimulates proliferation and cell 
migration by induction of a distinct gene set indicative of poor prognosis 
in breast cancer patients. Mol Cancer. 2014;13:22. 
451. Parekh K, Ramachandran S, Cooper J, Bigner D, Patterson A, 
Mohanakumar T. Tenascin-C, over expressed in lung cancer down 
regulates effector functions of tumor infiltrating lymphocytes. Lung 
Cancer. Jan 2005;47(1):17-29. 
452. Juhasz A, Bardos H, Repassy G, Adany R. Characteristic distribution 
patterns of tenascin in laryngeal and hypopharyngeal cancers. 
Laryngoscope. Jan 2000;110(1):84-92. 
453. Van Obberghen-Schilling E, Tucker RP, Saupe F, Gasser I, Cseh B, Orend 
G. Fibronectin and tenascin-C: accomplices in vascular morphogenesis 
during development and tumor growth. Int J Dev Biol. 2011;55(4-5):511-
525. 
454. Tanaka K, Hiraiwa N, Hashimoto H, Yamazaki Y, Kusakabe M. Tenascin-C 
regulates angiogenesis in tumor through the regulation of vascular 
endothelial growth factor expression. Int J Cancer. Jan 1 2004;108(1):31-
40. 
455. Chiquet M, Fambrough DM. Chick myotendinous antigen. I. A monoclonal 
antibody as a marker for tendon and muscle morphogenesis. J Cell Biol. 
Jun 1984;98(6):1926-1936. 
456. Chiquet-Ehrismann R, Tannheimer M, Koch M, et al. Tenascin-C expression 
by fibroblasts is elevated in stressed collagen gels. J Cell Biol. Dec 
1994;127(6 Pt 2):2093-2101. 
457. Trachslin J, Koch M, Chiquet M. Rapid and reversible regulation of 
collagen XII expression by changes in tensile stress. Exp Cell Res. Mar 15 
1999;247(2):320-328. 
458. Chiquet M, Sarasa-Renedo A, Tunc-Civelek V. Induction of tenascin-C by 
cyclic tensile strain versus growth factors: distinct contributions by 
240 
 
Rho/ROCK and MAPK signaling pathways. Biochim Biophys Acta. Sep 17 
2004;1693(3):193-204. 
459. Wang DZ, Li S, Hockemeyer D, et al. Potentiation of serum response 
factor activity by a family of myocardin-related transcription factors. Proc 
Natl Acad Sci U S A. Nov 12 2002;99(23):14855-14860. 
460. Sotiropoulos A, Gineitis D, Copeland J, Treisman R. Signal-regulated 
activation of serum response factor is mediated by changes in actin 
dynamics. Cell. Jul 23 1999;98(2):159-169. 
461. Asparuhova MB, Ferralli J, Chiquet M, Chiquet-Ehrismann R. The 
transcriptional regulator megakaryoblastic leukemia-1 mediates serum 
response factor-independent activation of tenascin-C transcription by 
mechanical stress. Faseb J. Oct 2011;25(10):3477-3488. 
462. Kaiser S, Park YK, Franklin JL, et al. Transcriptional recapitulation and 
subversion of embryonic colon development by mouse colon tumor models 
and human colon cancer. Genome Biol. 2007;8(7):R131. 
463. Comprehensive molecular characterization of human colon and rectal 
cancer. Nature. Jul 19 2012;487(7407):330-337. 
464. Skrzypczak M, Goryca K, Rubel T, et al. Modeling oncogenic signaling in 
colon tumors by multidirectional analyses of microarray data directed for 
maximization of analytical reliability. PLoS One. 2010;5(10). 
465. Hong Y, Downey T, Eu KW, Koh PK, Cheah PY. A 'metastasis-prone' 
signature for early-stage mismatch-repair proficient sporadic colorectal 
cancer patients and its implications for possible therapeutics. Clin Exp 
Metastasis. Feb 2010;27(2):83-90. 
466. Bestor T, Laudano A, Mattaliano R, Ingram V. Cloning and sequencing of a 
cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-
terminal domain of the mammalian enzymes is related to bacterial 
restriction methyltransferases. J Mol Biol. Oct 20 1988;203(4):971-983. 
241 
 
467. Monk M. Changes in DNA methylation during mouse embryonic 
development in relation to X-chromosome activity and imprinting. Philos 
Trans R Soc Lond B Biol Sci. Jan 30 1990;326(1235):299-312. 
468. Robertson KD, Uzvolgyi E, Liang G, et al. The human DNA 
methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in 
normal tissues and overexpression in tumors. Nucleic Acids Res. Jun 1 
1999;27(11):2291-2298. 
469. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. 
Aberrant patterns of DNA methylation, chromatin formation and gene 
expression in cancer. Hum Mol Genet. Apr 2001;10(7):687-692. 
470. Garinis GA, Patrinos GP, Spanakis NE, Menounos PG. DNA 
hypermethylation: when tumour suppressor genes go silent. Hum Genet. 
Aug 2002;111(2):115-127. 
471. Melki JR, Vincent PC, Brown RD, Clark SJ. Hypermethylation of E-cadherin 
in leukemia. Blood. May 15 2000;95(10):3208-3213. 
472. Boultwood J, Wainscoat JS. Gene silencing by DNA methylation in 
haematological malignancies. Br J Haematol. Jul 2007;138(1):3-11. 
473. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase 
inhibitors azacytidine and decitabine. International journal of cancer. Jul 
1 2008;123(1):8-13. 
474. Bender CM, Gonzalgo ML, Gonzales FA, Nguyen CT, Robertson KD, Jones 
PA. Roles of cell division and gene transcription in the methylation of CpG 
islands. Mol Cell Biol. Oct 1999;19(10):6690-6698. 
475. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA 
methylation. Cell. May 1980;20(1):85-93. 
476. Hagemann S, Heil O, Lyko F, Brueckner B. Azacytidine and decitabine 
induce gene-specific and non-random DNA demethylation in human cancer 
cell lines. PLoS One. 2011;6(3):e17388. 
242 
 
477. Friedel RH, Plump A, Lu X, et al. Gene targeting using a promoterless 
gene trap vector ("targeted trapping") is an efficient method to mutate a 
large fraction of genes. Proc Natl Acad Sci U S A. Sep 13 
2005;102(37):13188-13193. 
478. Croft DR, Olson MF. Conditional regulation of a ROCK-estrogen receptor 
fusion protein. Methods Enzymol. 2006;406:541-553. 
479. Samuel MS, Munro J, Bryson S, Forrow S, Stevenson D, Olson MF. Tissue 
selective expression of conditionally-regulated ROCK by gene targeting to 
a defined locus. Genesis. Jul 2009;47(7):440-446. 
480. Romer J, Pyke C, Lund LR, Ralfkiaer E, Dano K. Cancer cell expression of 
urokinase-type plasminogen activator receptor mRNA in squamous cell 
carcinomas of the skin. J Invest Dermatol. Mar 2001;116(3):353-358. 
481. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. 
Identification of the urokinase receptor as an adhesion receptor for 
vitronectin. J Biol Chem. Dec 23 1994;269(51):32380-32388. 
482. Shi M, He X, Wei W, Wang J, Zhang T, Shen X. Tenascin-C induces 
resistance to apoptosis in pancreatic cancer cell through activation of 
ERK/NF-kappaB pathway. Apoptosis. Jun 2015;20(6):843-857. 
483. Riker AI, Enkemann SA, Fodstad O, et al. The gene expression profiles of 
primary and metastatic melanoma yields a transition point of tumor 
progression and metastasis. BMC Med Genomics. 2008;1:13. 
484. Nindl I, Dang C, Forschner T, et al. Identification of differentially 
expressed genes in cutaneous squamous cell carcinoma by microarray 
expression profiling. Mol Cancer. 2006;5:30. 
485. Qiu RG, Chen J, McCormick F, Symons M. A role for Rho in Ras 
transformation. Proc Natl Acad Sci U S A. Dec 5 1995;92(25):11781-11785. 
486. Ihn H. Scleroderma, fibroblasts, signaling, and excessive extracellular 
matrix. Curr Rheumatol Rep. Apr 2005;7(2):156-162. 
243 
 
487. Hill CS, Wynne J, Treisman R. The Rho family GTPases RhoA, Rac1, and 
CDC42Hs regulate transcriptional activation by SRF. Cell. Jun 30 
1995;81(7):1159-1170. 
488. Riedl J, Crevenna AH, Kessenbrock K, et al. Lifeact: a versatile marker to 
visualize F-actin. Nat Methods. Jul 2008;5(7):605-607. 
489. Riedl J, Flynn KC, Raducanu A, et al. Lifeact mice for studying F-actin 
dynamics. Nat Methods. Mar 2010;7(3):168-169. 
490. McConnell BV, Koto K, Gutierrez-Hartmann A. Nuclear and cytoplasmic 
LIMK1 enhances human breast cancer progression. Mol Cancer. 
2011;10:75. 
491. Mardilovich K, Gabrielsen M, McGarry L, et al. Elevated LIM kinase 1 in 
nonmetastatic prostate cancer reflects its role in facilitating androgen 
receptor nuclear translocation. Mol Cancer Ther. Jan 2015;14(1):246-258. 
492. Rak R, Haklai R, Elad-Tzfadia G, Wolfson HJ, Carmeli S, Kloog Y. Novel 
LIMK2 Inhibitor Blocks Panc-1 Tumor Growth in a mouse xenograft model. 
Oncoscience. 2014;1(1):39-48. 
493. Gewirtz DA. A critical evaluation of the mechanisms of action proposed 
for the antitumor effects of the anthracycline antibiotics adriamycin and 
daunorubicin. Biochem Pharmacol. Apr 1 1999;57(7):727-741. 
494. Sumi T, Hashigasako A, Matsumoto K, Nakamura T. Different activity 
regulation and subcellular localization of LIMK1 and LIMK2 during cell 
cycle transition. Exp Cell Res. Apr 15 2006;312(7):1021-1030. 
495. Zhou Y, Su J, Shi L, Liao Q, Su Q. DADS downregulates the Rac1-
ROCK1/PAK1-LIMK1-ADF/cofilin signaling pathway, inhibiting cell 
migration and invasion. Oncol Rep. Feb 2013;29(2):605-612. 
496. Petersen VC, Baxter KJ, Love SB, Shepherd NA. Identification of objective 
pathological prognostic determinants and models of prognosis in Dukes' B 
colon cancer. Gut. Jul 2002;51(1):65-69. 
244 
 
497. McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS. Evaluation of 
an inflammation-based prognostic score (GPS) in patients undergoing 
resection for colon and rectal cancer. Int J Colorectal Dis. Aug 
2007;22(8):881-886. 
498. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in 
stage II and III resected colon cancer: results of the translational study on 
the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. Jan 20 
2010;28(3):466-474. 
499. Johnson EO, Chang KH, Ghosh S, et al. LIMK2 is a crucial regulator and 
effector of Aurora-A-kinase-mediated malignancy. J Cell Sci. Mar 1 
2012;125(Pt 5):1204-1216. 
500. Mashiach-Farkash E, Rak R, Elad-Sfadia G, et al. Computer-based 
identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to 
destabilize the actin cytoskeleton. Oncotarget. Jun 2012;3(6):629-639. 
501. Robanus-Maandag EC, Koelink PJ, Breukel C, et al. A new conditional Apc-
mutant mouse model for colorectal cancer. Carcinogenesis. May 
2010;31(5):946-952. 
502. Laird PW, Jackson-Grusby L, Fazeli A, et al. Suppression of intestinal 
neoplasia by DNA hypomethylation. Cell. Apr 21 1995;81(2):197-205. 
503. Flis S, Gnyszka A, Flis K. DNA methyltransferase inhibitors improve the 
effect of chemotherapeutic agents in SW48 and HT-29 colorectal cancer 
cells. PLoS One. 2014;9(3):e92305. 
504. Brown R, Curry E, Magnani L, Wilhelm-Benartzi CS, Borley J. Poised 
epigenetic states and acquired drug resistance in cancer. Nat Rev Cancer. 
Nov 2014;14(11):747-753. 
505. Tada S, Iwamoto H, Nakamuta M, et al. A selective ROCK inhibitor, 
Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. 
Journal of hepatology. Apr 2001;34(4):529-536. 
506. Bei Y, Hua-Huy T, Duong-Quy S, et al. Long-term treatment with fasudil 
improves bleomycin-induced pulmonary fibrosis and pulmonary 
245 
 
hypertension via inhibition of Smad2/3 phosphorylation. Pulmonary 
pharmacology & therapeutics. Dec 2013;26(6):635-643. 
507. Talts JF, Wirl G, Dictor M, Muller WJ, Fassler R. Tenascin-C modulates 
tumor stroma and monocyte/macrophage recruitment but not tumor 
growth or metastasis in a mouse strain with spontaneous mammary 
cancer. J Cell Sci. Jun 1999;112 ( Pt 12):1855-1864. 
508. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 
antibody in patients with advanced cancer. N Engl J Med. Jun 28 
2012;366(26):2455-2465. 
509. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response 
to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. Nov 27 
2014;515(7528):563-567. 
510. Kular J, Scheer KG, Pyne NT, et al. A Negative Regulatory Mechanism 
Involving 14-3-3zeta Limits Signaling Downstream of ROCK to Regulate 
Tissue Stiffness in Epidermal Homeostasis. Dev Cell. Dec 21 
2015;35(6):759-774. 
511. Maher CA, Kumar-Sinha C, Cao X, et al. Transcriptome sequencing to 
detect gene fusions in cancer. Nature. Mar 5 2009;458(7234):97-101. 
512. Liotta L, Petricoin E. Molecular profiling of human cancer. Nat Rev Genet. 
Oct 2000;1(1):48-56. 
513. Yokoyama-Kobayashi M, Saeki M, Sekine S, Kato S. Human cDNA encoding 
a novel TGF-beta superfamily protein highly expressed in placenta. J 
Biochem. Sep 1997;122(3):622-626. 
514. Lawton LN, Bonaldo MF, Jelenc PC, et al. Identification of a novel 
member of the TGF-beta superfamily highly expressed in human placenta. 
Gene. Dec 5 1997;203(1):17-26. 
515. Breit SN, Johnen H, Cook AD, et al. The TGF-beta superfamily cytokine, 
MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer 
and metabolism. Growth Factors. Oct 2011;29(5):187-195. 
246 
 
516. Bauskin AR, Brown DA, Kuffner T, et al. Role of macrophage inhibitory 
cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res. May 15 
2006;66(10):4983-4986. 
517. Brown DA, Stephan C, Ward RL, et al. Measurement of serum levels of 
macrophage inhibitory cytokine 1 combined with prostate-specific antigen 
improves prostate cancer diagnosis. Clin Cancer Res. Jan 1 2006;12(1):89-
96. 
518. Brown DA, Ward RL, Buckhaults P, et al. MIC-1 serum level and genotype: 
associations with progress and prognosis of colorectal carcinoma. Clin 
Cancer Res. Jul 2003;9(7):2642-2650. 
519. Bruzzese F, Hagglof C, Leone A, et al. Local and systemic protumorigenic 
effects of cancer-associated fibroblast-derived GDF15. Cancer Res. Jul 1 
2014;74(13):3408-3417. 
520. Yanaba K, Asano Y, Tada Y, Sugaya M, Kadono T, Sato S. Clinical 
significance of serum growth differentiation factor-15 levels in systemic 
sclerosis: association with disease severity. Mod Rheumatol. Sep 
2012;22(5):668-675. 
521. Lambrecht S, Smith V, De Wilde K, et al. Growth differentiation factor 15, 
a marker of lung involvement in systemic sclerosis, is involved in fibrosis 
development but is not indispensable for fibrosis development. Arthritis 
Rheumatol. Feb 2014;66(2):418-427. 
522. Taylor BC, Zaph C, Troy AE, et al. TSLP regulates intestinal immunity and 
inflammation in mouse models of helminth infection and colitis. J Exp 
Med. Mar 16 2009;206(3):655-667. 
523. Yoo J, Omori M, Gyarmati D, et al. Spontaneous atopic dermatitis in mice 
expressing an inducible thymic stromal lymphopoietin transgene 
specifically in the skin. J Exp Med. Aug 15 2005;202(4):541-549. 
524. Jariwala SP, Abrams E, Benson A, Fodeman J, Zheng T. The role of thymic 
stromal lymphopoietin in the immunopathogenesis of atopic dermatitis. 
Clin Exp Allergy. Nov 2011;41(11):1515-1520. 
247 
 
525. Christmann RB, Mathes A, Affandi AJ, et al. Thymic stromal lymphopoietin 
is up-regulated in the skin of patients with systemic sclerosis and induces 
profibrotic genes and intracellular signaling that overlap with those 
induced by interleukin-13 and transforming growth factor beta. Arthritis 
Rheum. May 2013;65(5):1335-1346. 
526. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. 
Cell. Mar 19 2010;140(6):883-899. 
527. De Monte L, Reni M, Tassi E, et al. Intratumor T helper type 2 cell 
infiltrate correlates with cancer-associated fibroblast thymic stromal 
lymphopoietin production and reduced survival in pancreatic cancer. J 
Exp Med. Mar 14 2011;208(3):469-478. 
528. Xie F, Meng YH, Liu LB, et al. Cervical carcinoma cells stimulate the 
angiogenesis through TSLP promoting growth and activation of vascular 
endothelial cells. Am J Reprod Immunol. Jul 2013;70(1):69-79. 
529. Olkhanud PB, Rochman Y, Bodogai M, et al. Thymic stromal lymphopoietin 
is a key mediator of breast cancer progression. J Immunol. May 15 
2011;186(10):5656-5662. 
 
 
